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aliA ami-like gene encoding peptide binding protein of an ABC transporter, 
 gene immediately downstream of capsule operon  
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Overview and summary of the thesis 
 
Chapter 1 gives an overview about Streptococcus pneumoniae, its role as a human 
pathogen and its virulence factors. Additionally, biofilm development and its relevance in 
clinics are introduced, and the innate immune response to pneumococcus as well as 
bacterial-viral interactions in the upper respiratory tract are also discussed. 
Chapter 2 emphasizes the three main topics of this thesis: the role of capsule and 
pneumolysin in the immune response in the respiratory tract, biofilm formation of S. 
pneumoniae serotypes and commensal streptococci in vitro, and host innate immune 
responses to RSV and S. pneumoniae during in vitro co-infections. Aims and hypotheses are 
provided here. 
Chapter 3 is divided into two parts: 
First, the release of the pro-inflammatory cytokines CXCL8 and IL-6 from the human 
pharyngeal epithelial cell line Detroit 562 and from human bronchial epithelial cells (iHBEC) 
is described in response to S. pneumoniae. Capsule was shown to suppress the release of 
both cytokines in both cell lines tested, but release was much less from iHBEC cells. During 
intranasal colonization of mice, suppression of CXCL8 release by the capsule was also 
observed in vivo, but the effect was only measured in the absence of pneumolysin. Long 
term, stable nasopharyngeal carriage in a mouse model resulted in the dissemination of 
nonencapsulated pneumococci into the lungs, whereas encapsulated strains remained in the 
nasopharynx. The S. pneumoniae capsule thus plays a role in modulation of the pro-
inflammatory immune response in the respiratory tract. 
Second, results on immunological cells and immune regulation in a long term, stable 
nasopharyngeal carriage mouse model are presented. Mice were infected with encapsulated 
or nonencapsulated pneumococcal strains, and after 1, 3, 8 and 15 days, were sacrificed to 
evaluate the numbers of CD45+ cells, neutrophils, macrophages, FoxP3+ regulatory T-cells 
and CD3+ T-cells in the nasal mucosa as well as the amount of secreted IL-10 in the 
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nasopharynx. Nasopharyngeal colonization which is effectively silent resulted in the 
stimulation of FoxP3+ regulatory T-cells and IL-10 release associated with immune 
homeostasis, whereas lung infiltration was required to increase the number of neutrophils 
and macrophages resulting in a stronger innate immune response in the nasal mucosa.  
Chapter 4 contains results of mono- and co-stimulation using RSV and pneumococci or 
pneumococcal virulence factors on the human bronchial epithelial cell line BEAS-2B. An 
increase in CXCL8 and IL-6 levels was measured for mixed stimulations of RSV and 
pneumococcus when encapsulated bacteria were used. Increasing pneumolysin 
concentrations resulted in enhanced CXCL8 levels. Priming of bronchial epithelial cells with 
RSV opens the door for more severe pneumococcal infections. 
Chapter 5 is composed of two parts: 
 The first part describes initial biofilm formation of serotypes 6B and 7F in a static 
model in vitro. Biofilms of both serotypes contained SCVs, but only serotype 6B increased in 
SCV formation between 16 and 65h of incubation. SCV stability was tested by passaging 
clones in complex medium, where SCV production is not associated with advantages in 
growth. Serotype 6B lost the SCV phenotype indicating a fast adaptation to a changing 
nutritional environment. Limitations of our in vitro model are discussed. 
 The second part is about initial biofilm formation of mixed culture growth of S. 
pneumoniae with commensal streptococci. Competition dominates this process. S. oralis 
and pneumococcus compete for nutrients, whereas mixed species growth of S. mitis or S. 
pseudopneumoniae with S. pneumoniae is mainly influenced by other factors. 
In Chapter 6 the findings of chapters 3, 4 and 5 are discussed and an outlook for further 
studies is provided. 
Chapters 7, 8, 9, 10 and 11 contain the references, the acknowledgements, the curriculum 
vitae, the appendix and the declaration of originality. 
 
8
  General introduction 
_______________________________________________________________________________________________________________________________________ 
1. General Introduction 
1.1 Streptococcus pneumoniae 
1.1.1 Description 
Billroth observed chain-forming cocci in wounds in 1878  and cocci were first isolated 
by Georg Miller Sternberg and Louis Pasteur in 1881 [1]. One member of this genus that 
they had discovered, Streptococcus, is Streptococcus pneumoniae, the subject of this thesis.  
 
Taxonomy level Description 
Kingdom Cellular organisms 
Superkingdom Bacteria 
Phylum Firmicutes 
Class Bacilli 
Order Lactobacillales 
Family Streptococcaceae 
Genus Streptococcus 
Species Streptococcus pneumoniae 
 
Table 1: Taxonomic classification of Streptococcus pneumoniae  
 
S. pneumoniae (the pneumococcus) is a Gram-positive diplococcus [2, 3]. This strict 
human pathogen [4] uses the nasopharynx as major ecological reservoir [4, 5] and has the 
potential to cause serious diseases such as pneumonia, meningitis and sepsis as well as the 
common childhood condition of otitis media. Bacterial cells show a spherical or ovoid shape, 
are facultatively anaerobic, non-spore forming, homofermentative, catalase negative and 
require complex nutritional environments for growth. They have a fermentative metabolism 
which produces L(+) lactic acid as major product in glucose fermentation [6]. One single 
circular chromosome of about 2 million base pairs (bp) forms the pneumococcal genome 
with a guanine + cytosine content  of 39.7% [7]. A 200 to 400 nm thick polysaccharide 
capsule covers the peptidoglycan cell wall in the majority of strains [8]. Each of the currently 
known 93 different serotypes [9, 10] of S. pneumoniae has capsular polysaccharides 
differing in structure and antigenicity [11]. First observed in 1928 by Griffith [12] and 
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described in more detail by Avery and co-workers in 1944 [13], the pneumococcus is 
naturally competent and able to take up DNA from the environment [14]. 
1.1.2 The genus streptococcus 
 One of the first methodologies to divide the streptococci into different groups was 
developed by Lancefield in 1933 using differences in precipitin reactions based on group-
specific carbohydrates [15]. Today, the genus streptococcus containing about 40 species [6] 
is grouped into α-, β-, and γ-hemolytic species and these groups are sub-divided into six 
clusters: the salivarius, the mitis, the angiosus,  the pyogenic, the mutans, and the bovis 
clusters[16]. The three first are also often termed viridans streptococci. Natural competence 
seems to occur mainly in the Mitis and the Angiosus groups [14]. The streptococcal species 
important for this study are S. pneumoniae, S. mitis, S. oralis as well as the recently  
described S. pseudopneumoniae [17] which belong to the Mitis cluster, whereas S. danieliae 
found in 2013 belongs to the Viridans streptococci [18]. There is a high degree of similarity 
between commensal streptococci and the pneumococcus which makes diagnostics more 
complicated [19]. 
 
  
 
Figure 1: Clustering of the genus Streptococcus (modified from [6]) 
Genus: Streptococcus
Pyogenic Mitis SalivariusAnginosus Mutans Bovis
Species included:
•S. pyogenes
•S. agalactiae
•S. canis
•S. dysgalactiae
•S. equi
•S. hyointestinalis
•S. iniae
•S. parauberis
•S. procinus
•S. uberis
Species included:
•S. anginosus
•S. constellatus
•S. intermedius
Species included:
•S. gordonii
•S. mitis
•S. oralis
•S. parasanguis
•S. pneumoniae
•S. sanguis
Species included:
•S. mutans
•S. cricetus
•S. doweni
•S. macace
•S. rattus
•S. sobrinus
Species included:
•S. salivarius
•S. thermophilus
•S. vestibularis
Species included:
•S. bovis
•S. alactolyticus
•S. equines
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1.1.3 Pneumococcal evolution 
 The most important factors influencing the evolution of bacterial clones are 
recombination, mutations, selective forces as well as bacterial and host properties which 
affect colonization and transmission [20]. As the pneumococcus is naturally competent, it is 
able to incorporate DNA fragments from pneumococcal and non-pneumococcal bacterial 
species into its genome. For this process, homologous recombination is the most important 
tool [21]. An extreme diversity in pneumococcal populations is observed as a result of high 
levels of recombination after which variant genotypes can easily emerge. Selective forces for 
this process are the ecological environment, the innate and adaptive immune responses of 
the host as well as antibiotic pressure. Interestingly, transformation-competent cells are able 
to kill non-competent cells and the DNA released can then be taken up [20, 21].  
1.1.4 Competence 
 Competence is defined as the process of DNA uptake from the surrounding medium 
to replace homologous regions in the host’s genome which results in a permanent change in 
the cell’s phenotype. In S. pneumoniae regulation of competence is performed via a quorum 
sensing system via the competence stimulating peptide (CSP) (Figure 1). For binding, 
uptake, and integration of foreign DNA, a unique set of genes is required. In naturally 
competent streptococci, the competence regulation operon comCDE is responsible for this 
process: ComC is a precursor of the competence-stimulating peptide CSP, processed and 
secreted by the ComAB transporter. ComD is a histidine kinase and comE encodes its 
cognate response regulator. Autophosphorylation of ComD leads to the transfer of a 
phosphoryl group to ComE which then leads to the activation of early genes comAB, 
comCDE, comW and comX [14]. ComX encodes a competence-specific σ-factor which is 
able to recognize a -10 σx-promoter. This promoter is found in front of the late com genes 
and thus leads to the transcription of genes responsible for DNA uptake and processing [22]. 
11
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Competence is induced when a certain level of CSP in reached in the medium [14]. 
Autocatalytic accumulation of CSP is started when a critical threshold concentration is 
reached. Thus, competence induction in pneumococcal cultures is highly synchronic: The 
transcription of early com genes reaches a maximum after 5-7 minutes and late com genes 
after 10-12 minutes [22, 23]. 
 
 
 
Figure 2: Regulation of competence in the pneumococcus. comC encodes pre-CSP which is then processed and secreted 
by the ComAB transporter. As a result, extracellular mature CSP accumulates. CSP then binds to its receptor ComD leading to 
autophosphorylation of ComD followed by transfer of the phosphoryl group to ComE. This leads to the activation of early genes 
and the auto-induction of a positive feedback loop increasing the extracellular CSP. Additionally, the alternative σ factor ComX 
as well as ComW are triggered. Proteolytic cleavage of ComX is prevented by ComW. The production of late genes involved in 
DNA uptake, recombination and virulence or stress is then induced (modified from [24]). 
 
In all S. pneumoniae strains a functional comCD unit is found which means that 
competence is a very important, if not essential, tool for these bacteria [23]. Besides 
pneumococci, other streptococci are also naturally competent. Most of these species are 
present in the Mitis cluster [25]. Generally, CSP seems to be pherotype-specific but for a few 
species cross-induction was observed to occur. [14].  
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1.2 The pneumococcus as a pathogen 
1.2.1 The human pathogen 
 Generally, pneumococci colonize the human nasopharynx asymptomatically by 
binding to the mucosal epithelial cells. However, if the bacteria spread to the sinuses or to 
the middle ear, if they are aspirated into the lungs or invade the bloodstream, infections are 
started [5]. More people die of S. pneumoniae infections than of the Human 
Immunodeficiency Virus (HIV) in the United States and mainly the very old and the very 
young are affected.   
One of the major pediatric problems worldwide is otitis media where antibiotic 
treatment is a big challenge [26]. In special cases, chronicity was shown to be caused by 
pneumococci surviving intracellularly in middle ear mucosa epithelial cells where the bacteria 
cannot be eliminated by antibiotic therapies. This phenomenon then might lead to hearing 
loss and associated learning difficulties in young children [27].   
1.2.1.1 Epidemiology 
Child-care centres (CCC) cause an increased risk for children to suffer from 
infectious diseases due to the frequency of contacts in crowded conditions. In addition to the 
significant morbidity there is also an important economic problem due to work loss and 
medical care cost. The biggest problems in CCCs are the increased risk of young children 
carrying pneumococci, the high rates of viral infections in these children and the poor 
hygienic behaviour. Children attending CCCs are at a 6x higher risk of becoming 
pneumococcal carriers than children not attending CCCs and these institutions are important 
for the variability of pneumococcal serotypes in carriage in the population [28]. Thus, often 
young children are responsible for the introduction of new serotypes into a household [29].  
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 Interestingly, there are differences in pneumococcal infections observed between 
different ethnicities. For example, the indigenous populations in Alaska, Canada, Greenland 
as well as the American Indians, African Americans in the USA, Australian Aborigines, 
Maoris of New Zealand and the Bedouins of Israel are more often affected by invasive 
pneumococcal diseases and there is evidence that genetic factors play a role [5, 30]. Socio-
economic factors also play a role in infections as shown by the fact that Moraxella 
catarrhalis, Staphylococcus aureus and antibiotic resistant S. pneumoniae were more often 
carried by children from lower socio-economic schools in Belgium as vaccination is less 
common than in higher socio-economic schools [31]. Additionally, passive cigarette smoke 
also significantly increases the risk factor for invasive disease, mainly in children aged 
younger than 5 years [32]. Patients suffering from B and T cell defects, congenital asplenia, 
defects of the complement pathway, interleukin-1 receptor-associated kinase 4 (IRAK-4) 
deficiency or ectodermal dysplasia with immunodeficiency form the high-risk group for 
developing severe and invasive pneumococcal disease [33]. People suffering from sickle cell 
disease show a 30-600 fold higher risk of developing invasive pneumococcal disease than 
individuals not suffering from sickle cell disease [34]. An absence of spleen increases the 
risk of pneumococcal infections 10-50 times, mainly in the blood and the lungs [35] whereas 
children suffering from acute lymphoblatic leukaemia show, depending on their age, a 8-50 
times increased risk for infectious pulmonary disease compared to the healthy population 
[36]. Organ transplantation is another risk factor for invasive pneumococcal disease, mainly 
if chronic graft versus host disease occurs [5].  
 Generally, mortality rates for bacteremic pneumococcal pneumoniae are <3% for 
children and 10-30% for adults. Fatal meningitis is observed in 16-37% of infected adults 
and in 1-2.6% of infected children [5]. Many factors have been shown to be associated with 
an increased risk to die from pneumococcal pneumonia such as, for example, underlying 
chronic disease, severity of illness, older age (> 65 years), immunosuppression [37], nursing 
home living, need for mechanical ventilation, chronic pulmonary disease [38], nosocomial 
14
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pneumococcal bacteremia, diabetes mellitus, congestive heart failure, malignancy, 
alcoholism [39] or parenteral nutrition [40]. 
1.2.1.2 Vaccination 
 Already one year after the first isolation of pneumococcus, immunizing experiments 
were performed. The first larger clinical trial dates back to 1911, but due to the lack of 
knowledge about the different pneumococcal serotypes the vaccinations failed. In the 1980s 
two polysaccharide-based pneumococcal vaccines were introduced, first a 14-valent 
pneumococcal vaccine, and 6 years later a 23-valent vaccine. Children younger than 2 years 
are not able to produce antibodies against polysaccharides as a T-cell independent immune 
response is induced and thus pneumococcal conjugate vaccines such as the 7-valent PCV7 
(Prevnar ®, Pfizer Inc.; which covers serotypes 4, 6B, 9V, 14, 18C, 19F and 23F [41])  and 
the 13-valent PCV13 (Prevnar 13 ®, Pfizer Inc.; which covers serotypes 4, 6B, 9V, 14, 18C, 
19F, 23F, 1, 3, 5, 6A, 7F and 19A [41]) were introduced [42]. In Switzerland, PCV7 was 
introduced in 2006 and replaced by PCV13 in 2011 [43]. Interestingly, in nature capsular 
switching is possible via transformation and recombination when genes encoding one 
capsular type are taken up by pneumococci of a different serotype. Of concern is the 
possibility of vaccine-to-nonvaccine serotype switching as the rate of serotype replacement 
is significantly increased by vaccination [44]. Different types of polysaccharide-based 
vaccines are currently available or being tested (Table 2): 
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Table 2: polysaccharide-based vaccines (modified from [45]). 
 
 
 
 
 
Table 3: The most promising vaccine candidates  
against pneumococcus (modified from  [46]) 
 
 Currently, other pneumococcal components are also being tested as candidates for 
a non-serotype-specific vaccine. Table 3 lists the most promising candidates. All the different 
components have already been tested in mouse models resulting in an increased survival of 
infected animals [46]. 
 Another approach to reduce pneumococcal infection is the principle of bacterial 
replacement. In oral microbiology for example, a reduction in dental caries was observed 
after ingestion of probiotic lactobacilli. In the nasopharynx of infants it was shown that an 
infection with S. pneumoniae results in a reduced microbial diversity compared to healthy 
children [47]The main idea of bacterial replacement is to add a non-pathogenic “effector” 
bacterium which is able to out-compete potential pathogens but a prerequisite for this 
process is the persistence of the effector in the normal flora which is often is difficult to 
obtain [48].  
 
Type of vaccine Advantages Disadvantages 
Capsular polysaccharides Elicit antibodies similar to natural 
response, safe, easy to purify 
Poorly immunogenic, no immunological 
memory 
Capsular polysaccharide-protein 
conjugate 
Elicit antibodies similar to natural 
response, T-lymphocyte dependent 
response in infants and children, safe 
No T-lymphocyte dependent response 
in elderly, most opsonic IgG subclasses 
not produced, undesired immunity 
against carrier protein possible 
Peptide mimotype of polysaccharide 
antigen 
Biochemically defined, T-lymphocyte 
dependent response and immunological 
memory, focus response on protective 
antibodies 
Poorly immunogenic without carrier 
molecule, no experience for efficacy in 
humans 
Vaccine candidates 
Pneumolysin (PLY) 
Pneumococcal surface protein A (PspA) 
Pneumococcal surface protein C (PspC) 
Pneumococcal surface antigen A (PsaA) 
Adhesins (targeting diferent infection stages) 
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1.2.2 Pneumococcus in the human body 
1.2.2.1 Nutritional environment 
 S. pneumoniae is able to use a huge variety of different sugars for growth such as 
pentose, cellobiose, galactose, galactitol, fucose, fructose, lactose, glucose, mannitol, 
glycerol, raffinose, mannose, maltosaccharides and trehalose [7]. All of them are directly 
involved in the glycolytic pathway. As a nitrogen and a carbon source, ten different amino 
acids and N-acetylglucosamine can be used. Many different ATP-dependent transporters 
have been identified and over 30% of all transporters are involved in sugar transport. Host 
glycoproteins as well as murein polysaccharides are used as major carbon sources but the 
pneumococci’s own capsular polysaccharides (mainly mucins, hyaluronic acid and 
glycolipids) are important donors as well. ATP- and ion-driven transporters for amino acids, 
uracil, xanthine and polyamines were identified but there was only one single transporter 
found able to transfer di- and monocarboxylates [7]. 
1.2.2.2 Ecology 
 S. pneumoniae is generally a strict human pathogen but serotype 3 has been found 
as a natural pathogen in horses [11]. The major ecological reservoir of the pneumococcus is 
the nasopharynx with 30-50% of young children, 4-10% of all adults and 8% of all 
adolescents being carriers [5]. The evolutionary selective pressure for absolute pathogenicity 
factors is very low and thus S. pneumoniae colonizes the nasopharynx without causing an 
invasive disease in most cases. Nasopharyngeal colonization is a good way to spread to 
other hosts via aerosols and mucous exchange [4]. Nutrients, space, attachment as well as 
co-inhabitants are important ecological factors influencing bacterial presence in a 
microecosystem. Co-colonization is mainly influenced by the production of harmful 
substances and the induction of distinct immune responses. Competition of bacteria from the 
same species is mainly due to limited shared resources whereas competition between two 
different species is mediated by inhibitory agents and toxins or the immune system [49]. 
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 In changing environmental conditions bacteria are able to change the transcription of 
carbohydrate utilization genes and virulence factors. Studies in Bacillus subtilis, the model 
organism of Gram-positive bacteria, have shown that changes in environmental 
carbohydrate concentrations result in different expression levels of the catabolite control 
protein A (CcpA). CcpA is the direct link between the environmental carbohydrate levels and 
the transcriptional regulation of carbohydrate utilization genes. Even virulence genes were 
affected which results from the fact that CcpA is a global regulator of carbohydrate 
metabolism in S. pneumoniae with important effects on transcriptional regulator and 
virulence factor genes [50]. CodY, a nutritional repressor, is able to repress the transcription 
of more than 100 genes during exponential growth involved in different processes such as 
development of genetic competence, peptide uptake, branched-chain amino acid 
biosynthesis, motility, and sugar uptake [51]. 
 In B. subtilis it was shown that during starvation the extracellular signals are able to 
induce more than one regulon and at least 400 genes change their expression program. 
Most of the glucose-starvation inducible proteins show similar expression kinetics: The 
induction period is short, then the gene expression is switched off but there still is a transient 
induction observed which results in the accumulation of proteins which are required during 
glucose starvation [52]. 
1.2.2.3 Bacterial colonization of the human body 
 Microbial colonization starts immediately after birth and a few weeks later the child’s 
microbial flora has developed to become remarkably similar to that of the adult [53]. One of 
the most important features of the normal microbial flora is the formation of a barrier against 
infectious agents. For example, viridans streptococci are important to prevent S. 
pneumoniae, S. pyogenes or Gram-negative bacilli colonization. For this process, 
bacteriocin and short-chain fatty acid production are very important factors. The short chain 
fatty acids are metabolic end products of the normal flora which inhibit growth of potential 
18
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pathogens either by being directly toxic or by indirect inhibition due to lowering the local 
oxidation potentials [54].  
1.2.2.4 Nasopharyngeal colonization 
 The human nasopharyngeal mucosal surface is nutritionally poor. Fluctuations in 
osmolarity, nutrient availability and pH have been measured. The temperature is about 
34°C, pH-values range from 6.4 to 6.9, chloride from 82 to 108 mM, sodium from 82 to 91 
mM and glucose from 3.9 to 5.8 mM. In nutritionally limited areas such as the nasopharynx, 
sessile growth in biofilms is a survival strategy [55]. 
 The most important species colonizing the human nasopharynx are staphylococci 
(including S. aureus), streptococci (including S. pneumoniae), Moraxella (Branhamella) 
catarrhalis, Neisseria sp. and Haemophilus sp. In the human oropharynx viridans 
streptococci are important to suppress the spreading of S. pyogenes, S. pneumoniae, N. 
meningitidis, S. aureus, Mycobacterium tuberculosis, Legionella pneumophila and additional 
Gram-negative bacilli. In physiologically normal humans few Gram-negative bacilli are 
observed in the oropharynx but they increase greatly when illness occurs as the epithelial 
cells in ill humans are better targets for adherence. Reduction of oropharyngeal bacteria 
leads to the emergence of different pathogens. Obligate anaerobes were observed to 
produce much fewer infections than aerobic microorganisms [54]. Pneumococcus produces 
only small amounts of exotoxins and thus disease is mainly caused by bacterial replication 
and also the host’s inflammatory response [56]. 
 Nasopharyngeal colonization requires different steps such as availability of nutrients 
from the human tissues, tropism to specific host cells and evasion of the innate immune 
system [57]. Sugars present in the nasopharynx are important as nutrients but also for 
adhesion of the pneumococcus. Additionally, there is evidence that sugars may also serve 
as signals leading to enhanced virulence. Sialic acid is shown to increase the colonization 
and the spread of pneumococcus in the nasopharynx [58]. 
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1.2.2.5 Colonization of the upper respiratory tract 
 Pathogens which are located in the nasopharynx can become able to invade the 
upper and the lower respiratory tract. Lack of competing bacteria has been shown to be 
associated with a higher rate of reinfection after otitis media treatment. In this context mainly 
α-streptococci are of importance as increased recurrences were measured when these 
bacteria were absent. Other species such as Prevotella or Peptostreptococcus have the 
same effects i.e. their presence reduced recurrence of otitis [59]. Additionally, pathogenic 
factors of one microbial species may affect other bacteria present in this environment, for 
example, supernatants of S. pneumoniae cultures have been shown to inhibit H. influenzae 
growth [60]. 
 Performing 16S rRNA analysis of the whole microbiome showed shifts in the upper 
respiratory tract depending on age, vaccination, antibiotic use or respiratory tract infections. 
A lower microbial diversity was measured when S. pneumoniae was present and a negative 
correlation was observed between Corynebacterium, Dolosigranulum and Streptococcus 
[61]. The most prevalent phyla isolated from nasopharyngeal swabs are Firmicutes (73%), 
Proteobacteria (12.6%), Bacterioidetes (7%), and Actinobacteria (5.6%). Streptococcus, 
Shigella, Acitenobacter, and Corynebacterium spp. are commonly identified but also some 
environmentally linked Leuconostoc, Lactococcus, and Weissella spp. often can be found. 
Interestingly, nasopharyngeal communities seem to be less stable over time compared to 
oropharyngeal communities [62]. 
1.2.2.6 Pneumococcal adhesion to human epithelial cells 
 Some bacterial adherence is specific for different epithelial cell types and depends on 
species-specific surface antigens termed adhesins (lectins) which bind the bacteria to cell-
specific receptors of the host. Carbohydrates in variable chain structures are responsible for 
the adhesion specificity [54]. S. pneumoniae can be internalized by mammalian cells as a 
result of cell-specific mechanisms [63]. PspC is the only pneumococcal protein identified as 
an adhesin and it is specific for human secretory component (SC), the extracellular domain 
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of polymeric immunoglobulin receptor A (PIgR). PspC is able to bind free SC and SIgA 
which results in phagocytosis prevention [63, 64]. Non-encapsulated pneumococci have an 
advantage over encapsulated in terms of binding to host cells in the respiratory tract [65] but 
encapsulated S. pneumoniae strains have an advantage in transiting from the luminal 
mucus, their initial site in the host, to the epithelial surface. Only the bacteria in close 
association with the epithelial surface are able to produce a stable colonization and thus 
escape from the mucus seems to be an important step in persistence but the capsule inhibits 
the adhesion to bacterial host cells. S. pneumoniae in close association with epithelial cells 
was shown to down-regulate its capsule. [66]. Encapsulated strains are resistant to 
opsonophagocytosis and so have an advantage in surviving in the bloodstream [65, 67].  
Binding of the bacterium to the epithelium occurs via the cell-surface carbohydrates, 
e.g. N-acetyl-glucosamine on the respiratory epithelium [68]. Cell-wall associated surface 
proteins of the bacterium are important for this binding. Cell wall hydrolases (CWHs), for 
example LytB and LytC, which are found on the surface of pneumococci, cleave specific 
covalent bonds of the cell wall and they also modify bacterial peptidoglycan and as this is a 
main pathogen-associated molecular pattern, modifications are used to overcome host 
innate immunity. Hydrolases for peptidoglycan are important for attachment to hydrophobic 
surfaces and are important for bacterial pathogenesis and full virulence. LytB and LytC are 
involved in the attachment to the nasopharynx but some degree of colonization is still 
possible in the absence of both of these factors, indicating that there are additional proteins 
involved in this process. [69]. 
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1.2.3 Pneumococcal virulence factors 
The main pneumococcal virulence factors are listed in Table 3. 
 
Pneumococcal virulence factor Main role in colonization 
Upper-airway colonization 
Capsule Inhibiting effective opsonophagocytosis, preventing entrapment in the nasal 
mucus 
ChoP Binding of rPAF on epithelial surface of nasopharynx 
CbpA (also known as PspC) Binds to human secretory component on polymeric Ig receptor during first 
stage of translocation through epithelium 
NanA, BgaA, StrH Cleaving of terminal sugars from glycoconjugates, revealing receptors for 
adherence 
Hyl Breaking down of hyaluronan-containing extracellular matrix components  
PavA Binding to fibronectin 
Enolase Binds to plasminogen 
Competition in upper airway 
Bacteriocin (pneumocin) Small antimicrobial peptide targeting members of the same species 
Respiratory-tract infection and pneumonia 
Ply Cytolytic toxin activating complement. Important virulence factor for in vivo 
models. Wide range of effects at sub-lytic concentrations 
PspA C3 binding on pneumococcal surface prevented. Binds lactoferrin 
LytA Cell wall digestion resulting in Ply release 
PsaA Component of ABC transport system, resistance to oxidative stress 
PiaA, PiuA Component of ABC transport system 
NanA, NanB Reveals receptors for adherence by modification of the surface of competing 
bacteria within the same niche. Modification of host clearance glycoprotein 
functions 
IgA protease Cleaving of human IgA1 
 
Table 4: The most important pneumococcal virulence factors and their main role in colonization are listed in this table. 
Modified from [11]. 
1.2.3.1 Capsule 
 The anti-phagocytic polysaccharide capsule is one of the main virulence factors as it 
forms a shield to prevent phagocytosis or killing in neutrophil extracellular traps [11, 70-72] 
and reduces the total load of complement, mainly C3b [73], on the bacterial surface [71] and 
thus gives an advantage in colonization for the bacterium [65]. As a result, non-encapsulated 
pneumococci are less virulent [74], but these strains are important pathogens producing 
superficial infections such as conjunctivitis [75, 76]. 
 The S. pneumoniae capsule is 200-400 nm thick [8] and is attached to the outer 
surface of the cell wall peptidoglycan covalently [77]. Capsular polysaccharides are acidic in 
most cases and constructed of a core oligosaccharide next to the lipid part and an O-
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polysaccharide which is based on repeating units [45]. Structural types of capsule vary 
between linear polymers composed of two or more monosaccharides to branched 
polysaccharides containing one to six monosaccharides in combination with additional side 
chains [77]. The sugars detected most frequently in pneumococcal capsules are listed in 
Table 2.  
 
Sugar 
α/β-D-glucose 
α/β-D-galactose 
α/β-L-rhamnose 
N-acetyl-α/β-D-glucosamine 
N-acetyl-α/β-D-galactosamine 
N-acetyl-β-D-mannosamine 
N-acetyl-α-L-fucosamine 
α/β-D-glucuronic acid 
 
Table 5: Sugars detected most frequently in pneumococcal capsules (from [78]). 
 
One of the common things between the different capsule types is that none of them 
shows a net positive charge [65]. Differences in the thickness of encapsulation result in 
colonization of different niches of the human body. Thicker capsules reduce entrapment in 
the mucus [79], and, due to the reduced opsonophagocytosis, survival in the blood stream is 
increased [80]. In contrast, thinner capsules show an advantage in adhering to host tissue 
due to increased exposure of adhesion molecules [81]. 
Genetic organization of capsule operon 
 Clusters of up to 20 different tightly linked genes are required for serotype-specific 
capsular polysaccharide synthesis [65]. Most serotypes encode their polysaccharide capsule 
in a gene cluster which is located between genes dexB and aliA [82]. Figure 3 shows 
serotypes 6B and 7F as examples. One exception to this rule are serotypes 37 [44] and 3 
[83]. The pneumococcal capsular locus shows an average size of 20,174 bp [10]. The first 
four genes of the operon, cpsA-D (also termed wzg, wzh, wzd and wze), are quite conserved 
and affect the capsule expression level [11] while further downstream the serotype-specific 
genes are located. The first gene of the capsule operon is cpsA which is the most conserved 
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and might have a role in capsule the regulation of capsule expression. Generally, higher 
cpsA expression is observed in serotypes causing invasive diseases than in serotypes with a 
higher prevalence for colonization resulting in a correlation between cpsA expression and 
invasiveness. A new finding showed a connection between the upregulation of cpsA and the 
production of essential components for survival and growth in difficult and stressful 
environments such as the nasopharynx [82]. In the central region of the cps locus, genes 
encoding for specific glycosyl transferases have been identified which are responsible for the 
serotype-specific oligosaccharide-repeat unit on a lipid carrier, for example a flippase 
transporting the repeat unit to the external face of the membrane and a polymer responsible 
for linking both units. At the end of the locus genes encoding proteins for the synthesis of 
activated sugar precursors have been identified [11]. Interestingly, capsular switching via 
transformation and recombination is possible when genes encoding one capsule type are 
replaced by those of another [44].  
 
 
 
 
Figure 3: Capsule biosynthesis genes of pneumococcal serotypes 6B and 7F (modified from [10]).  
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Biosynthesis of pneumococcal polysaccharide capsule 
 For 91 serotypes [84], capsular synthesis occurs via the Wzx/Wzy-dependent 
pathway [10] (see Figure 4), only serotypes 3 and 37 use a processive transferase for 
capsule synthesis [83]. In the Wzy-dependent pathway, first the polysaccharide repeat unit is 
synthesized on an undecaprenyl lipid carrier (UndPP), then the oligosaccharide is 
translocated across the membrane by the help of a Wzx flippase. On the outer side of the 
membrane the oligosaccharide is then polymerized with the help of Wzy to produce a 
UndPP-attached polymer [85]. 
 
Figure 4: Representation of the Wzx/Wzy-dependent pathway for biosynthesis of CPS 9A [10]: 
Pictured is a hypothetical model for capsule biosynthesis in S. pneumoniae based on a mixture of experimental evidence and 
speculation. 
1) Non-housekeeping nucleotide sugar biosynthesis 
2) The initial transferase (WchA) in this case links the initial sugar as a sugar phosphate (Glc-P) to a membrane-associated  
 lipid carrier (widely assumed to be undecaprenyl phosphate). 
3) Glycosyl transferases sequentially link further sugars to generate repeat unit. 
4) Wzx flippase transports the repeat unit across the cytoplasmic membrane. 
5) Wzy polymerase links individual repeat units to form lipid-linked CPS. 
6) Wzd/Wze complex translocates mature CPS to the cell surface and may be responsible for the attachment to  
 peptidoglycan. The complex of WchA, Wzy, Wzx, Wzd and Wze shown in the membrane is based on that in Figure 2 of  
 Whitfield and Paiment for the related Escherichia coli Type 1 capsule. 
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Regulation of capsular polysaccharide production 
 No control element for transcription of the pneumococcal capsular genes associated 
with the pneumococcal σ70 cps promoter has been identified so far [11] but it is suggested 
that there are differences in the level of expression between transparent and opaque 
serotypes as there was a reduction of CpsD measured by Western Blotting in transparent 
variants [86]. The proteins derived from the genes cpsA-D were shown to be involved in 
capsular production [11]. cpsA-deficient mutants showed reduced capsular levels but 
virulence was not affected in a murine in vivo model [87]. The manganese-dependent 
phosphotyrosine-protein phosphatase CpsB, the polysaccharide co-polymerase related 
membrane protein CpsC and the autophosphorylating protein-tyrosine kinase CpsD act 
together as regulatory system for capsule production [83]. 
 
 
 
Figure 5: Model showing the regulation of capsular polysaccharide (CPS) production by tyrosine phosphorylation of 
CpsD. a) CpsC, CpsD and ATP interact to promote CPS biosynthesis by the polysaccharide polymerase (step 1). CpsD 
autophosphorylates, which causes a change in protein interactions and slows CPS biosynthesis (step 2). b) The CPS polymer 
is then transferred to the putative CPS cell-wall ligase, and is ligated to the cell wall (step 3). Finally, CspB dephosphorylates 
CspD, thereby allowing the cycle to be repeated (step 4) [11]. 
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1.2.3.2 Pneumolysin 
Beside the capsule, S. pneumoniae is also able to produce pneumolysin (Ply), a toxic 
intracellular protein of 471 amino acids and 53 kDa in size [88] which belongs to the family of 
cholesterol-binding cytolysins and which is produced during the late log phase of growth 
[89]. This toxin is able to form oligomers which then form pores into the epithelial 
membranes to trigger pro-inflammatory signaling and activates the classical pathway of 
complement [74]. Additionally, it is able to stimulate the production of TNF-α, IL-1β, nitric 
oxide, IL-8, prostaglandins and leukotrienes. Inhibition of non-specific defenses such as the 
respiratory cilial beat [71, 90] or phagocytosis and lymphocyte function are other main 
activities. Ply also causes damage to the ependymal cilia of the brain and thus is responsible 
for pathogenesis of meningitis as well as for hearing losses due to ultrastructural damage to 
the cochlea [71, 89]. Ply attachment to the cell membrane requires cholesterol [88] and thus 
pneumolysin is lytic to all cells containing cholesterol in their membrane [91]. Pneumolysin is 
able to bind to membrane cholesterol, 20-80 toxin molecules are associated within the 
membrane to form transmembrane pores of 30-35 nm in diameter. As a result, cytolysis by 
leakage of cytosolic proteins occurs [90]. 
Ply is found in almost all pneumococcal isolates. Its amino-acid sequence is well 
conserved and the toxin was shown to be essential for the pneumococcal survival in the 
murine upper and lower respiratory tract [91-93]. Ply-deficient pneumococci showed a 
delayed infiltration of the lungs in a murine model [89]. 
Ply interacts with epithelial cells forming pores in the cell membrane. Large molecular 
weight osmoles are allowed to enter the cell and signal transduction, osmosensing, is started 
resulting in the activation of p38 mitogen-activated protein kinase (MAPK9) and the nuclear 
factor κ-B (NF-κB). Interaction with Toll-like receptor (TLR)-4 and its adaptor protein MyD88 
is another possible pathway to activate NF-κB. As a result, cytokine and chemokine 
production is activated which results in neutrophil activation (for interleukin-8 (IL-8 / CXCL8)) 
which increases bacterial killing. Neutrophils additionally release reactive oxygen species 
and proteases which cause tissue injury [88] (see Figure 2 and Table 4).  
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Figure 6: Interaction of pneumolysin with epithelial cells causing pore formation results in NF-κB activation, 
cytokine/chemokine production and tissue injury. From [88]. 
 
 
Function Mechanism of alteration Consequence 
Membrane integrity 
Lytic concentration: pore formation Cell cytotoxicity, mitochondrial swelling, membrane blebbing.  
sub-lytic concentration: pore formation 
Osmosensing, in epithelial cells: 
activation of p38 mitogen-activated 
protein kinase and innate responses 
Cell signalling 
GTPases: direct / indirect activation of 
GTPases, protein kinases and 
phospholipases 
Roles in host responses, inflammatory 
responses and tissue injury 
Gene transcription 
Activation / expression of transcription 
factors 
Large number of genes (mainly involved 
in host responses, cell adherence / 
survival): Altered transcription  
Epigenetic regulation via Histone H3 
dephosphorylation 
Downregulation of genes involved in 
host defense 
Cytokine production TLR45-stimulated or TLR-independent (e.g. by osmosensing) 
Pro-inflammatory cytokines (e.g. 
including TNFα, IL-1β and IL-6): 
Increased production 
Generation of microbicidal 
molecules 
Expression of reactive oxygen species, 
nitric oxide and proteases by neutrophils 
and macrophages increased 
Role in microbial killing / tissue injury 
Cell adhesion 
Adhesion molecules (e.g. intercellular 
adhesion molecule 1): Transcriptional 
upregulation 
Potential enhancement of inflammatory 
response 
Apoptosis Cell death induction (cytotoxic effects of toxin or due to host-mediated response)  
Tissue damage / host responses 
enhancing bacterial killing  
 
Table 6: Major functions / consequences of pneumolysin on eukaryotic cells (modified from [88]). 
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1.3 Innate immune response to pneumococcus 
 
 Complement activation, phagocytosis and the inflammatory response are the 
principal mechanism of innate immunity induced by extracellular bacteria [94]. During the 
innate immunity to S. pneumoniae, the classical pathway with binding of IgM to bacteria is  
important [95].  
1.3.1 Mucosal immunity 
 The first line of defense against S. pneumoniae infections are intact mucosal 
surfaces as well as mucosal immune responses [96]. Additional components of the first non-
specific barrier are antibacterial peptides, ciliated cells and the simultaneous action of mucus 
[97]. The most important factor preventing pneumococcal carriage is secretory IgA. This 
process of mucosal immunity is relatively immature in young children [96]. 
1.3.2 Recognition of pathogen 
 The first step in innate immunity is recognition of pathogens by their conserved 
pathogen-associated molecular patterns (PAMPs) [98]. PAMPs are recognized by pattern 
recognition receptors which mainly regulate the production of inflammatory mediators such 
as IL-1β, TNF-α, IFN-α/-β or IL-6 [99]. One family of receptors which recognize PAMPs are 
the Toll-like receptors (TLRs) which are expressed on innate immune cells. Pneumococcal 
cell wall components (lipoteichoic acid and lipoproteins [99]) are recognized by TLR-2 [98]. 
Murine macrophage responses to pneumolysin were shown to be dependent on TLR-4 
[100]. Pneumolysin mainly stimulates processing of IL-1β via caspase-1. Additionally, 
pneumolysin pore formation seems to be a prerequisite for IL-1β release  [101]. 
Pneumococci are autolytic bacteria releasing DNA containing unmethylated CpG motifs 
which has shown to be recognized by TLR-9 within endosomes [99, 102]. Activation of TLRs 
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leads to the expression of Nuclear Factor κB (NF-κB) which is essential for neutrophil 
recruitment (NF-κB is necessary and sufficient for this process), cytokine expression and 
bacterial killing in pneumococcal pneumonia. Another important pathway is the tumor 
necrosis factor α (TNF-α) cascade activated in alveolar macrophages and the airway 
epithelium. TNF-α in combination with IL-1 is a critical cytokine for early response as they 
are responsible for the induction of the nuclear translocation of NF-κB [103].  
1.3.3 Cellular reactions 
 For co-ordination of the innate immune response and the phagocytosis of bacteria, 
dendritic cells and alveolar macrophages are of main importance [104]. After streptococcal 
invasion of the lungs a massive local inflammatory response is measured with massive 
immigration of granulocytes, neutrophils and activated monocytes/macrophages [105]. After 
the infiltration of neutrophils into the tissue, they become the major cell types for 
phagocytosis. Alveolar macrophages are still present, but no longer of main importance 
[103]. For pneumococcal clearance, neutrophils are of essential importance as they are able 
to phagocytose, to adhere to blood vessels as well as to react to chemotaxis [106]. 
Chemotaxis and as a result the motility of neutrophils are stimulated by IL-8 which is induced 
by TNF-α and IL-1 [103]. Another important cytokine is IL-6 which is able to delay neutrophil 
apoptosis and enhances their reactive cytotoxicity. As a result, the resolution of neutrophil-
mediated inflammation is delayed [107]. IL-6 also plays an important role in adaptive 
immunity as it stimulates B-cells, induced T-cell proliferation as well as the development of 
antigen-specific cytotoxic T-lymphocytes [103]. Already early in the development of 
pneumonia T-cells increase in the peribronchiolar region.  For an optimal response a certain 
level of CD4+ T-cells is required [101]. Anti-inflammatory cytokines are then important to 
regulate the inflammation and to prevent further tissue damage. Regulatory T-cells (Tregs, 
CD4+Foxp3+ cells) were shown to play an important role to mediate resistance to 
pneumococcal pneumonia [108] and are known as suppressors of immune responses [109]. 
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Tregs are required to keep the inflammatory reaction in balance and to prevent tissue 
damage and dissemination of bacteria into the blood. IL-10 plays an important role in 
immune homeostasis by suppressing the immunological reactivity to limit infection-related 
tissue damages [108, 110].  
 A chronology of pneumococcal infection using an inoculum of 107 CFU counts is 
shown in Table 11. Lower inocula of pneumococci resulted in a plateau of 107 CFUs/g lung 
tissue 48h after infection. Inflammatory response then still increased and reached a 
maximum 84h after infection as at this time point, pneumococci started to auto-lyse and to 
release large amounts of toxin [111].  
Infection (107 CFUs) Step 1 (0-4h) Step 2(2-24h) Step 3(24-48h) Step 4 (48-72h) Step5 (72-96h) 
Bronchoalveolar lavage TNF, IL-6 Neutrophils, TNF, IL-6, IL-1 Downregulation of TNF, IL-1 Monocytes, lymphocytes  
Tissue TNF, IL-6, IL-1 Neutrophils, TNF, IL-6, IL-1 
Downregulation of TNF, IL-1; 
bacteria in tissue   
Serum levels IL-6 IL-1 Bacteraemia Reduction in leukocytes; bacteraemia; TNF, IL-6  
Histopathology Inflammatory cells Inflammatory cells 
Low intensity of inflammatory 
cells, tissue injury 
regeneration 
High intensity of 
inflammatory cells, tissue 
injury regeneration 
Severe air-space 
disorganisation, diffuse 
tissue damage, 
regeneration 
 
Table 9: Chronology of pneumococcal infection in the mouse model (modified from [103]). 
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Figure 8: Summary of some aspects of the host immune response to pneumococcal infection during 
bronchopneumonia. Pneumococci infect bronchiolar airspaces, subsequently invading bronchoepithelial cells. This eventually 
leads to activation of these cells and the subsequent release of chemokines, such as IL-8. Alveolar macrophages also release 
IL-8 as well as TNF-α on pneumococcal infiltration. The release of IL-8 and TNF-α attracts neutrophils to areas of 
pneumococcal invasion. Neutrophils subsequently phagocytose pneumococci through complement C3 deposition and its 
associated receptor (opsonophagocytosis). Cytokines, such as TNF-α, are also released by neutrophils, which leads to 
increased neutrophil infiltration into infected areas. CD4 T-cell infiltration into infected tissue also occurs with increased release 
of IFN-γ and IL-10. Lysed pneumococcal populations release pneumolysin into tissue surroundings, which have a wide range of 
cytotoxic and inhibitory effects on host tissue and immune cells. The release of pneumolysin increases the chances of 
pneumococcal survival and growth in vivo [95]. 
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1.4 Pneumococcal colonization and viruses 
  Local viral infections, particularly in the upper respiratory tract, predispose for 
invasive bacterial diseases [112] and often increase the severity of the disease. 
Epidemiological evidence for this phenomenon was already gained during the 1918, 1957 
and 1968/69 influenza pandemics where complications were often associated with bacterial 
superinfections [113]. 
 One of the best studied examples of bacterial-viral interactions is that of influenza 
and parainfluenza viruses which are able to cleave sialic acids on eukaryotic cells by the 
action of their neuraminidases resulting in increased resulting in increased binding 
possibilities and adherence of S. pneumoniae and H. influenzae [114]. Sialic acid signaling 
additionally increases the production of co-transcribed transporters and metabolic enzymes. 
A local increase of free sialic acid is produced by influenza viruses what then serves as a 
signal for increasing the amount of pneumococci on the epithelium. A passive transfer of S. 
pneumoniae to the lower respiratory tract then results [58]. 
1.4.1 Bacterial-viral interactions in the upper respiratory tract 
 Viruses are able to disrupt the respiratory mucosal epithelium by inducing cell 
death and thus facilitating adherence and translocation of bacteria [60]. This may be 
because the basement membrane of the epithelial layer is exposed, increasing for example 
the binding of S. pneumoniae to the now freely accessible fibronectin [115]. Other species 
such as M. catarrhalis show binding to extracellular matrix proteins [116] indicating the 
benefit to the bacteria  of disrupted epithelia. Another important factor is the upregulation of 
adherence proteins such as platelet-activating factor receptor (PAFr), intracellular adhesion 
molecule 1 (ICAM-1), carcinoembryonic adhesion molecule-1 (CEACAM-1) [114] or the 
outer membrane protein P5-homologous fimbriae (P5 fimbriae) [117]. Viral factors such as 
neuraminidases (influenza virus) or protein G (RSV) also increase bacterial adhesion to host 
epithelial tissue. Increased bacterial colonization can also be the result of changes in the 
33
  General introduction 
_______________________________________________________________________________________________________________________________________ 
immune system caused by viruses such as enhanced neutrophil apoptosis, impairing 
neutrophil function or affecting biological activity and production of cytokines, e.g. 
downregulation of TNF-α production. The equilibrium of microbiota can be destroyed by 
microbial interactions which might result in viral invasion and transmission [118]. 
Retroviruses are even able escape immune clearance by the help of their microbial 
environment [119]. 
 
Figure 9: Viral-bacterial interactions. Viral-bacterial interaction on the respiratory epithelial surface. Viral presence is thought 
to predispose the respiratory niche to bacterial colonization by different mechanisms. First, viruses may render the epithelium 
more susceptible to bacterial colonization by altering the mucosal surfaces. Ciliae may be damaged, leading to decreased 
mucociliar function of the respiratory epithelium. Additionally, due to viral-induced damage and loss of integrity of the epithelium 
layer, bacterial colonization may be enhanced and translocation may be increased. Virus-infected cells may decrease the 
expression of antimicrobial peptides, as shown for β-defensins, thereby affecting the natural defense of the host epithelium. 
Viral neuraminidase (NA) activity is able to cleave sialic acids residues, thereby giving access to bacterial receptors that were 
covered by these residues. Finally, viruses may induce bacterial colonization and replication both directly and indirectly, the 
latter by inducing upregulation of various receptors required for bacterial adherence, including PAFr, CAECAM-1, P5F, ICAM-1 
and G-protein.  
PAFr, platelet activating factor receptor; ICAM-1, intracellular adhesion molecule 1; P5 fimbriae, outer membrane protein P%-
homologous fimbriae; CAECAM-1, carcinoembryonic adhesion molecule-1; PhC, phosphorylcholine; SA, sialic acids; rSA, 
receptor for sialic acids; NA, neuraminidase; mRNA messenger RNA; AMPs, antimicrobial peptides (from [118]). 
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1.4.2 Respiratory Syncytial Virus and bacterial co-infections 
 Respiratory Syncytial Virus (RSV), a non-segmented, negative-strand RNA virus of 
the genus Pneumovirus [120] is one of the leading causes of lower respiratory tract 
infections in infants and children causing cold-like symptoms in most healthy adults and 
children [121, 122] causing worldwide 64 million infections and 160,000 deaths per year 
[123]. Generally, only airway luminal ciliated epithelial cells and in some special cases non-
ciliated cells are affected. A loss of ciliated cells results from RSV infections, additionally 
excess mucus production or occlusion of the airways by sloughed cells. Immune cells, 
mainly macrophages, neutrophils and T-cells, massively infiltrate the airways and some pro-
inflammatory cytokines are positively correlated with disease severity (see Table 5) [124]. 
Cytokine or chemokine RSV-infected infants Ranking 
CXCL8 > 1000 pg/ml  +++ 
CXCL10 > 1000 pg/ml +++ 
IL-6 100-1000 pg/ml ++ 
CCL5 100-1000 pg/ml ++ 
CCL2 100-1000 pg/ml ++ 
CCL3 100-1000 pg/ml ++ 
IL-1β < 100 – 1000 pg/ml +/++ 
TNF-α < 100 pg/ml + 
IL-10 < 100 pg/ml + 
IFN-α, IFN-β  - 
 
Table 10: Cytokine and chemokine levels in aspirates from RSV-infected infants (modified from [124]). 
 
 RSV infections of human epithelial cells result in a significant increase of bacterial 
binding [125, 126] and decreased bactericidal functions were measured in murine alveolar 
macrophages [127]. Experiments with the human monocytic leukaemia cell line THP-1 
showed a reduced binding capacity of cells infected with RSV which resulted in lower 
amounts of bacterial killing. Additionally, the TNF-α bioactivity from cells infected with 
bacteria was reduced resulting in prolonged bacterial infection of patients [128]. Bacteria are 
also able to bind to RSV G protein which is expressed on respiratory epithelial cells 
increasing the binding capacity of pathogens to the host cells [129]. 
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1.5 Biofilm formation 
1.5.1 Introduction 
More than 99% of all bacteria found on Earth grow in biofilms. As organic compounds 
are found in higher concentrations on surfaces than in liquid medium, bacteria tend to grow 
on surfaces particularly those which are hydrophobic and nonpolar to which it is easier to 
attach [130], However, biofilms are not only observed attached to a host surface but they are 
also able to form in the surrounding mucus layer of fluid [131]. Thus, more than 60% of all 
human bacterial infections and up to 80% of all chronic infections are related to bacterial 
biofilms [132]. Bacteria in this growth phase are also up to one thousand times more 
resistant to antibiotics than when they are grown planktonically [133] and thus biofilm 
formation is a key factor for bacteria to survive in different environments [130, 134]. The 
most important trigger for bacterial assembly into biofilms is nutrient stress [135]. The 
formation of microcolonies is enhanced by predation stress on bacteria [136].  
1.5.2 Biofilm development 
Biofilms are complex three-dimensional structures formed by behavior coordination 
of bacteria and are defined as structured communities of bacterial cells which are enclosed 
in self-produced polymeric matrix [132, 137]. In biofilms, gradients of nutrients and oxygen 
availability are created and thus a heterogenic bacterial population is observed as each 
bacterium is adapted to the environment in which it is found [131], and thus, metabolic 
variation between biofilm bacteria themselves is measured during biofilm development. As 
much as 50% of the proteome can be differentially produced between planktonic and biofilm 
growth [134]. 
In the beginning, proteins and polysaccharides are bound to the surface in a liquid 
environment and form a so-called “conditioning film” to which the microbes can then attach. 
36
  General introduction 
_______________________________________________________________________________________________________________________________________ 
Hydrophobic and rough materials are the easiest for microbes to attach to but they are also 
able to attach to most other surfaces. [133]. At first, bacteria are associated in a loose or 
transient state with the surface [134]. This process is reversible as it is only based on 
electrostatic attraction and not on chemical bonds [130] and some bacteria still leave the 
surface to continue planktonic growth. Attachment seems to be responsible for the formation 
synthesis of extracellular matrix substances in which the bacteria then become embedded 
[138]. In a second step, attachment requires bacterial surface protein interaction and 
becomes irreversible [130]. Bacteria start to form microcolonies, grow and mature. There is 
evidence that the nutrient source influences clonal growth and rearrangements of cells.  
Quorum sensing seems to be very important for the maturation process: When a critical 
density of cells is reached the quorum sensing system is activated to start the transcription 
of specific genes [138]. The formation of extracellular polymeric substances then leads to the 
third step of biofilm formation. In this process, polysaccharides, nucleic acids and proteins 
are involved to form the extracellular polymeric substance [130]. The last step of biofilm 
development is the formation of a mature biofilm structure. Open water channels are of 
importance in this step as they are able to form a primitive circulatory system to form 
homeostatic conditions within the biofilm. The late stage of biofilm formation which is 
characterized by cell-to-cell interactions, cell adhesion, the formation of a multi-layered 
architecture and microcolony formation is positively influenced by competence-stimulating 
peptide (CSP) addition [139]. In a mature biofilm 70-95% of the space will be occupied by 
the EPS matrix and only 5-25% by bacterial cells [130]. In the last stage, bacteria become 
able to return to transient motility again [134] and colonize other surfaces [137]. After 24 
hours, biofilms form an extracellular polymeric matrix (EPM) and after 48h, the EPM makes 
up the majority of the biofilm – only 27% of all cells are still viable [140]. 
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Figure 7: (modified from [141]): Life cycle of biofilms . First, bacteria adhere reversibly to a surface. In a second step, 
attachment becomes permanent and biofilms start to grow. The bigger the biofilm gets, the more specialized to their 
microenviroment the bacteria get. From a mature biofilm, bacteria can detach and spread to colonize new surfaces. 
 
1.5.2.1 Exopolysaccharide matrix 
 For the three-dimensional structure of a biofilm, the exopolysaccharide matrix (EPS) 
is of main importance to hold bacterial cells on the surface and to provide binding sites 
enabling continuous accumulation of bacterial cells. Additionally, the EPS is also responsible 
for structural stability and vertical growth of the biofilm. During the early phase of biofilm 
formation (2-8h), the EPS is continuously formed. In Streptococcus mutans biofilms an EPS 
increase of more than 30x was measured in this early phase. After 20 to 30 hours, the EPS 
was observed to spread vertically and also occupying upper biofilm parts [142]. 
 
Colonization Biofilm development Spreading 
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1.5.2.2 Extracellular DNA in biofilms 
In 2002 it was shown for the first time that the biofilm extracellular material 
responsible for structural stability was DNA and not only exopolysaccharide and that DNaseI 
treatment had a strong inhibitory effect on biofilm formation [143], mainly in young biofilms 
[144]. There are differences in the amount of extracellular DNA (eDNA) production between 
different species, but even low eDNA-producers have significant influences on the amount of 
eDNA in multispecies biofilms [145]. For biofilms of the Gram-positive soil bacterium Bacillus 
cereus it was shown that most of the bacteria in the biofilm are embedded in a DNA-
containing matrix and as a consequence, most of the eDNA was cell associated and not 
freely present in the culture broth [146]. DNA-rich environments like biofilms are cation 
limited as eDNA binds cations, mainly Mg2+. As a result, modification of LPS and induction of 
resistance genes to antimicrobials were measured in Pseudomonas aeruginosa [147]. In a 
first step, eDNA is important for attachment, aggregation as well as stabilization and 
maturation of a biofilm. In a second step, exopolysaccharides (EPS) are accumulated and 
mature biofilms developed [148]. In P. aeruginosa biofilms eDNA presence was shown to be 
different depending on the biofilm age: after 2 days eDNA was observed as a grid-like 
structure on the substratum and in the microcolonies, whereas 4-day old biofilms contained 
the highest concentration of eDNA in the outer parts of the stalks [149]. As a result of 
increased biofilm formation, an accumulation of DNA at infection sites is propagated. In 
cystic fibrosis (CF) patients, for example, a clearly increased DNA concentration [150] in 
lung secretions as well as reduced Mg2+-levels were measured.  
The most important effect of CSP is on cell survival: In the absence of CSP only 1% 
of all S. mutans in a biofilm are dead but after adding 5 μM of CSP more than 50% of the 
cells died. Cells dying in a biofilm make it possible for planktonic cells to attach to the 
structure. Thus, biofilm dispersal and differentiation is increased. Extracellular DNA, which is 
released after cell death, is the most important factor for intercellular connection in biofilms 
as well as for adhesion matrix formation [139]. eDNA, polysaccharides and proteins are 
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important components of the extracellular matrix whereas eDNA appears to be a critical 
element for structural stability and protection against antimicrobial agents [151]. Fragmented 
DNA is not able to increase biofilm mass production which means that DNA plays structural 
role for biofilm architecture development [151]. 
1.5.3 Pneumococcal biofilms 
The most important event in the pathogenesis of pneumococcal infection is the 
switch from planktonic life to biofilm production. [152]. Only bacteria in planktonic state of 
growth were able to induce bacteremia and death in mice. In contrast, biofilm bacteria only 
showed low levels in mice lungs and were not detectable in the blood. All of the biofilm-
infected mice were able to clear the infection successfully. But planktonic bacteria die much 
faster in mice than biofilm ones – the latter are able to remain alive for a long time. Mutants 
which lost the capacity of biofilm formation were shown to be out-competed in the 
nasopharynx of mice. Thus, no biofilms are required for invasive diseases but they are 
required for long-term colonization of the nasopharynx and as a result, for transmission of 
pneumococci from one host to another [140]. Patients suffering from chronic rhinosinusitis 
were shown to suffer from mixed biofilms also containing pneumococci on adenoid tissue 
and mucosal epithelial cells [153]. Colonized mice show pneumococcal biofilms on their 
nasal septa [154] and mutants which lost the capacity of biofilm formation were shown to be 
out-competed in the nasopharynx of mice [140]. But it was shown that pneumococci isolated 
from biofilms are not able to cause invasive diseases. This might be due to the reduced 
production of capsular polysaccharides (CPS), pneumolysin, choline binding protein A 
(CbpA), phosphorylcholine (ChoP) and pneumococcal serine-rich repeat protein (PsrP). 
There is evidence that biofilms are of main importance for long-term quiescent colonization 
[140]. Interestingly, pneumolysin is increased in pneumococcal biofilms compared to 
planktonic cultures and knockout mutants showed a reduced ability to form biofilms, mainly 
in the early phase (8-10h postinoculation) [155]. 
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1.5.3.1 Gene expression and mutations in biofilms 
  In pneumococcal biofilms, capsule expression seems to be down-regulated up to 
10-fold giving evidence for a variable modulation during adherence and sessile growth [156, 
157] and different types of colony morphologies are observed in vitro. Additionally to the 
normal-shaped pneumococci, more aggregative, hyperadherent, small, non-mucoid colonies 
are present. [158]. Interestingly, selection for small colony variants (SCVs) was shown for S. 
pneumoniae serotypes 3, 8 and 19 biofilms. SCVs are smaller in size, able to 
autoaggregate, less mucoid and deficient in capsule production. Under biofilm conditions 
SCVs show a selective advantage in growth. A random tandem duplication within the cps3D 
and cap8E genes was shown to be responsible for colony variation [159-161]. 
 
Comparing protein expression of biofilm and planktonic growth of S. uberis showed 
that in biofilms proteins important for adhesion, glutamine transport, internalization and sugar 
metabolisms are increased. A relatively large number of proteins, mainly involved in cell wall 
synthesis, cell division and metabolism, are down-regulated. A decrease in metabolic activity 
and thus in growth rate results. This process is increased as the biofilm ages (comparison of 
biofilms after 8 and 36h of growth) [162]. In Pseudomonas aeruginosa biofilms, only 40% of 
the proteins tested were similar to the ones found in planktonic growth, 60% were expressed 
over time.  But on DNA microarray technology only 1% of all genes were differentially 
expressed in planktonic and biofilm growth [144]. Genetic variation in biofilms is arises 
through mutation or recombination. Differences in gene expression often often due to 
stochastic responses of the individual bacteria [134]. Biofilm bacteria occur in a quiescent 
state. As a result, 32 genes encoding ribosomal proteins or translation initiation and 
elongation factors showed a reduced level during pneumococcal biofilm growth. Additionally, 
a reduction in 8 genes for the ATP synthase machinery was measured. Fatty acid 
metabolism and phospholipid biosynthesis also show lower levels. 8 genes of the capsule 
expressing CPS cassette were reduced as well. However, during biofilm growth, the 
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virulence factor pneumococcal serine-rich repeat protein (PsrP) was enhanced. PsrP is used 
as a host cell and intra-species bacterial adhesin which contributes to biofilm formation 
[140]. 
Gene or component / Species Function Reference 
brpA / Streptococcus mutans 
Surface-associated protein, involved in autolysis, 
stress tolerance and cell division regulation. 
Mutant: biofilm accumulation defects, low 
capacity of surface binding, longer chains, 
weakened acid tolerance. 
Wen et al. 2006 [163] 
recA / Streptococcus mutans 
Sensor for stress response (e.g.) to low pH and 
thus crucial protein for biofilm formation and 
regulation 
Inagaki et al. 2009 [164] 
ciaH / Streptococcus mutans Regulation of biofilm formation, mainly in sucrose Inagaki et al. 2009 [164] 
ComDE / Streptococcus mutans 
Quorum sensing signalling system, responding 
to peptide pheromone by inducing genetic 
competence 
Li et al. 2002 [165] 
hk11 / Streptococcus mutans Membrane-associated protein, pH sensor, important determinant of biofilm formation Li et al. 2002 [165] 
cps locus / Streptococcus pneumoniae 
Synthesis of capsule. If impaired, enhanced 
biofilm formation observed Qin et al. 2013 [166] 
cps3D / Streptococcus pneumoniae Capsule operon gene; capsule synthesis. If impaired, enhanced biofilm formation Allegrucci et al. 2007 [159] 
cap8E / Streptococcus pneumoniae 
Capsule operon gene; capsule synthesis. If 
impaired, enhanced biofilm formation Waite et al. 2003 [160] 
lytA / Streptococcus pneumoniae Cell wall hydrolase. If impaired, 20% reduction in biofilm formation Moscoso et al. 2006 [55] 
lytB / Streptococcus pneumoniae 
Cell wall hydrolase. If impaired, 45% reduction in 
biofilm formation. Moscoso et al. 2006 [55] 
lytC / Streptococcus pneumoniae Cell wall hydrolase. If impaired, 25% reduction in biofilm formation Moscoso et al. 2006 [55] 
Peptidoglycane breaks / Lactococcus lactis Positive correlation between peptidoglycane 
breaks and biofilm formation 
Mercier et al. 2002 [167] 
eDNA / Streptococcus pneumoniae 
Spontaneously released into environment, 
important component. Significantly reduced 
biofilm formation when DNase I is added. 
Moscoso et al. 2006 [55] 
cbpA / Streptococcus pneumoniae Critical for colonization Mutant: reduced binding opportunities 
Blanchette-Cain et al. 
2013 [168] 
luxS / Streptococcus pneumoniae 
Important for biofilm formation in vitro; important 
in quorum sensing system. 
Mutant: blocking of bacterial communication, 
biofilm phenotype cannot be formed 
Vidal et al 2013 [169] 
pspR / Streptococcus pneumoniae 
Adhesin for intraspecies aggregation; biofilm 
formation increased by homodimerization of 
pneumococci; binding to cytokeratin 10 on host 
cells 
Mutant: dramatically reduced biofilm formation in 
vivo 
Blanchette-Cain et al. 
2013 [168] 
spxB / Streptococcus pneumoniae 
Hydrogen peroxide production; trigger of 
autolysis 
Mutant: reduced biofilm formation 
Blanchette-Cain et al. 
2013 [168] 
 
Table 7: Genes and components involved in increased biofilm formation. 
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1.5.4 Biofilm formation in clinics 
In more than half of all infectious diseases commensal bacteria are involved and they 
often grown in biofilms [138]. Due to their reduced metabolic state, these bacteria only cause 
very little systemic response and are able to persist for longer time periods [170]. Chronic 
otitis media as well as chronic rhinosinusitis both are linked to biofilm formation. On the 
epithelium of the middle-ear biofilm aggregates of S. pneumoniae, H. influenzae and M. 
catarrhalis were observed [131, 170]. But also 54% of all tonsils removed from children 
showed biofilm formation [171] with biofilms mainly occurring within crypts of tonsils. In some 
cases, the biofilms grew to a thickness of several millimetres, and Gram-positive cocci were 
the predominant species [172]. There is evidence that pneumococcal biofilms are an 
important factor for chronic middle ear effusion. Isolates taken from the middle ear are better 
in biofilm formation when they are cultured compared to blood isolates [156]. An additional 
factor responsible for chronic otitis media are intracellularly persisting bacteria [27].  
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Infection or disease Common biofilm bacterial speices 
Dental caries Acidogenic Gram-positive cocci (e.g. Streptococcus) 
Periodonitis Gram-negative anaerobic oral bacteria 
Otitis media Nontypable strains of Haemophilus influenzae 
Musculoskeletal infections Gram-positive cocci (e.g. staphylococci) 
Necrotizing fasciitis Group A streptococci 
Bilary tract infection Enteric bacteria (e.g. Escherichia coli) 
Osteomyelitis Various bacterial and fungal species – often mixed 
Bacterial prostatitis E. coli and other Gram-negative bacteria 
Native valve endocarditis Viridans group streptococci 
Cystic fibrosis pneumonia Pseudomonas aeruginosa and Burkholderia cepacia 
Meloidosis Pseudomonas pseudomallei 
Nosocomial infections 
    ICU (Intensive care unit) pneumonia Gram-negative rods 
    Sutures Staphylococcus epidermidis and S. aureus 
    Exit sites S. epidermidis and S. aureus 
    Arteriovenous shunts S. epidermidis and S. aureus 
    Schleral buckles Gram-positive cocci 
    Contact lens P. aeruginosa and Gram-positive cocci 
    Urinary catheter cystitis E. coli and other Gram-negative rods 
    Peritoneal dialysis  peritonitis A variety of bacteria and fungi 
    IUDs (Intra uterine Device) Actinomyces israelii and many others 
    Endotracheal tubes A variety of bacteria and fungi 
    Hickman catheters S. epidermidis and C. albicans 
    Central venous catheters S. epidermidis and others 
    Mechanical heart valves S. aureus and S. epidermidi 
    Vascular grafts Gram-positive cocci 
    Biliary stent blockage A variety of enteric bacteria and fungi 
    Orthopedic devices S. aureus and S. epidermidis 
    Penile prostheses S. aureus and S. epidermidis 
 
Table 8: Infectious diseases produced by biofilm forming bacteria (from [138] 
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2. Aims of this thesis 
 
Three main areas were of interest in this thesis. 
 
2.1 The role of capsule and pneumolysin in the immune response in the respiratory 
tract 
2.1.1 The pneumococcal polysaccharide capsule and pneumolysin differentially affect 
CXCL8 and IL-6 release form cells of the respiratory tract 
This is a study of the role of pneumococcal capsule in pro-inflammatory cytokine induction 
using human pharyngeal and bronchial epithelial cells as well as in a murine model of 
nasopharyngeal colonization. 
Hypotheses: 
a) Pneumococcal capsule plays a role in the regulation of innate immune responses in 
the respiratory tract  
b) Pneumolysin stimulates the release of the pro-inflammatory cytokines CXCL8 and IL-
6 from respiratory tract cells in vitro and in vivo. 
Aims:  
a) To determine the effect of capsule on release of CXCL8 and IL-6 from respiratory 
tract cells using isogenic pneumococci mutants with and without capsule  
b) To determine the effect of pneumolysin on release of CXCL8 and IL-6 from 
respiratory tract epithelial cells using isogenic mutants. 
c) To determine whether any effects observed in vitro are also seen in vivo in a murine 
model of intranasal colonization. 
d) To determine whether encapsulation affects dissemination of the pneumococci in the 
murine model. 
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Strategy: To test the effect of an S. pneumoniae serotype 2 strain (D39) and its isogenic 
mutants D39cps-, D39ply- and D39cps-ply- as well as a naturally nonencapsulated clinical 
isolate (110.58) and its isogenic encapsulated mutant 110.58::D39cps on CXCL8 and IL-6 
release from the human pharyngeal epithelial cell line Detroit 562 and the human bronchial 
epithelial cell line iHBEC. Also, to study CXCL8 release induced by these strains and 
bacterial dissemination in a murine model of nasopharyngeal colonization.  
 
2.1.2 Immunological cells and immune regulation 
The focus of this study is on comparing encapsulated and non-encapsulated pneumococcal 
strains with the same background with respect to invasiveness and immunological response 
in a murine nasopharyngeal colonization model. 
Hypotheses: 
a) IL-10 secreted by FoxP3+ regulatory T-cells is induced by nasopharyngeal 
colonization in a murine model and depends on pneumococcal strain 
b) Nasopharyngeal colonization increases FoxP3+ regulatory T-cell numbers in the 
nasal mucosa. 
c) Lung infiltration results in increased levels of CD45+ cells, macrophages and 
neutrophils in the nasal mucosa. 
Aims: 
a) To test whether dissemination of pneumococci to the lungs is associated with 
changes in numbers of CD45+ cells (leukocytes), F4/80+ cells (macrophages) and 
Gr-1+ cells (neutrophils). 
b) To test the effect of nasopharyngeal colonization on numbers of FoxP3+ regulatory 
T-cells, CD3+ T-cells and levels of IL-10 in the nasal mucosa. 
46
  Aims of this thesis 
_______________________________________________________________________________________________________________________________________ 
Strategy: To test the effect of the pneumococcal strains described in Aim 1 plus strain 
106.66 (serotype 6B) on immune cell induction in a murine nasopharyngeal colonization 
model by quanitifying CD45+ cells, F4/80+ cells Gr-1+ cells, CD3+ T-cells and FoxP3+ 
regulatory T-cells in the nasal mucosa and the amount of secreted IL-10 in the nasopharynx. 
 
 
2.2 Investigating host innate immune responses to Respiratory Syncytial Virus and 
Streptococcus pneumoniae: co-stimulation in vitro model of human airway epithelial 
cells 
This study is focused on pneumococcal/RSV co-infections on bronchial epithelial cells in 
vitro to gain new information on the influence of co-stimulation on innate immune responses. 
Hypotheses: 
a) RSV and pneumococcus act synergistically on CXCL8 and IL-6 induction in 
respiratory epithelial cells 
b) CXCL8 release is affected by the presence pneumolysin and capsule in the 
pneumococcus. 
c) The synergistic effect differs according to whether epithelial cells are exposed first to 
the bacteria or to the virus. 
Aims: To test whether: 
a) Co-stimulation of the human bronchial epithelial cell line BEAS-2B with RSV and 
pneumococcus results in increased CXCL8 and IL-6 levels. 
b) Differences in IL-6 and CXCL8 response occur when bronchial cells are either 
primed with RSV or with pneumococcus or whether both pathogens are added 
together. 
c) Encapsulated pneumococci result in different levels of IL-6 and CXCL8 secretion 
than non-encapsulated. 
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d) A pneumolysin-secreting strain increases CXCL8 levels in co-stimulation with RSV 
compared to a non-pore forming pneumolysin mutant. 
e) Increasing free pneumolysin concentrations results in increased CXCL8 secretion in 
pneumolysin/RSV co-stimulations. 
Strategy: Test mono- and co-stimulation with RSV and pneumococcus on the human 
bronchial epithelial cell line BEAS-2B in vitro. Pneumococcal strain D39 and its isogenic 
mutants PLN-A (expressing non-pore forming pneumolysin) and R36A (non-encapsulated) 
will be used to investigate the role of pneumolysin and capsule on CXCL8 and IL-6 release 
in co-stimulations with RSV. Different concentrations of free pneumolysin and a PdB (non-
pore forming pneumolysin) will be used to investigate their effect on CXCL8 and IL-6 
release. 
 
2.3 Biofilm formation of S. pneumoniae and commensal streptococci 
2.3.1 Differences of initial biofilm formation among pneumococcal serotypes 
The goal of this study is to investigate differences in initial biofilm forming behaviour among 
typical invasive compared to colonizing pneumococcal serotypes  
Hypotheses: 
a) Pneumococcal serotypes differ in their ability to initial biofilm formation  
b) Serotypes differ in their propensity to form small colony variants (SCV) in biofilms  
c) Serotypes differ in their ability to adapt to a change in the nutritional environment 
Aims:  
a) To compare the initial attachment of different pneumococcal serotypes under 
different growth conditions (carbon sources). 
b) To compare biofilm quantity and structural composition between serotypes. 
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c) To compare adaptation to different nutritional environments between serotypes by 
comparing their ability to adjust the proportion of SCVs (over time). 
Strategy: To investigate the impact of carbon source on biofilm formation, chemically defined 
medium (CDM) supplemented with either 5 mM glucose or 5 mM galactose will be used in a 
static biofilm model. Pneumococcal serotypes 6B and 7F, which differ significantly in their in 
vitro growth behaviour, will be used to study the impact of capsule type on biofilm formation. 
Differences in numbers of living cells in biofilms and SCVs will be analyzed over time. To 
study their adaptation to a change in the nutrient environment SCVs of both serotypes will be 
grown in different media and FITC-Dextran imaging used to determine whether SCVs 
remained stable after growth in a complex medium. Whole genome sequencing of a wild-
type and a SCV 7F clone will be performed to understand how SCVs are produced. 
 
2.3.2 Interactions between commensal streptococcal strains and S. pneumoniae serotypes 
The main focus of this study will be on nutrient competition and the influence of commensal 
streptococcal strains on pneumococcal biofilm formation and vice versa. 
Hypotheses: 
a) Competition for nutrients occurs in mixed cultures of S. pneumoniae with commensal 
streptococci S. pseudopneumoniae, S. mitis or S. oralis. 
b) Commensal streptococci and pneumococcus influence one another in initial biofilm 
formation.  
Aims: 
a) To compare initial biofilm formation of S. oralis, S. pseudopneumoniae, S. mitis and 
S. pneumoniae in monoculture 
b) To determine the impact of carbon source on initial monocultural biofilm formation of 
S. oralis, S. pseudopneumoniae, S. mitis and S. pneumoniae 
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c) To study initial biofilm formation in mixed cultures of S. pneumoniae with S. oralis, S. 
mitis or S. pseudopneumoniae and to determine differences to monocultural growth 
d) To study the effect of carbon source competition on S. pneumoniae with S. oralis, S. 
mitis or S. pseudopneumoniae 
Strategy: A chemically defined medium (CDM) supplemented with either 5 mM glucose or 5 
mM galactose will be used and monoculture as well as mixed culture biofilm growth of S. 
pneumoniae with S. oralis, S. mitis and S. pneumoniae strains will be analyzed in planktonic 
growth as well as using a static biofilm model. 
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3. The role of pneumococcal capsule and pneumolysin in the 
immune response in the respiratory tract 
 
 
 
3.1 Submitted manuscript 
The pneumococcal polysaccharide capsule and pneumolysin differentially affect 
CXCL8 and IL-6 release from cells of the upper and lower respiratory tract 
Eliane Küng, William R. Coward, Daniel R. Neill, Hesham A. Malak, Kathrin Mühlemann, 
Aras Kadioglu, Markus Hilty and Lucy J. Hathaway 
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Abstract 22 
The polysaccharide capsule and pneumolysin toxin are major virulence factors of the 23 
human bacterial pathogen Streptococcus pneumoniae. Colonization of the nasopharynx is 24 
asymptomatic but invasion of the lungs can result in invasive pneumonia. Here we show that 25 
the capsule suppresses the release of the pro-inflammatory cytokines CXCL8 (IL-8) and IL-6 26 
from the human pharyngeal epithelial cell line Detroit 562. Release of both cytokines was 27 
much less from human bronchial epithelial cells (iHBEC) but levels were also affected by 28 
capsule. Pneumolysin stimulates CXCL8 release from both cell lines. Suppression of CXCL8 29 
release by the capsule was also observed in vivo during intranasal colonization of mice but 30 
was only discernable in the absence of pneumolysin. 31 
 When pneumococci were administered intranasally to mice in a model of long term, 32 
stable nasopharyngeal carriage, encapsulated S. pneumoniae remained in the nasopharynx 33 
whereas the nonencapsulated pneumococci disseminated into the lungs.  34 
Pneumococcal capsule plays a role not only in protection from phagocytosis but also 35 
in modulation of the pro-inflammatory immune response in the respiratory tract. 36 
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Introduction 37 
Two of the main virulence factors of Streptococcus pneumoniae are the 38 
polysaccharide capsule that surrounds most S. pneumoniae strains and the toxin 39 
pneumolysin [1]. It has been shown that pneumolysin can stimulate the innate immune 40 
response including release of the inflammatory cytokine CXCL8 from the host’s airway 41 
epithelial cells [2-4]. 42 
The pneumococcal capsule is mainly composed of polysaccharides, with each 43 
capsule type having a different composition and linkage of the sugars and other components 44 
[5]. S. pneumoniae is classified into over 90 different serotypes on the basis of antibody 45 
reactions with the capsule [6-9]. Some serotypes frequently colonize the human 46 
nasopharynx asymptomatically whereas others are more associated with invasive diseases 47 
such as pneumonia, sepsis or meningitis, but are found less frequently in the nasopharynx 48 
because they colonize for a shorter duration [10-12]. 49 
Epithelial cells express pattern-recognition receptors (PRRs) that are required to 50 
signal the presence of pathogens and to recruit and activate professional antigen presenting 51 
cells such as macrophages or dendritic cells [13]. Numerous pro-inflammatory chemokines 52 
and cytokines are secreted such as CXCL8, IL-6, IL-1β, granulocyte-macrophage colony 53 
stimulating factor (GM-CSF), transforming growth factor (TGF) α and –β [14]. Secretion of 54 
cytokines tends to be a brief, self-limited event with synthesis beginning with gene 55 
transcription and mRNA having a short half-life [15]. 56 
Toll-like receptors (TLRs) 2-6 are expressed on airway epithelial cells. TLR2 is the 57 
principal receptor for recognition of bacterial components (e.g. lipoprotein, lipoteichoic acid, 58 
peptidoglycan, GPI anchor) and some viral envelope proteins [16]. TLR signaling in epithelial 59 
cells is not only important for microbial defence but also for mucosal homeostasis which is 60 
determined by the magnitude of signaling [13]. CXCL8 plays a major role in the initial control 61 
of respiratory tract infection due to its chemotactic activity for neutrophils and monocytes [17] 62 
and can be secreted by all cells which have TLRs [18].  63 
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In the current study we tested the role of the pneumococcal capsule in pro-64 
inflammatory cytokine induction using human pharyngeal and bronchial epithelial cells and in 65 
a murine model of nasopharyngeal colonization. We also looked at the effect of the capsule 66 
on the ability of the bacteria to disseminate into the lungs following nasopharyngeal 67 
colonization. 68 
69 
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Materials and Methods 70 
Bacteria 71 
The bacterial wild type and mutants strains used are listed in Table 1. The capsule 72 
mutants were constructed according to the protocols described previously [9,19]. D39 strain 73 
was kindly provided by Professor Jeffrey Weiser (University of Pennsylvania, USA). The 74 
pneumolysin mutant was a kind gift from Professor Jeremy Brown (University College 75 
London, UK) [20]. For the construction of D39cps-ply- mutant, the D39cps- mutant was used 76 
and mutant construction performed according to the method described previously [21]. 77 
Briefly, the up- and downstream flanking regions of the pneumolysin-gene were amplified 78 
using iProof polymerase (Bio-Rad, Switzerland) using the following primers: upstream 79 
forward primer KO_Ply_us_F 5’-GATTGATAATACCAGCACTC-3’, upstream reverse primer 80 
KO_Ply_us_R  5’-GGTAGAGGATAAGGTAG-3’, downstream forward primer KO_Ply_ds_F 81 
5’-ATCGTAATTCATAGCTAG-3’ and downstream reverse primer KO_Ply_ds_R. PCR 82 
conditions were:  98°C for 30 sec, 35 cycles of 98°C for 10 sec, 55°C for 15 sec, 72°C for 20 83 
sec and then 72°C for 10 min. PCR, using the same conditions, was also performed to 84 
amplify a spectinomycin cassette from the plasmid. The primers (us_Ply_Spec_F1 5’-85 
CTAGCTATGAATTACGACTAGTGGATCCCCCGTTTGA-3’ and Spec_ds_Ply_R1 5’-86 
CTACCTTATCCTCTACCATAGTTCCCTTCAAGAGCGATACC-3’) were designed to create 87 
overhangs which allowed fusion of the three PCR products as described elsewhere [22]. The 88 
fusion reaction, using Phusion High Fidelity Polymerase (Fisher Scientific, Switzerland), was: 89 
98°C for 1 min, 10 cycles of 98°C for 10 sec, 50°C for 15 sec, 72°C for 1 min then the 90 
primers (KO_Ply_us_F and KO_Ply_ds_R) were added followed by 25 cycles of 98°C for 10 91 
sec, 62°C for 15 sec, 72°C for 2 min 30 sec and then 72°C for 10 min. The amplified 92 
construct was then isolated from a 1% agarose gel. After transformation, clones were 93 
selected on CSBA plates supplemented with 200 µg/ml spectinomycin [23]. Incubation was 94 
performed under anaerobic conditions. Knockout of the pneumolysin gene was confirmed by 95 
PCR and by sequencing using primers KO_Ply_us_F and KO_Ply_ds_R using the following 96 
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conditions: 98°C for 30 sec, 35 cycles of 98°C for 10 sec, 55°C for 15 sec, 72°C for 1 min 15 97 
sec followed by 72°C for 10 min [24]. 98 
Bacteria were plated on Columbia sheep blood agar (CSBA) plates and incubated 99 
overnight at 37˚C and 5% CO2. Liquid cultures of bacteria were prepared using either 5 ml of 100 
Chemically Defined Medium (CDM) [25] supplemented with 50 mM of filter-sterilized sucrose 101 
or 5 ml of Brain Heart Infusion (BHI) broth. Bacteria were grown to mid-log phase, meaning 102 
to OD600 of 0.1 to 0.2 in CDM and to OD600nm of 0.5 to 0.8 in BHI, and then counted in a 103 
Neubauer chamber. The bacteria were pelleted, washed twice with pyrogen-free PBS then 104 
resuspended in 1 ml Eagle’s minimum essential medium (MEM; Invitrogen, Basel, 105 
Switzerland) without FCS and warmed in a water bath to 37˚C. 106 
Epithelial cell culture, exposure to pneumococcus and cytokine assays 107 
The human pharyngeal epithelial cell line Detroit 562 (ATCC CCL 138) was cultured 108 
as published earlier in MEM supplemented with 10% of heat-inactivated fetal calf serum 109 
(FCS), 2mM of L-glutamine (Invitrogen, Basel, Switzerland), 1% sodium bicarbonate 110 
(Invitrogen, Basel, Switzerland), 1x MEM non-essential amino acid solution (Sigma, St. 111 
Louis, MO, USA), 1mM sodium pyruvate (Sigma, St. Louis, MO, USA), 100 μg/ml 112 
streptomycin and 100 U/ml penicillin at 37˚C in 5% CO2 [26]. Cells were grown in 24-well 113 
plates to a confluent cell layer (≈3x105 cells per well). MEM containing the bacteria at three 114 
CFU concentrations (1, 1.5 and 2 x 106) were added to the Detroit 562 cells and the plates 115 
centrifuged at 173 g for 5 min at 25˚C.  After 24 h of incubation at 37˚C and 5% CO2 116 
supernatants from the wells were collected in Eppendorf tubes, spun down at 132 g for 3 min 117 
at room temperature, and then stored at -80˚C until further use. 118 
Immortalised human bronchial epithelial cells (iHBEC) were kindly provided by 119 
Professor Jerry W. Shay, (University of Texas, Dallas, USA). The iHBECs were grown in 120 
Keratinocyte serum-free media (Invitrogen) supplemented with epidermal growth factor and 121 
bovine pituitary extract. All cells were grown and experimented upon in humidified 5% CO2, 122 
95% humidity air at 37°C, in the absence of antibiotics. Confluent iHBECs monolayers were 123 
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grown in 24 well plates and incubated in serum-free media for 18h prior to investigation.  124 
Unstimulated cells were used as controls. Cells were cultured in 24 well cell culture plates 125 
for 24h with medium or live S. pneumoniae. After incubation, culture supernatants were 126 
collected, centrifuged at 10 000 g for 5 minutes to remove cellular debris and filter sterilized 127 
and stored at -80°C until assayed. 128 
The amounts of CXCL8 and IL-6 were measured by ELISA (R&D systems ELISA 129 
kits, Abingdon, United Kingdom). 130 
Mouse model 131 
Ethics statement 132 
All animal experiments were performed at the University of Liverpool and with prior 133 
approval from the UK Home Office and the University Ethics Committee. 134 
Age-matched 8-12 week old female MF1 mice (Charles River, UK) were intranasally 135 
infected with 1 x 105 colony forming units of S. pneumoniae in 10 µl PBS as previously 136 
described [27]. Mice were sacrificed at pre-determined time points post-infection and organs 137 
removed for assessment of bacterial numbers and ELISA analysis.  Nasopharynx and lungs 138 
were homogenized in PBS and serially diluted onto blood agar for enumeration of bacterial 139 
numbers by the Miles and Misra method.  Homogenates were retained for use in ELISA.   140 
Statistics 141 
Student t test was used to assess the significance of the results. 142 
143 
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Results and Discussion 144 
We investigated the effect of capsule on CXCL8 and IL-6 induction in cells of the 145 
upper and lower respiratory tract using wild type S. pneumoniae serotype 2 (strain D39) and 146 
its capsule-deleted mutant. In addition, we compared the naturally occurring 147 
nonencapsulated clinical isolate 110.58 with its mutant in which the capsule of D39 has been 148 
inserted. Furthermore, D39 mutants in which pneumolysin alone was deleted or both 149 
pneumolysin and capsule were deleted were tested to investigate the role of capsule in the 150 
presence or absence of toxin (see Table 1 for bacterial wild type and mutant strains).   151 
Deletion of capsule from D39 caused a small, but non-significant, increase of CXCL8 152 
from the upper respiratory tract cells and insertion of the D39 capsule into strain 110.58 153 
significantly decreased CXCL8 levels (p = 0.04) (Figure 1A). Deletion of pneumolysin 154 
significantly decreased CXCL8 compared to wild type control (p = 0.0009) but CXCL8 levels 155 
increased when the capsule was additionally deleted when compared to pneumolysin 156 
deletion alone (p = 0.0036). The same pattern was seen for IL-6 but the cytokine 157 
concentrations were lower and not significantly different between cells exposed to different 158 
strains (Figure 1B). For the bronchial epithelial cells, deletion of capsule in D39 caused a 159 
decrease in CXCL8 (p < 0.0001) but insertion of D39 capsule in strain 110.58 also caused a 160 
decrease in CXCL8 (p < 0.0001) (Figure 1C). These responses were in contrast to upper 161 
respiratory cells indicating a clear niche difference in host responses to pneumococcal 162 
capsule. Deletion of pneumolysin in D39 decreased CXCL8 levels in keeping with the 163 
response of upper respiratory cells (p < 0.0001), however CXCL8 was only slightly increased 164 
upon the additional deletion of the capsule (p < 0.0001) once again indicating a capsule-165 
dependent difference in upper versus lower respiratory tract responses. IL-6 values were low 166 
with no difference between D39 and its capsule-deficient mutant but with levels reduced by 167 
insertion of the capsule into strain 110.58 (p = 0.0002). Deletion of pneumolysin increased 168 
IL-6 level (p < 0.0001) but additionally deleting the capsule reduced the level (p < 0.0001) 169 
(Figure 1D). 170 
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Overall, capsule restricted the release of CXCL8 from respiratory tract epithelial cells 171 
in contrast to pneumolysin, which stimulated the release of CXCL8.  172 
No significant difference in cytotoxicity or haemolytic activity was observed between 173 
the encapsulated or nonencapsulated pneumococci (data not shown).   174 
 Having found that the capsule plays an important role in regulating CXCL8 induction 175 
in vitro, we next tested the influence of the capsule in a mouse model of nasopharyngeal 176 
carriage. Figure 2 shows that no difference in CXCL8 levels were detected between 177 
encapsulated or nonencapsulated strains in the nasopharynx and that deletion of 178 
pneumolysin did not have a measurable effect either. Importantly however, when the 179 
capsule was additionally deleted in the pneumolysin mutant, CXCL8 level increased (p = 180 
0.05) supporting the in vitro finding that capsule suppresses CXCL8 release but that this 181 
effect may be masked by the presence of pneumolysin. 182 
Interestingly, in vivo bacterial kinetics showed that, while the presence or absence of 183 
capsule did not appear to affect the ability of the pneumococcus to colonize the 184 
nasopharynx, only nonencapsulated pneumococci disseminated from the nasopharynx to 185 
the lungs (Figure 3) suggesting that the absence of capsule is important in facilitating 186 
pneumococcal movement from the nasopharynx to the lungs. Although nonencapsulated 187 
strains are expected to adhere to epithelial cells more efficiently than encapsulated strains, 188 
we did not detect higher numbers of nonencapsulated strains than encapsulated colonizing 189 
the nasopharynx.  190 
The capsule is an important virulence factor as the thick polysaccharide layer helps 191 
the bacteria to escape opsonization and phagocytosis [28]. Encapsulation of the 192 
pneumococcus protects from complement activation. IgG and c-Adenosyl-monophosphate 193 
receptor protein (CRP) binding to the bacterial surface are reduced and thus activation of the 194 
classical pathway is impaired. Additionally, the degradation of C3b to iC3b is decreased by 195 
the capsule and phagocytosis by Fcγ receptor occurs less frequently [29]. Therefore, innate 196 
immunity initiated by encapsulated bacteria that causes macrophages and neutrophils to 197 
enter the nasopharynx as a result of chemotactic activity of CXCL8 will then not lead to 198 
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efficient opsonophagocytosis of the bacteria due to the polysaccharide capsule. Here we 199 
suggest that restriction of the initial step of CXCL8 release from the epithelial cells by the 200 
polysaccharide capsule may also contribute to bacterial survival. 201 
There has been a recent study which also investigated the innate immune response 202 
due to Streptococcus pneumoniae in epithelial cells and which did not find a clear difference 203 
between wildtype strains and their capsule knock out mutants in terms of CXCL8 induction 204 
[30]. However, this group used microarrays to characterize the in vitro transcriptional 205 
response whereas here we have detected CXCL8 itself both in vitro and in a mouse model 206 
of nasopharyngeal colonization. Another group, like us, found greater CXCL8 production in 207 
response to nonencapsulated pneumococci than their encapsulated parent strains [31].  208 
In conclusion, we find that the pneumococcal capsule plays an important role in 209 
regulation of innate immunity by reducing CXCL8 release from upper respiratory tract cells 210 
and also by restricting pneumococcal dissemination into the lower respiratory tract, where 211 
the pneumococcus would normal elicit a strong pro-inflammatory response leading to its 212 
clearance. We would argue that this is in keeping with the natural role of the pneumococcus 213 
as a commensal of the upper respiratory tract, whereby its primary function is to establish 214 
colonization with limited or no host inflammation to sustain its longer term survival in the 215 
nasopharynx without host mediated clearance. 216 
 217 
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Table 1 316 
 317 
Strain Description Capsule Pneumolysin 
D39 Wild type serotype 2 + + 
D39cps- Mutant lacking capsule [32] - + 
D39ply- Mutant lacking pneumolysin [20] + - 
D39cps-ply- Mutant lacking both capsule and 
pneumolysin (current study) 
- - 
110.58 Wild type nonencapsulated [33]  - + 
110.58::D39cps Mutant with serotype 2 capsule [19] + + 
 318 
319 
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Figure legends 320 
Figure 1: Effect of capsule and pneumolysin on CXCL8 and IL-6 induction in human 321 
nasopharyngeal and bronchial epithelial cells. Detroit 562 nasopharyngeal epithelial cells 322 
(A and B) and bronchial epithelial cells (C and D) were assessed for CXCL8 (A and C) and 323 
IL-6 (B and D) release after exposure to wild type or mutant pneumococcal strains. All 324 
experiments were performed in triplicate at each of three CFU concentrations (1, 1.5 and 2 x 325 
106) and the results pooled for each strain. Error bars indicate SEM. * indicates significant 326 
difference from value of the parent strain. 327 
 328 
Figure 2: Effect of capsule and pneumolysin on CXCL8 induction in the mouse 329 
nasopharynx. CXCL8 detected in nasopharyngeal homogenate of mice three days after 330 
exposure to wild type or mutant pneumococci expressed as a percentage of the value 331 
obtained with the wild type strain. Error bars indicate SEM. * indicates significant difference 332 
from value of the parent strain. 333 
 334 
 335 
Figure 3: Capsule did not affect colonization of the nasopharynx but only 336 
nonencapsulated strains reached the lungs. Each symbol represents the CFU from the 337 
nasopharynx or lungs of an individual mouse on days 0, 1, 3, 8 and 15 after intranasal 338 
inoculation. Horizontal bars indicate means. 339 
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3.2 Immunological cells and immune regulation 
Immunological cells and immune regulation in a mouse model of pneumococcal 
nasopharyngeal carriage 
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Immunological cells and immune regulation 
 
Abstract  
Immune responses against encapsulated and non-encapsulated pneumococcal 
strains were tested in a murine carriage model. Leukocytes, neutrophils, macrophages, 
regulatory T-cells and Interleukin-10 response were measured over 15 days of infection. 
Pneumococcal colonization of the mouse nasopharynx mainly remains asymptomatic. The 
encapsulated S. pneumoniae strains D39 (serotype 2) and the mutant strain 110.58::D39cap 
(serotype 2), which remained in the murine nasopharynx, resulted in an increase in FoxP3+ 
regulatory T-cells and IL-10 in the nasal mucosa. However, the strains 106.66 (serotype 6B), 
110.58 (non-encapsulated) and the mutant strain D39cps- (non-encapsulated), which 
infiltrated the lungs, resulted in a stronger immune response with increased numbers of 
neutrophils, macrophages and leukocytes measured at 8 and 15 days after infection in the 
nasal mucosa. For strain 106.66, where infiltration of the lungs was recorded on day 8, a 
reduction in bacterial numbers in the lungs as well as in the nasopharynx was measured on 
day 15 indicating that immune cells stimulated in the lungs also attained access to the 
nasopharynx and that clearance of the infection had begun at both sites. 
Introduction 
Streptococcus pneumoniae (the pneumococcus) is a Gram-positive, strictly human 
pathogen. Two of the main pneumococcal virulence factors are pneumolysin (Ply) and the 
anti-phagocytic capsule, which most S. pneumoniae strains possess [1]. Ply is the major 
toxin of S. pneumoniae and its targets cholesterol-containing membranes of eukaryotic cells. 
Ply has been demonstrated to be necessary and sufficient for airway epithelium activation 
[2]. This process occurs independently of TLR4 as membrane pores are created by Ply 
which leads to an increased spread of pneumococcal components to the cytoplasm of the 
host epithelial cells. Inside the cells these components then are capable of stimulating innate 
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immune responses [2]. The pores created by pneumolysin might allow an increased release 
of CXCL8 [3].  
Colonization of the human nasopharynx by S. pneumoniae generally occurs 
asymptomatically and transiently [4, 5]. Colonization might be followed by invasive disease 
leading to sepsis, meningitis, pneumonia, or non-invasive mucosal infection such as acute 
otitis media [6]. Children younger than six years, elderly and immunosuppressed people are 
at increased risk [7]. Regulatory T-cells, including FoxP3+ cells, were shown to play an 
important role in preventing immunopathological effects, but they are also responsible for the 
inhibition of protective immunity which might result in prolonged infections and chronicity [8, 
9]. Children colonized by pneumococcus showed significantly higher numbers of regulatory 
T-cells in their adenoids, but not in the peripheral blood, compared to non-colonized children. 
Regulatory T-cells are increased in number by local colonization with S. pneumoniae which 
results in delayed clearance and/or nasopharyngeal carriage [8]. In the lungs FoxP3+ 
regulatory T cells secrete IL-10 which results in a reduction of immunological reactivity during 
infection and limits the tissue damage [10]. In the early postnatal period, pneumococcal 
nasopharyngeal carriage resulted in an increase of IFN-γ and IL-10 response resulting in 
protection against pneumococcal infections but increasing the high rate of pneumococcal 
persistence in this age group [11]. In a recent study, specificity of regulatory T-cells for 
pneumococcal pneumolysin in tonsillar populations was shown indicating a role for these 
cells in the suppression of CD4+ T-cell responses to S. pneumoniae. Interestingly, the 
amount of pneumococcal-specific regulatory T-cells was much lower in the peripheral blood 
than in the tonsils [12]. 
As soon as S. pneumoniae leaves the nasopharynx and invades the lungs, local 
inflammatory responses are observed resulting in a massive infiltration of neutrophils and 
monocytes/macrophages [13] Neutrophils are one of the primary mediators of early defense 
[10].  Interestingly, also T-cells seem to play an important role in the earliest stages of 
pneumococcal immunity as bacterial growth in the lungs coincides with T-cell infiltrations into 
the lungs and a subsequent decrease in pneumococcal growth [14]. Thus, neutrophil 
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infiltration is followed by an increase of macrophages and lymphocytes. In a next step, 
induction of apoptosis of neutrophils and other recruited cells is started where the surface 
membranes stay intact and macrophages can clear these cells without spreading potential 
injurious contents. In a last step, macrophage apoptosis is induced [13, 15].  
Material and Methods 
Bacterial strains and growth conditions 
 The S. pneumoniae strains used to test immunological response in a stable 
nasopharyngeal carriage model are listed in Table 1. 
 Brain Heart Infusion (BHI) broth (Becton and Dickinson and Company, le Pont de 
Claix, France) alone own or supplemented with 20% Fetal Calf serum (FCS) (Biochrom KG, 
Berlin, Germany) was used for growth. Bacteria were plated onto Columbia Sheep Blood 
Agar (CSBA) plates and incubated overnight at 37°C in a microaerophilic milieu. As a quality 
control, optochin sensitivity was tested by placing an optochin disc onto the plate. The next 
day, a sweep of colonies was inoculated into 10 ml BHI broth and incubated statically for 16-
18h at 37°C until OD500 reached 1.4. The tubes were then centrifuged at 1500xg for 15 
minutes at room temperature, and the supernatant was discarded using a sterile Pasteur 
pipette. The pellet was resuspended in 1 ml BHI broth (80% v/v BHI broth and 20% v/v 
filtered FCS). 700 µl of the re-suspended pellet was added to 10 ml fresh BHI serum broth 
and incubated statically at 37°C for 5h. The cultures were then divided into 500 µl aliquots 
and frozen at -80°C. After aliquots had been at -80°C for longer than 24h, the viability was 
tested and absence of contamination checked by plated out the bacteria on CSBA plates. To 
measure colony forming unit (CFU) counts of frozen aliquots, serial dilutions were performed 
and plated out onto CSBA plates. After overnight incubation at 37°C under microaerophilic 
conditions, CFUs were counted. To inoculate animals, CFU counts were adjusted to 2x105 
CFUs/10µl using phosphate buffered saline (PBS).  
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Mouse strains 
 As a model of pneumococcal carriage outbred, female MF1 mice (Charles River, UK) 
were used at an age of 8-12 weeks.  
Carriage model 
 The murine carriage model has been published previously [16]. In brief, mild 
anesthesia was used (2.5% v/v Isofluorane USP (Isocare) over oxygen (1.4-1.6 litres/min) to 
inoculate the required CFU counts into the mice. 10 µl of sterile PBS containing 2x105 S. 
pneumoniae CFU counts were distributed between both nostrils. Groups of 4 mice were 
sacrificed on days 1, 3, 8 and 15 after inoculation by cervical dislocation. Nasopharyngeal 
tissue, cervical lymph nodes, nasal mucosa and the lungs then were dissected and placed 
into PBS (3 ml for nasopharynx, 5 ml for lungs, 500 µl for cervical lymph nodes and nasal 
mucosa).  [17]  
Colony forming unit counts in lung and nasopharynx 
 At the various timepoints after bacterial inoculation, the viable counts of bacteria in 
the lungs and the nasopharynx were determined. After dissection, nasopharyngeal and lung 
samples were disrupted with an Ultra-Turrax T8 homogeniser (IKA) and CFU counts were 
determined by serial dilutions in 1x PBS and plating on blood agar plates containing 5% (v/v) 
defibrinated horse blood (Oxoid) [14]. 
Flow cytometry 
 Mouse tissue suspensions from nasal mucosa and cervical lymph nodes were 
incubated with purified anti-Fc receptor blocking antibody (anti-CD16/CD32) before addition 
of specific antibodies. A combination of fluorescein isothiocyanate (FITC)-, phycoerythrin 
(PE)-, PE-Cy7- and allophycocyanin (APC)-conjugated monoclonal antibodies was used to 
stain cell surface markers. Intracellular staining for FoxP3 with monoclonal antibodies was 
performed according to the manufacturer’s instructions (eBioscience). Analysis was 
performed using a Becton Dickinson FACScalibur flow cytometer running CellQuest 
acquisition and analyzed using FlowJo software (version 8.8.3, Tree Star). 
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Statistics 
 A two-tailed unpaired Student T test or one-way ANOVA was used, as appropriate, 
for data analysis. p-values lower than 0.05 were considered significant. GraphPad Prism 6 
was used for statistical analysis. 
Results 
Immunological cells in the nasal mucosa 
 CD45+ cells represent all immunological cells present in the nasal mucosa. For most 
strains an increase in the number of CD45+ cells between day 1 and day 15 was observed, 
for strain 106.66 between day 1 and day 8 (p<0.05), for D39cps- between day 8 and day 15 
(p<0.05) and for 110.58 between day 3 and day 8 (p<0.05). Interestingly, the increase of 
CD45+ cells correlated with lung infiltration (Supplementary Figure S1). For strains D39 and 
110.58::D39cps, which generally remained in the nasopharynx and did not reach the lungs, 
no significant increase in CD45+ cells was measured (Figure 1A). Strain D39 infiltrated the 
lungs in one out of four mice on day 15. An increased CD45+ recruitment was observed for 
this mouse only and not for those three where the pneumococci remained in the 
nasopharynx (Supplementary Figure S2). Thus in Figure 1 the apparent increase in CD45+ 
cells in the nasal mucosa on day 15 for strain D39 is solely due to the infiltration of cells in 
the one mouse in which D39 reached the lungs. 
 An increasing number of macrophages (F4/80+ cells) was measured for the strains 
infiltrating the lungs (Supplementary Figure S3): Infection with strain 106.66 resulted in a 
non-significant (p=0.3) increase from 27 cells (range: 18.6-37.6) on day 3 to 396 cells (range: 
29.3-1371) on day 15. Cell numbers were significantly increased from day 8 to day 15 for 
D39cps- (p<0.05) and from day 3 to day 8 for 110.58 (p<0.05) (Figure 1B). Cell numbers did 
not increase after infection with 110.58::D39cps or D39, both of which did not reach the lungs 
(Figure 1B and Supplementary Figure S3). 
 Neutrophil (Gr-1+ cells) infiltration of the nasal mucosa is also show to be dependent 
on lung CFU counts (Supplementary Figure S3). A significant increase was measured 
between day 1 and day 8 (p<0.05) for strain 106.66, between day 8 and day 15 (p<0.05) for 
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strain D39cps-, and a non-significant trend (p=0.08) for an increase of Gr-1+ cells between 
day 1 and day 8 after infecting the mice with strain 110.58. Infection with strains 
110.58::D39cps and D39, which remained in the nasopharynx, and did not infiltrate the 
lungs, showed in no increase (Figure 1C and Supplementary Figure S4). 
 A significant increase of CD3+ T-cells is measured between day 1 and day 8 for 
infection with strain 106.66 (p<0.01), for strain D39 between day 1 and day 3 (p<0.05), for 
strain D39cps- between day 1 and day 3 (p<0.05), for strain 110.58 between day 1 and day 
15 (p<0.05). Interestingly, CD3+ T-cell numbers remained on the same level throughout the 
experiment for 110.58::D39cps with a mean of 376.3 cells (range: 165-709.3) on day 1 
(Figure 1D and Supplementary Figure S5). 
 For FoxP3+ regulatory T-cells infiltration of the nasal mucosa a dependency on 
nasopharyngeal CFU counts was observed (Figure 1E and Supplementary Figure S6). 
Infection with strain 106.66 resulted in a significant (p<0.05) increase between day 1 and 3, 
for D39cps- an increase between days 1 and 3 (p<0.05) as well as between days 8 and 15 
(p<0.05) was measured, strain 110.58 infection resulted in a significant increase between 
days 1 and 8 (p<0.05), whereas a trend (p=0.39) towards increased FoxP3+ cells was 
observed for strain D39 with 66 cells (range: 5.3-168) on day 1 and 105 cells (range: 55.33-
144) on day 3. T-cell numbers remained on the level of day 1 with a mean of 18 cells (range: 
5.3-34.7) for 110.58::D39cps. As results for strains with 110.58 genetic background were 
shown to induce FoxP3+ cells infiltration on similar levels, whereas infiltration after infection 
with strains with a D39 genetic background resulted in higher FoxP3+ cell counts in the 
nasopharynx, genetic background also might have an influence on FoxP3+ recruitment. 
Cytokine Interleukin 10 (IL-10) 
 We observed a trend towards increased IL-10 expression in mice after 
nasopharyngeal colonization compared to the untreated controls (Supplementary Figure S7). 
A significant increase was observed for strain D39 from day 0 to day 3 (p<0.05) and for 
110.58 (p<0.05) whereas the significant increase occurred already from day 0 to day 1 for 
strain 110.58::D39cps (p<0.0001). The increase for strain 106.66 between day 0 and day 8 
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was not significant (p=0.18) and strain D39cps- also did not result in a significant increase 
(p=0.54) between day 0 and day 8, but the mean of absolute cell numbers increased from 
774.3 on day 0 to 925.6 (range: 439-1478) on day 8 (Figure 1F). Strains with a 110.58 
genetic background induced significantly (p<0.05) more IL-10 than strains with a D39 
background on all timepoints tested. 
Discussion 
 For the stimulation of FoxP3+ cells and the IL-10 response only nasopharyngeal 
colonization was required. However, pneumococcal strains 110.58, 106.66 and D39cps-, 
which were able to infiltrate the lungs, also caused an increase in neutrophils and 
macrophages in the nasopharynx compared to strains 110.58::D39cps and D39 which 
remained in the nasopharynx. Thus, the IL-10 response is dependent on the presence of 
pneumococci in the nasopharynx and no lung infiltration is required for secretion of this 
cytokine. Induction of IL-10 secretion was observed for all strains tested. This is evidence for 
successful carriage as IL-10 secretion is induced by carriage [8, 12]. Nasopharyngeal 
colonization is effectively silent and induces little or no immune response except of IL-10 
response and the stimulation of FoxP3+ regulatory T cells both of which are responsible for 
immune homeostasis rather than for the induction of a strong immune response [10]. This 
allows the bacteria to persist in the niche. Once the bacteria reach the lung, a strong 
inflammatory response is initiated and this clears the bacteria from both the nasopharynx and 
the lung.  
 Interestingly, nonencapsulated strains infiltrated the lungs more easily than their 
encapsulated isogenic mutants. Generally, nonencapsulated pneumococci have a 
disadvantage in invading from the nasopharynx to other sites of the human body as they are 
more susceptible to opsonophagocytosis than encapsulated strains [18]. The presence of a 
capsule is not required for nasophayngeal colonization as nonencapsulated pneumococci 
are often isolated from this part of the body. Interestingly, also pneumococcal lineages are 
known which lack capsule, but show a clear ability to cause disease [19]. In cases of 
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conjunctivitis, nonencapsulated strains were even shown to have an advantage over 
encapsulated pneumococci [20]. Our results indicate an advantage for nonencapsulated S. 
pneumoniae strains in infiltrating the lungs (Figure 2). 
 For the IL-10 response mainly the genetic background was important: strain 110.58 
and its isogenic mutant expressing a serotype 2 capsule 110.58::D39cps were able to induce 
a higher IL-10 response in the nasal mucosa compared to strains with a D39 or 106.66 
genetic background.  
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Strain Serotype Remarks 
D39 2 Lab strain, International Reference 
D39cps- Non-encapsulated Mutant of D39; capsule operon (cpsA-O) replaced with Janus-cassette 
110.58 Non-encapsulated Swiss clinical strain, naturally non-encapsulated 
110.58::D39cps 2 Mutant of 110.58; capsule operon (cpsA-O) of strain D39 inserted 
106.66 6B Swiss clinical strain 
 
Table 1: S. pneumoniae strains used for in vivo studies. 
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Figure 1 
 
 
   
 
 
Figure 1: Induction of immune response by pneumococcal strains 1 to 15 days after infection. 106.66 (serotype 6B), D39 
(serotype 2), mutant strain D39cps- (non-encapsulated); mutant strain 110.58D39cps (serotype 2) and strains 110.58 (non-
encapsulated) in the murine nasopharynx. A) CD45+-cells. B) Macrophages (F4/80+ cells) C) Gr1+ cells (neutrophils) D) CD3+ 
T cells E) FoxP3+ Regulatory T-cells F) IL-10 secretion. * p<0.05, ** p<0.01, *** p<0.001, **** p<0.0001. n=4 mice per time 
point. 
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Figure 2 
 
 
Figure 2: Summary of immune response to pneumococci residing in the nasopharynx and/or infiltrating the lungs. 
Pneumococcal strains colonizing only the nasopharynx induce a silent immune response where mainly FoxP3+ regulatory T-
cells and Interleukin 10 (IL-10) are increased. This results in a moderate immune response, persistence in the niche and 
asymptomatic carriage. In contrast, S. pneumoniae strains invading from the nasopharynx and infiltrating the lungs result in a 
stronger immune response where also leukocytes (CD45+ cells), neutrophils and macrophages are increased. These immune 
cells are then able to migrate from the lungs also to the nasopharynx and the infections in the lungs as well as in the 
nasopharynx are cleared. 
 
 
 
 
  
 
   
84
Immunological cells and immune regulation 
_______________________________________________________________________________________________________________________________________ 
 
 
                            
 
 
  
 
Supplementary Figure S1: Absolute numbers of CD45-positive cells measured in nasal mucosa for all different strains 
tested. Black bar: Reference for absolute cell count on day 0 from different experiments. n = 4. Error bars: Standard error of the 
mean.  
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Supplementary Figure S2: S. pneumoniae strain D39 successfully infiltrated the lungs in one out of four mice resulting in an 
increased recruitment of CD45+ cells into the nasal mucosa for this mouse. 
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Supplementary Figure S3: Absolute numbers of F4/80-positive cells measured in the nasal mucosa for all different strains 
tested. Black bar: Reference for absolute cell count on day 0 from different experiments. n = 4. Error bars: Standard error of the 
mean.  
 
 
 
   
87
Immunological cells and immune regulation 
_______________________________________________________________________________________________________________________________________ 
 
 
 
 
               
Supplementary Figure S4: Absolute numbers of Gr-1-positive cells measured in the nasal mucosa for all different strains 
tested. Black bar: Reference for absolute cell count on day 0 from different experiments. n = 4.  Error bars: Standard error of 
the mean.  
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Supplementary Figure S5: Absolute numbers of CD3-positive cells measured in the nasal mucosa for all different strains 
tested. Black bar: Reference for absolute cell count on day 0 from different experiments. n = 4. Error bars: Standard error of the 
mean.  
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Supplementary Figure S6: Absolute numbers of FoxP3-positive cells measured in the nasal mucosa for all different strains 
tested. Black bar: Reference for absolute cell count on day 0 from different experiments. n = 4. Error bars: Standard error of the 
mean.  
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Supplementary Figure S7: IL-10 concentrations measured in the nasal mucosa for all different strains tested. Red line: CFU 
counts nasal mucosa. Blue line: CFU counts lungs. Bars: Absolute IL-10 concentration. n = 4. Error bars: Standard error of the 
mean. 
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4. Investigating host innate immune responses to Respiratory 
Syncytial Virus and Streptococcus pneumoniae: co-stimulation in 
vitro model of human airway epithelial cells 
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Investigating host innate immune responses to Respiratory Syncytial Virus and 
Streptococcus pneumoniae: co-stimulation in vitro model of human airway 
epithelial cells 
 
Abstract  
 The effect of mono- and mixed infections of Streptococcus pneumoniae and 
Respiratory Syncytial Virus (RSV) on the human bronchial epithelial cell line BEAS-2B 
interleukin-6 (IL-6) and interleukin-8 (CXCL8) release was determined. Mixed infections 
resulted in more IL-6 and CXCL-8 secretion than mono-infections. Two hours of RSV-priming 
of the cells also increased IL-6 and CXCL-8 release. The two major pneumococcal virulence 
factors, capsule and pneumolysin, both had an effect on IL-6 and CXCL-8 secretion: 
Encapsulated bacteria in combination with RSV resulted in IL-6 secretion by BEAS-2B cells 
whereas non-encapsulated ones did not induce a clear IL-6 response. Increasing 
pneumolysin concentrations resulted in increased IL-8 secretion whereas the presence of a 
capsule played a less significant role for CXCL-8 induction but still, encapsulated bacteria 
resulted in slightly increased CXCL-8 secretion on RSV-primed cells compared to the non-
encapsulated mutant.  
Introduction 
One of the leading causes of lower respiratory tract infections in infants and children 
is Respiratory Syncytial Virus (RSV) which causes cold-like symptoms in most healthy adults 
and children [1, 2]. Factors such as premature birth, immune deficiency, congenital heart 
disease or chronic lung disease of prematurity increase the risk of suffering more severe 
infections leading to the need for intensive care and mechanically assisted ventilation or 
even death [3]. Additionally, the clinical severity can be directly linked to the viral load of an 
infant. Thus, early antiviral treatment might be an important factor to improve the disease 
outcome [4]. RSV has also been shown to be an important cause of acute otitis media in 
older children [5] where the peak seasons for RSV infections are the winter and spring 
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months [6, 7]. RSV induces only incomplete immunity thus re-infections can occur [8]. 
According to the World Health Organization (WHO), RSV causes worldwide 64 million 
infections and 160,000 deaths per year [9]. 
This non-segmented, negative-strand RNA virus is grouped into the genus 
Pneumovirus [10] of the family Paramyxoviridae [11] and was first isolated in 1957 [12]. The 
first reported case of RSV infection goes back to the year 1931 (Vanderbilt Medical School, 
Nashville, USA) [13]. 11 proteins are encoded on 15 200 nucleotides. One virion has a 
diameter of about 200 nm and is composed of a nucleocapsid within a lipid envelope where 
the lipid bilayer is taken from the host plasma membrane but is completed with viral 
transmembrane surface glycoproteins of 11-20 nm in size [8]. 
Upper airway epithelial cells are the main target of RSV infection but there are also 
cases reported where the virus infected alveolar epithelial cells [13]. Entry of the virus into 
the cell is the first critical step of infection [8]. In primary airway epithelial cells RSV 
replication is 100 times greater and cytotoxicity 15 times greater than in the human bronchial 
epithelial cell line BEAS-2B which might be due to differences in expression of cell surface 
receptors and the resulting increased viral infection rate [14].  Attachment to the cells occurs 
mainly via two different surface proteins. One is the G glycoprotein, a glycosylated type II 
transmembrane protein composed of 289-299 amino acids, depending on the strain, which is 
used as an accessory protein to increase the efficiency of attachment [15, 16]. The other is 
the essential F protein which is required for the fusion of the infected cell membranes with 
uninfected cell membranes or the viral envelope [17] [18]. F protein is also able to activate 
RhoA, a Ras family protein which results in actin cytoskeleton reorganization [19]. Lung cells 
show a higher RhoA expression than other cells [20] which results in an increased replication 
rate for RSV . The third important protein for RSV infection of airway epithelial cells is the M 
protein which is of major importance for the coordination of assembly of the virus [8, 21]. 
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Flow cytometry of RSV-infected cells has shown that they are more often found in the G0/G1-
phase than are non-infected controls indicating remodeling of the airway epithelium, 
beneficial for the virus [22]. 
During RSV infection lymphocytic infiltrates are observed around small airways as 
well as cell debris in airway lumens. Neutrophils then attach to epithelial cells infected with 
RSV and, as a result of activation, start damaging the epithelium [23]. Toll-like receptor 4 
(TLR4) on pulmonary cells, stimulated by the major surface glycoproteins G and F, is one of 
the most important factors for innate immunity against RSV infection. NK cell and monocyte 
(CD14+cell) responses are stimulated [24]. RSV-induced CXCL-8 production requires 
interactions between different transcription factors in a cooperative way [25]. IL-6 and CXCL-
8 were shown to play an important role in chemotaxis for neutrophils and macrophages and 
expression of IL-6 at the site of infection is essential for disease progression [24, 26]. 
Epithelial cells, monocytes and pulmonary epithelial cells increase CXCL-8 secretion after 
RSV infection [27]. Large amounts of lactate dehydrogenase (LDH) are produced by RSV-
infected epithelial cells and thus, LDH can be used as a predictor of disease severity [14, 28].  
Genetic predisposition plays a role as it was shown that severe RSV bronchiolitis is 
linked to a CXCL-8 anomaly (IL8-251A) and children containing such a variation suffer much 
more often from severe wheezing than children with normal CXCL-8 expression [29, 30]. 
Additionally, control mechanisms responsible for the regulation of disease pathogenesis and 
chronicity are determined by the spectrum of cytokines expressed [31]. The following factors 
are upregulated in response to RSV infections (Table 1): 
Cells / Secretions Factor(s) Reference 
Primary airway epithelial cells B-cell activating factor (BAFF) McNamara et al. 2013 [32] 
Pulmonary epithelial cells IL-6 and IL-8 Yokota et al. 2012 [33] 
Bronchoalveolar lavage (infants suffering from RSV 
bronchiolitis) 
IL-8, IL-10, MCP-1, MIP-1a/b mRNA McNamara et al. [34] 
 
Table 1: Factors upregulated during RSV infection. 
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A Japanese study showed that almost half of the children with bronchopulmonary 
RSV infection suffered from secondary bacterial infections, most commonly H. influenzae 
and S. pneumoniae [35]. Another study found evidence that viral co-infections are associated 
with more severe invasive pneumococcal disease [7]. In children with higher RSV loads a 
synergistic interaction between the virus and S. pneumoniae was measured which increased 
the risk of acute otitis media [36]. A major risk for secondary bacterial infections after RSV 
infections is the upregulation of platelet-activating factor (PAF) receptor and the following 
enhanced adhesion of pathogenic bacteria, such as S. pneumoniae [33]. When the two 
human epithelial cell lines HEp-2 and A549 were infected with RSV this led to an increased 
adherence of pneumococcal serotypes 3, 9, 14, 18, 19 and 23, some of the most pathogenic 
serotypes for infants and young children [37]. The same effect was also shown in another 
study using serotype 19 with an increase in adherence over time between 24 and 72 hours 
after viral infection. On the epithelial cell lines A549, BEAS-2B and NHBE, the expression of 
ICAM-1, CEACAM1 and PAF-r was increased by infection with RSV. Blocking of the 
receptors ICAM-1 and PAF-r prevented the adhesion of S. pneumoniae strain 19 to A549 
cells [38].  
In our study the effect of two of the main pneumococcal virulence factors, the pore-
forming hemolytic toxin pneumolysin [39-42] and the polysaccharide capsule in combination 
with RSV were analyzed in terms of IL-6 and CXCL-8 induction in BEAS-2B cells. 
Material and Methods 
The human bronchial epithelial cell line BEAS-2B (ATCC CRL-9609) was used for in 
vitro experiments. As growth medium, Bronchial Epithelial Growth Medium (BEGM) (Lonza, 
Wokingham, UK) supplemented with the additives listed in Table 2 was used. 
 Cells were grown in T75 flasks (Sarstedt, Leicester, UK) coated with a mixture of 0.01 
mg/ml fibronectin (Sigma-Aldrich), 0.03 mg/ml collagen (Type 1, from human skin, Sigma-
Aldrich) and 0.001 mg/ml bovine serum albumin (BSA) (Sigma-Aldrich) dissolved in BEGM 
for 7 days. Every second day the growth medium was changed. 
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To perform infection experiments, the cells were seeded in a collagen-coated 
(fibronectin, collagen and BSA, as above) 96-well plate with 30 000 cells per well. After 
seeding, the plates were incubated for 2 days at 37°C + 5% CO2 for 3 days with the medium 
changed after 2 days. Four different assays of incubation were performed (see Figure 1). 
The pneumococcal strains or purified virulence factors used in this study are listed in Table 
3. The next day, pictures were taken using a 40-fold magnification from all the different 
incubations, then the supernatant was removed and stored at -80°C in a 96-well plate. 
CXCL-8 and IL-6 ELISA (R&D systems, Oxford, UK) were performed using a 1:20 dilution of 
the supernatants. 
Results 
An IL-6 response higher than the untreated control (5970 pg/ml) was only measured 
when BEAS-2B cells were stimulated with either encapsulated pneumococcal strain D39 or 
its mutant PLN-A expressing non-pore forming pneumolysin in combination with RSV. IL-6 
response after addition of either RSV (5960 pg/ml), D39 (5830 pg/ml) or PLN-A (3500 pg/ml) 
as single treatment was lower than the untreated control, but RSV-priming or bacterial 
priming of the cells or even co-stimulation resulted in IL-6 secretion (Figure 2): For D39, a 
significantly greater level of IL-6 was measured when the cells were primed with RSV 
compared to co-stimulation (p<0.05) or bacterial priming (p<0.05), whereas PLN-A treatment 
resulted in no significant difference (p-vaule ANOVA=0.7). When either pneumolysin, the 
non-pore forming pneumolysin PdB or LPS were used, IL-6 secretion was lower than the 
untreated control for the mono-treatment as well as in combination with RSV (Supplementary 
Figure 1).  
Priming of BEAS-2B cells with either D39, PLN-A, 25 ng/ml pneumolysin, R36A or 
PdB resulted in higher CXCL-8 secretion than the untreated control (760 pg/ml). For 
pneumolysin (p<0.01) and PdB (p<0.05) the amount of CXCL-8 measured after bacterial 
priming was significantly greater compared to RSV mono-treatment which resulted in only 
minimal CXCL-8 induction (23 pg/ml) (Figure 3a). Only mono-treatment with 25 ng/ml 
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pneumolysin resulted in CXCL-8 secretion, all other bacteria or bacterial products did not 
induce CXCL-8 higher than the untreated control (Supplementary Figure 2). Co-stimulation of 
BEAS-2B cells with whole bacteria D39 (734 pg/ml) and PLN-A (588 pg/ml) resulted in 
CXCL-8 secretion, but the amount of cytokine measured was not significantly increased 
compared to RSV mono-treatment (p=0.97 for D39 and p=0.9 for PLN-A). 730 pg/ml and 580 
pg/ml CXCL-8 were measured after RSV-priming and stimulating the cells with D39 or PLN-
A, respectively (Figure 3b). 
No dose-dependency in terms of IL-6 secretion for pneumolysin was measured. 
Using 125 ng/ml pneumolysin resulted in IL-6 secretion (1800 pg/ml) without the need of a 
co-infection using RSV. But no pattern of dose-dependency was observed for RSV priming, 
as co-stimulation with 5 ng/ml PLY (805 pg/ml) as well as with 125 ng/ml PLY (330 pg/ml) 
resulted in IL-6 secretion, but not with 25 ng/ml PLY, whereas only priming with 25 ng/ml 
PLY induced IL-6 (130 pg/ml) (Supplementary Figure 3a). In contrast, CXCL-8 secretion was 
shown to be dependent on pneumolysin concentration: 5 ng/ml pneumolysin mono-treatment 
did not result in CXCL-8 secretion higher than the untreated control, whereas after adding 25 
ng/ml or 125 ng/ml, 120 pg/ml and 320 pg/ml CXCL-8 were measured. Bacterial priming only 
resulted in significantly (p<0.05) increased CXCL-8 levels compared to RSV mono-treatment 
after stimulating the BEAS-2B cells with at least 25 ng/ml pneumolysin. A significantly 
(ANOVA: p<0.0001) increased CXCL-8 secretion after RSV-priming compared to bacterial 
mono-treatment, RSV mono-treatment and bacterial priming was only measured when 125 
ng/ml pneumolysin were used (Figure 4). The non-pore-forming pneumolysin mutant protein 
PdB did not show any concentration-dependency for the concentrations tested (5, 25 and 
125 ng), neither in mono- or co-infections nor in RSV- or PdB-primed infections. None of the 
conditions tested reached a level higher than the uninfected control (Supplementary Figure 
3b). 
 For all the different treatments pictures were also taken. All treatments resulted in 
necrosis of the BEAS-2B cells, but there were visible differences in the amount of dead cells 
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(Figure 5). With mono-infections the most cell death occurred with S. pneumoniae strain D39 
and with RSV (Figure 5a). Additionally, dose-dependency of purified pneumolysin protein 
was shown. In contrast, RSV-primed cells (Figure 5b) showed the strongest damage for 
RSV-treatment, D39 wild-type PLN-A and, to a smaller amount, also for R36A treatment. 
After adding 125 ng of purified pneumolysin, more necrosis was observed than with either 5 
ng or 25 ng protein. Co-infected cells (Figure 5c) produced most necrosis with co-infections 
of RSV with D39 wild-type strain, R36A and PLN-A. There was no clear dose-depenency of 
pneumolysin- or PdB-treatment observed. For bacterial-primed cells (Figure 5d) damage of 
the cell layer was most intensive after priming with D39 wild-type strain, R36A, PLNA and all 
three different pneumolysin concentrations. 
Discussion 
 IL-6 and CXCL-8 responses of BEAS-2B cells after either mono-infection or co-
stimulation with RSV and/or pneumococcus bacteria or bacterial components were 
compared. Necrosis was viewed by pictures taken of the monolayers after each treatment. 
For purified LPS, pneumolysin, the non-pore forming pneumolysin PdB as well as for the 
non-encapsulated pneumococcal strain R36A no differences between mono- or mixed 
treatments was measured. In contrast, a clear increase in IL-6 secretion was measured after 
mixed infections using RSV and either the encapsulated S. pneumoniae strain D39 (serotype 
2) or PLN-A, a pneumolysin-deficient D39-mutant. From previous studies [7, 35, 36] it is 
known that RSV-infections of epithelial cells also results in more severe bacterial secondary 
infections. Enhanced adhesion of pathogenic bacteria is the main reason for this increase 
[33, 37, 38]. Our results for IL-6 secretion confirm these findings as we observed an IL-6 
increase in the supernatant of cells primed with RSV for 2 hours and addition of D39 or PLN-
A afterwards. Interestingly, this increase was only measured when encapsulated, bacteria 
were used but not when purified hemolytic or non-hemolytic pneumolysin, LPS or non-
encapsulated pneumococcus was added indicating the importance of encapsulation. Co-
stimulation of BEAS-2B cells with RSV and pneumococcus or bacterial-primed cells also 
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showed increased IL-6 secretion compared to mono-infection but for the wild-type D39 strain 
RSV-primed cells resulted in a higher IL-6 secretion than the other mixed infections which is 
in accordance to the clinical findings mentioned before [7, 35, 36]. Increasing pneumolysin 
concentrations did not show an effect on IL-6 secretion and there was also no difference 
measured between mono- and mixed infections indicating that pneumolysin by itself does not 
have a major effect on IL-6 induction but that encapsulated bacteria are required to show a 
clear increase.  
 The CXCL-8 results of our assays show a similar trend.  Again, encapsulated bacteria 
are required to get an increased response in mixed compared to mono-infected cells. D39 
and PLN-A again show a slightly increased CXCL-8 response in mixed infections with RSV 
compared to mono-infections. But additionally, also an effect of increasing pneumolysin 
concentrations was measured, which is in accordance with previous findings [43]. 
Pneumolysin-primed cells resulted in an increased CXCL-8 response when RSV was added 
compared to RSV mono-infections.  
 In summary, both IL-6 and CXCL-8 secretion of BEAS-2B cells is increased for mixed 
infections of RSV and pneumococcus when encapsulated bacteria were used. For CXCL-8 
induction pneumolysin plays an important role as was shown for the pharyngeal epithelial cell 
line Detroit 562 [43]. Our results indicate that priming of BEAS-2B cells with pneumolysin and 
the associated cell damage favor secondary viral infections but also that priming of bronchial 
epithelial cells with RSV opens the door for more severe pneumococcal infections. 
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Additive Amount Supplier 
Bovine pituitary extract 50  µg/ml Invitrogen 
Hydrocortisone 0.5 µg/ml Sigma-Aldrich 
Epidermal growth factor 25  ng/ml Sigma-Aldrich 
Epinephrine 0.5 µg/ml Sigma-Aldrich 
Insulin 5    µg/ml Sigma-Aldrich 
Transferrin 10  µg/ml Sigma-Aldrich 
Triiodothyronine 6.5 ng/ml Sigma-Aldrich 
Retinoic acid 0.2 ng/ml Sigma-Aldrich 
Gentamicin 50  mg/ml Sigma-Aldrich 
 
Table 2: Additives in BEGM medium 
 
 
 
 
Table 3: Overview of treatments used for infection of BEAS-2B cells 
 
 
  
Treatment Concentration 
RSV 2.5 Multiplicity of infection (MOI) 
S. pneumoniae strain D39 105 CFUs 
PLN-A (D39 mutant secreting non-pore forming PLY) 105 CFUs 
Purified pneumolysin (PLY) 5, 25 or 125 ug/ml 
Lipopolysaccharide (LPS) (from Escherichia coli) 2.5 ug/ml 
R36A (D39 non-encapsulated mutant) 105 CFUs 
PdB (purified non-pore forming PLY) 2, 25, 125 ug/ml 
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Figure 1: Incubation assays with BEAS 2B cells. Treatment 1: RSV and pneumococci or virulence factors were added at the 
same time. Treatment 2: Control infections with pneumococcus, pneumococcal virulence factors, or RSV for 24h. Treatment 3: 
The virus was added first to the cells, incubated for 2h, and then either complete pneumococci or pneumococcal virulence 
factors were added for another 24h. Treatment 4: First added bacteria or virulence factors for 2h to the cells, then added RSV 
for 24h. 
  
Incubation protocol 
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Figure 2: Increased IL6 expression requires encapsulated pneumococci plus RSV infection. D39: S. pneumoniae strain 
D39 (serotype 2), PLN-A: Mutant strain of S. pneumoniae strain D39 expressing non-pore forming pneumolysin. Error bars: 
Standard error of the mean. n = 3. Exceptions: for D39 co-stimulation n = 2. Statistical test: One-way ANOVA with Tukey’s test 
to correct for multiple testing. * = p<0.05. ANOVA D39: p<0.001 
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Figure 3a: CXCL-8 secretion of BEAS-2B cells after stimulation with RSV or bacterial products. Priming of BEAS-2B cells 
with pneumolysin or its non-pore forming mutant PdB resulted in significantly increased CXCL-8 secretion compared to RSV 
mono-infections. PLY (25ng/ml): 25ng/ml of purified pneumolysin added. PdB (25ng/ml): 25ng/ml of purified non-pore-forming 
pneumolysin added. Error bars: Standard error of the mean. n = 3. Exceptions: PLN-A and PdB bacterial mono-treatments, PdB 
RSV-primed n = 2. Statistical test: One-way ANOVA with Tukey’s test to correct for multiple testing. * = p<0.05; ** = p<0.01. 
ANOVA for PLY (25ng) p<0.05; for PdB p<0.01 
 
 
Figure 3b: CXCL-8 secretion of BEAS-2B cells after stimulation with RSV and/or pneumococcus. Mono-treatment with 
RSV and a mixed treatment using RSV and the encapsulated bacterial strains D39 and PLN-A resulted in CXCL-8 secretion. 
D39: S. pneumoniae strain D39 (serotype 2). PLN-A: Mutant strain of S. pneumoniae strain D39 expressing non-pore forming 
pneumolysin. Error bars: Standard error of the mean. n = 3. CXCL-8 concentration of untreated control was subtracted. 
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Figure 4: Increasing pneumolysin concentrations result in increased IL-8 secretion. A strong increase in IL-8 expression 
was also observed after RSV-priming and adding 125 ng of pneumolysin compared to the addition of 5 ng and 25 ng. Error 
bars: Standard error of the mean. n = 2. ANOVA for PLY (25ng) p<0.05; for PLY (125ng) p<0.0001 
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Figure 5a: Mono-infected cells, different treatments. Compared to the untreated control (A), all treatments showed necrosis 
of BEAS-2B cells. The strongest effects were observed with D39 wild-type (D) and RSV (C). For PLY dose-dependency (J-L) is 
seen on the pictures; * indicates treatments with strongest effect. LPS: Lipopolysaccharides. RSV: Respiratory syncytial virus. 
D39: S. pneumoniae strain D39 (serotype 2).  R36A: non-encapsulated mutant of S. pneumoniae strain D39. PLN-A: mutant 
strain of S. pneumoniae D39 expressing non-pore forming pneumolysin. PdB: non-pore forming pneumolysin. PLY: 
pneumolysin. Magnification: 40x 
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Figure 5b: RSV-primed cells (2h pre-treatment with RSV). Clear signs of necrosis can be observed with all treatments 
compared to the non-infected control (A). The greatest damage to cell layer is shown for RSV-treatment (C) and D39 wild-type 
(D). PLN-A treatment (F) and R36A treatment (E) also had a necrotic effect on the cell layer. For pneumolysin treatment, much 
stronger necrosis is observed after addition of 125 ng (L) than of either 5 ng or 25 ng (J and K). * indicates treatments with 
strongest effect. LPS: Lipopolysaccharides. RSV: Respiratory syncytial virus. D39: S. pneumoniae strain D39 (serotype 2).  
R36A: non-encapsulated mutant of S. pneumoniae strain D39. PLN-A: mutant strain of S. pneumoniae D39 expressing non-
pore forming pneumolysin. PdB: non-pore forming pneumolysin. PLY: pneumolysin. Magnification: 40x 
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Figure 5c: Co-infected cells. Necrosis is observed for all different conditions tested, but most necrotic cells are shown on cells 
with co-infections of RSV with D39 wild-type strain, (D), R36A (E) and PLN-A (F). Treating BEAS-2B cells with 125 ng/ml 
pneumolysin also resulted in increased necrosis. * indicates treatments with strongest effect. LPS: Lipopolysaccharides. RSV: 
Respiratory syncytial virus. D39: S. pneumoniae strain D39 (serotype 2).  R36A: non-encapsulated mutant of S. pneumoniae 
strain D39. PLN-A: mutant strain of S. pneumoniae D39 expressing non-pore forming pneumolysin. PdB: non-pore forming 
pneumolysin. PLY: pneumolysin. Magnification: 40x 
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Figure 5d: Bacterial-primed cells (2h of pre-treatment with either bacteria or bacterial products). Necrosis is shown on all 
pictures compared to untreated control (A), but the strongest effect is observed for D39 wild-type (D), R36A (E), PLN-A (F) and 
with 25 and 125 ng/ml pneumoylsin (K-L). *indicates treatments with strongest effect. LPS: Lipopolysaccharides. RSV: 
Respiratory syncytial virus. D39: S. pneumoniae strain D39 (serotype 2).  R36A: non-encapsulated mutant of S. pneumoniae 
strain D39. PLN-A: mutant strain of S. pneumoniae D39 expressing non-pore forming pneumolysin. PdB: non-pore forming 
pneumolysin. PLY: pneumolysin. Magnification: 40x 
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Supplementary Figure 1 
 
 
 
Suplementary Figure 1: Increased IL6 expression requires encapsulated pneumococci plus RSV infection but does not 
depend on functioning pneumolysin. Addition of purified pneumolysin, LPS, PdB or even non-encapsulated S. pneumoniae 
(R36A) does not result in a IL-6 expression higher than the untreated control (6000 pg/ml). D39: S. pneumoniae strain D39 
(serotype 2), PLN-A: Mutant strain of S. pneumoniae strain D39 expressing non-pore forming pneumolysin, PLY (25ng): purified 
pneumolysin LPS: 2.5 µg/ml purified lipopolysaccharides added. R36A: non-encapsulated mutant of D39 (D39Δcps). PdB 
(25ng/ml): 25ng/ml of purified non-pore-forming pneumolysin. Error bars: Standard error of the mean. n = 3. Exceptions: for D39 
co-stimulation, LPS bacterial-primed, LPS mono-treatment, R36A mono-treatment, PdB mono-treatment and all untreated 
controls n = 2. Statistical test: One-way ANOVA with Tukey’s test to correct for multiple testing 
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Supplementary Figure 2 
 
 
Supplementary Figure 2: CXCL-8 secretion of BEAS-2B cells after stimulation with RSV and/or pneumococcus . 
Bacterial-priming of BEAS-2B cells results in a trend towards increased IL-8 secretion compared to mono-infections. Mono-
infections did not show an increase in IL-8 induction compared to the untreated control, whereas priming with pneumococcus, 
pneumolysin or the non-pore forming PdB resulted in higher IL-8 concentrations. PLN-A: Mutant strain of S. pneumoniae strain 
D39 not expressing pneumolysin. PLY (25ng/ml): 25ng of purified pneumolysin added. LPS: 2.5 µg/ml purified 
lipopolysaccharides added. R36A: Mutant strain of S. pneumoniae strain D39 (D39Δcps) not expressing serotype 2 capsule. 
PdB (25ng/ml): 25ng/ml of purified non-pore-forming pneumolysin added. Error bars: Standard error of the mean. n = 3. 
Exceptions: for all untreated controls, PLN-A, LPS, R36A and PdB bacterial mono-treatments, PdB RSV-primed, R36A co-
stimulation and R36A bacterial-priming n = 2. Statistical test: One-way ANOVA with Tukey’s test to correct for multiple testing. 
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Supplementary Figure 3 
          
 
Supplementary Figure 3a: Increasing pneumolysin concentrations do not have an effect on IL-6 secretion. Adding 5, 25 
or 125 ng/µl pneumolysin to BEAS-2B cells did not result in an increased IL-6 secretion compared to the control. Orange: 
untreated control. Error bars: Standard error of the mean. n =-3. Exceptions: for untreated controls and PLY (125ng) mono-
treatment, n =2. 
 
 
Supplementary Figure 3b: Pneumolysin-priming effect on CXCL-8 secretion is independent of concentration whereas 
RSV-priming resulted in an increase of chemokine after adding 125 ng of pneumolysin. 2h of priming with either 5 ng, 25 
ng or 125 ng of pneumolysin followed by a 24h-incubation with RSV resulted in an equal amount of IL-8 measured in the 
supernatant for all different concentrations. Co-stimulation also was concentration-independent. A strong increase in IL-8 
expression was observed after RSV-priming and adding 125 ng of pneumolysin compared to the addition of 5 ng and 25 ng. 
Error bars: Standard error of the mean. n = 2 
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5.  Biofilm formation of Streptococcus pneumoniae and commensal 
streptococci 
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Abstract  
Background 
More than 90 serotypes of Streptococcus pneumoniae have been described 
and these are determined by the biochemistry of their polysaccharide capsules. 
Some serotypes such as 6B are associated with colonization whereas others like 
serotype 7F are more often associated with invasive disease. Capsule-deficient small 
colony variants (SCV) have been observed for several serotypes and play a role in 
increasing biofilm biomass and stability. We aimed at investigating initial biofilm 
formation of 6B and 7F in a quantitative and descriptive (SCV building) manner over 
time. 
Results 
No absolute quantitative difference between serotype 6B and 7F in biofilm 
building was observed. Both formed SCVs in a static biofilm model when grown in a 
chemically defined medium (CDM) supplemented with either 5 mM galactose or 
glucose. After 16 h, serotype 7F resulted in more relative SCVs than 6B, but 
prolonged incubation time led to a gradual increase over time (16 to 64 h) (p<0.01) 
only for serotype 6B. This indicates an expression-regulated mechanism of SCV 
formation for serotype 6B strains, whereas this process might depend on point 
mutations for serotype 7F.  
Conclusions 
An increase in SCV was associated only with the colonizing serotype 6B. This 
might indicate efficient adaptation to the nutrient-limited environment of the 
nasopharynx resulting in better biofilm formation and, as a result, in better 
colonization than a serotype like 7F which is a less efficient colonizer. 
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Background  
The strict human pathogen Streptococcus pneumoniae (the pneumococcus) 
is a Gram-positive diplococcus using the nasopharynx as major ecological reservoir 
[1]. Currently, 93 different serotypes with differences in capsular structures and 
antigenicity are known [2]. Pneumococcal biofilms have been isolated from adenoid 
tissues, mucosal epithelial cells and nasal septa [3-5]. Pneumococci growing in 
biofilms induce reduced immune responses and have massively increased antibiotic 
resistance compared to planktonic pneumococci creating a major problem in clinics 
[5-7].  
Differences in biofilm forming capacity have been observed between different 
pneumococcal serotypes but the relationship between serotype and biofilm building 
was not clear. [8-14]. Interestingly, growth conditions also have an impact on 
pneumococcal biofilm formation. Lower temperatures (34°C) and atmospheric 
oxygen pressure as well as the presence of Fe(III) had a positive effect on biofilm 
formation, whereas xylitol reduced biofilm growth [14-18]. There is evidence that 
pneumococci show enhanced biofilm formation in nutrient limited media compared to 
complex media [15]. LytA-triggered autolysis starting 12-24h after inducing biofilm 
formation was shown to occur [19, 20]. 
In a transposon library screen of TIGR4, 69 mutations in the pneumococcal 
genome were found to affect biofilm growth [21]. Among the genes mainly involved in 
biofilm formation are the neuraminidase NanA, the serine-rich repeat protein PsrP, 
the lic operon involved in choline uptake, and, for early biofilm formation, the LuxS-
controlled quorum sensing system as well as the competence system [13, 16, 20, 22-
26]. Natural transformation was increased in biofilm pneumococci [15]. Major 
differences between planktonic and biofilm growth was also observed in terms of 
capsular expression. Rough morphology and transparent phenotype are increased 
[11, 26]. A decrease in cpsA and cps2 expression was measured during biofilm 
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growth [9, 15]. For serotype 3 biofilms, point mutations in the cps3DSU genes were 
measured, whereas TIGR4 showed insertions in the cps4E gene, all resulting in 
acapsular nonrevertible colony variants. Serotype 19 also generated acapsular non 
phase-variable variants [11, 21, 27]. Generally, deficiency of capsule resulted in 
increased biofilm formation [28] and small, acapsular colony variants (SCVs) 
dominated in the first day of biofilm formation over normal-shaped pneumococci [27, 
29]. 
According to Allegrucci et al. [30] pneumococcal biofilm formation can be 
divided into three different stages: Initial attachment to the surface occurred during 
day 1 followed (days 2 and 3) by the aggregation of cellular aggregates, mainly due 
to the replication of the bacteria attached before. After 6 days of incubation, the 
biofilms were fully developed, microcolony formation, a maximum cell density and 
height was measured.  
The aim of our study was to investigate the initial attachment of 
pneumococcus under different growth conditions.  As growth medium, CDM 
supplemented with either glucose or galactose was used to determine the impact of 
carbon source on biofilm formation. In particular, we aimed to investigate whether 
there are differences between pneumococcal serotypes 6B and 7F in biofilm 
formation at two different time points (16h and 64h).  
 
Results  
Determination of optimal incubation time for biofilm growth 
In order to decide on the ideal time point for experimental biofilm set up, 
planktonic growth of pneumococcal strains 106.66 (serotype 6B) and 208.41 
(serotype 7F) was first performed in CDM glucose and CDM galactose, respectively. 
We found that the mid-log phase of growth occurred after 3 to 4h in CDM glucose 
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whereas an incubation time of 16 h was required for CDM galactose (Figure 1A and 
1B). The optimal conditions for pneumococcal biofilm growth were therefore chosen 
with an incubation period of 16 h (CDM galactose) and 4 h (CDM glucose * ), 
respectively. In addition we also chose 16 h for CDM glucose in order to evaluate the 
influence of pneumococcal lysis on our results. 
Quantifying CFU of pneumococcal serotypes 6B and 7F at initial biofilm formation 
Next, the planktonic and biofilm growth of strains 106.66 (serotype 6B) and 
208.41 (serotype 7F) as well as of their isogenic capsule-switch mutants 
208.41cps106.66 (serotype 6B) and 106.66cps208.41 (serotype 7F) in CDM glucose 
after 4h† and 16h or in CDM galactose after 16h of incubation was measured (Table 
1; Figures 2A and 2B) to investigate whether an increased planktonic growth also 
results in more biofilm formation. As expected from the growth curves where OD450nm 
was measured over time, 6B strain resulted in an increased planktonic growth 
compared to 7F, though this was not significant (p=0.13) when counting CFU. The 
same trend also was observed for the isogenic mutants where 208.41cps106.66 
resulted in increased planktonic CFUs compared to 106.66cps208.41 in glucose 
(p=0.26) as well as in galactose (p<0.05).  
Absolute biofilm CFU counts resulted in no significant differences between serotypes 
(Wild types: p=0.25 for CDM glucose, p=0.42 for CDM galactose; isogenic mutants: 
p=0.48 for CDM glucose, p=0.12 for CDM galactose). Based on our growth curves, 
pneumococci reach their maximal density in CDM glucose after 5-6 h, and then 
autolysis begins.  
Relative amount of biofilm building 
In order to balance out differences in growth behaviour, we next calculated 
the relative amount of initial biofilm building. For this serotype 7F strains resulted in a 
* At the time of press, these experiments were not yet analyzed 
† At the time of press, these experiments were not yet analyzed 
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significantly increased relative amount of biofilm CFUs from the total of living bacteria 
counted compared to serotype 6B in CDM glucose (p<0.01) as well as in CDM 
galactose (p<0.01).  The same finding was true for the isogenic mutants where 
208.41cps106.66 showed a significant increase over 106.66cps208.41 in CDM 
glucose (p<0.05) and in CDM galactose (p<0.0001) (Figures 2C and 2D), indicating 
that capsule plays an important role for initial biofilm formation resulting in more CFU 
counts for serotype 7F after 16h of incubation.  
Small colony variant building in biofilms of serotypes 6B and 7F 
Wild type serotype 6B and 7F strains both showed SCV formation with a 
mean of 4.9% (range: 0-27.4) for 106.66 and 8.5% (range: 0-28.6) for 208.41 of total 
biofilm CFU counts, resulting in a non-significant increase for 208.41 SCVs 
compared to 106.66 SCVs (p=0.24) (Figure 3).  
Presence of SCV was confirmed by Fluorescein isothiocyanate-dextran 
(FITC-Dextran) imaging. To get a better understanding of the stability of SCVs, the 
bacteria were passaged once in a complex medium (BHI + 5% FCS) before FITC-
Dextran imaging was proceeded. SCVs of strain 208.41 remained small (Figure 4A) 
and a clear difference in bacterial size was observed when compared to the normal 
phenotype (Figure 4B). SCVs of 106.66 switched to normal size after one passage in 
a complex medium indicating rapid adaptation to environmental changes (Figure 4C 
vs Figure 4D).   
Initial biofilm building of serotypes 6B and 7F after 64 h 
We then were interested in the development of biofilms and SCVs over time 
and therefore, growth experiments were next performed after 64h of incubation. No 
significant difference in planktonic CFU counts was measured between serotypes 6B 
and 7F (p=0.97) after 64 h of incubation, and absolute CFU/200 µl of biofilms 
reached levels comparable to those in 16 h biofilms: 7.6x104 (range: 37-4.3x105) for 
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106.66 (p=0.45) and 6x105 (range: 2.9x103-4.7x106) for 208.41 (p=0.3), and serotype 
7F was non-significantly increased (p=0.1) compared to 6B after 64h of incubation 
(Figure 5A). Strikingly, a significant increase in the relative amount of biofilm CFUs 
was measured for serotype 6B from 16 h to 64 h of incubation (p<0.01), whereas 
serotype 7F remained stable (p=0.56) (Figure 5B). Also, a significant (p<0.01), 
relative increase in SCV formation was measured for serotype 6B from 4.9% (range: 
0-27.4) to 21.7% (range: 0-54%) (Figure 5C). Serotype 7F strains showed no pattern 
in SCV formation over time with 8.5% (range: 0-28.6) at 16h and 11.3% (range: 0-
70.8) after 64h of growth and also resulting in a higher variation than data from 
serotype 6B (Figure 5C).  
 
Discussion  
Differences in initial biofilm growth behaviour over time indicate that serotype 
matters in the process of biofilm formation: To get long-term access to the 
nasopharynx, it is important to adapt to this nutrient-poor environment. Biofilm 
formation is one of the most efficient responses to starvation [31]. SCV formation is 
an important process in biofilm development, as SCVs show enhanced biofilm 
forming capacity compared to normal colonies, and biofilm biomass increases when 
there are more SCV  [27, 29] . Stable adaptation to distinct host niches has been 
shown for pneumococci resulting, for example, in different biofilm forming capacities 
of strains isolated from the human nasopharynx compared to blood isolates [17]. Our 
results indicate an increase of SCV formation for serotype 6B strains during growth in 
a nutrient-limited medium, whereas the process of SCV formation in serotype 7F 
strains might not be dependent on the nutritional environment, but driven by a 
different mechanism. For example, an increase in point mutations due to growth in a 
stressful environment might play a role, as in recent studies SCVs of serotypes 3, 8 
and 19 were shown to be irreversible due to mutations in their capsule region [27, 29, 
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32]. We did not observe more biofilm CFU counts after 64h of growth, but this might 
be due to the limitations of our model. For example, lysis occurs due to the use of a 
static biofilm model, and when the medium was changed after 16h and 40h, all 
planktonically growing bacteria were removed and thus, biofilm formation only 
occurred with the remaining bacteria attaching to the surface. But after 64h of biofilm 
growth, 6B strains resulted in higher relative and absolute SCV counts compared to 
7F strains. This process indicates a faster adaptation capability of serotype 6B 
strains to a different nutrient environment resulting in an enhanced and organized 
development of SCVs in a nutrient limited environment.  
 
There are limitations within this study. A static biofilm model was used with an 
abiotic surface for attachment allowing us to gain general information about the 
biofilm growth behaviour of pneumococcal serotypes and commensal streptococci. 
Using a continuous flow bioreactor with living cultures of human cells as published 
recently [20], would mimic in vivo conditions more precisely. Additionally, there were 
only 4 time points (4, 16, 40 and 64h) analysed which gives a basic picture of biofilm 
development over time, but no information about its continuity. The exact time point 
of autolysis induction, the amount of biofilm that is reduced during this process as 
well as the timing of redevelopment after lysis, is, for example, not evaluated. Future 
experiments would benefit from confocal microscopy to visualize the biofilms of the 
different serotypes. Here we only can speculate that there are no full biofilms 
developed, but that our model only supports adherence and initial biofilm formation. 
Finally, information about in vivo biofilm formation of the pneumococcal serotypes 
used in this study is missing. Biofilm formation in vivo was shown to be highly distinct 
in shape from in vitro biofilms [7] and thus, an important follow-up experiment would 
be to test our findings in vivo. 
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Conclusions  
Our results reveal the difference in initial biofilm formation between two 
serotypes: After 16 h of incubation, serotype 7F strains showed more relative biofilm 
CFU counts as well as increased numbers of SCVs compared to 6B. However, only 
serotype 6B resulted in a gradual increase of SCV numbers and, as a result, in an 
increase of relative biofilm CFU counts over time. This indicates an expression-
regulated mechanism of SCV formation for serotype 6B which allows adaptation to 
changing nutritional environments. For serotype 7F, which did not show an increase 
in SCV formation over time, another mechanism as for example the induction of point 
mutations might be responsible for SCV development 
 
Methods 
Bacterial strains and growth conditions 
The S. pneumoniae strains used for biofilm growth experiments are listed in 
Table 1.  
For biofilm growth, bacteria were plated on Columbia sheep blood agar 
(CSBA) plates and incubated overnight at 37°C and 5% CO2, then grown overnight in 
a waterbath in 5 ml of Chemically Defined medium (CDM) [33] with the following 
modifications: Copper sulphate solution, manganese sulphate solution and cysteine 
solution were stored separately from the rest of the medium to prevent precipitations. 
Copper sulphate and manganese sulphate were stored at -20°C, the cysteine 
solution at 4°C. For overnight growth, CDM was supplemented with 50 mM of filter-
sterilized glucose for strains. The next day, bacteria were subcultured into 5 ml of 
CDM supplemented with 5 mM of filter-sterilized glucose. Pneumococcal strains  
were grown to an OD600nm of 0.1 to 0.2 in a water bath, then 10-20% of glycerol was 
added to the cultures and bacteria were stored at -80°C. After at least 20h at -80°C, 
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one aliquot was thawed and serial dilutions in phosphate-buffered saline (PBS) were 
plated out on CSBA plates to count colony forming units (CFUs).  
For biofilm formation studies, CDM was supplemented either with 5 mM 
glucose or 5 mM galactose. 
For planktonic growth, bacteria were plated on CSBA plates and incubated 
overnight at 37°C and 5% CO2. Then, the strains were grown overnight in 10 ml 
Lacks medium supplemented with 1.5M glucose as carbon source to an OD600nm of 
0.5 [34]. The next day, cultures were centrifuged at 3000 g for 5 min at room 
temperature (Heraeus Megafuge 16R), and pellet was washed with 10 ml CDM 
without carbon source. Pellet then was resuspended in 10 ml CDM without carbon 
source.  
For FITC-Dextran imaging after one passage, single colonies of normal size 
and SCV were taken from CSBA plates used for counting biofilm CFUs, plated out on 
CSBA plates and incubated overnight at 37°C + 5% CO2. Then, they were grown 
overnight in Brain Heart Infusion (BHI) broth supplemented with 5% Fetal Bovine 
Serum (FBS). The next day, subcultures of overnight growth were performed and 
liquid cultures grown to an OD600nm of 0.3 to 0.45.  
Planktonic growth 
96-well microtiter polystyrene plates (Thermo Fisher Scientific, Denmark) 
were used for planktonic growth. The inside of the plate lid was covered with 3 ml of 
0.05% Triton X-100 (Merck, Darmstadt, Germany) in 20% ethanol and air-dried. 192 
µl CDM supplemented with either 5.5 mM glucose or 5.5 mM galactose were added 
per well. 8 µl (dilution = 1:25) of fresh bacterial suspension was added per well. Plate 
was sealed with parafilm, and OD450nm was measured on an ELISA plate reader 
(THERMOmax Microplate Reader, Molecular Devices Corporation, California) every 
30 minutes for 30 hours using SOFTmax Pro 3.1.2.  
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Growth of biofilms 
96-well microtiter polystyrene plates (Thermo Fisher Scientific, Denmark) 
were used for biofilm growth. 200 µl of CDM supplemented with either 5 mM glucose 
or 5 mM galactose and frozen bacterial culture adjusted to 1x105 CFU/200µl was 
added per well. As extracellular DNA was shown to increase biofilm formation [35, 
36], also 2 µl of salmon sperm DNA (Sigma, Zürich, Switzerland) were added per 
well. The plates then were incubated statically for 16h at 37°C and 5% CO2 
according to previous publications [10, 37]. For 64h of biofilm incubation, the 
supernatant was removed as published before [9] after 16h and 40h and fresh CDM 
supplemented with either 5 mM glucose or 5 mM galactose was added. 
Colony forming units (CFU) counting of biofilms 
After 16 h or 64 h of incubation, the liquid medium and the planktonic cells 
were removed from the wells using a multichannel pipette. Biofilms then were 
washed twice with 200 µl PBS and  sonicated in the water bath (Branson Water Bath 
3210) for 6 seconds. Serial dilutions of biofilms then were plated out on CSBA plates 
and incubated at 37°C and 5% CO2. The next day, the bacteria were counted and the 
CFU/200 µl was calculated. 
Colony size differentiation / Fluorescein isothiocyanate-dextran imaging 
Serial dilutions of biofilm CFU counts were screened for differences in colony 
sizes. Small colony variants were discriminated from normal colonies by eye. For 
clearer discrimination, normal and small colonies were grown in Brain Heart Infusion 
(see “Bacterial strains and growth conditions”).  FITC-Dextran imaging was 
performed according to previously published protocols (Weinberger et al. 2009 [38], 
Hathaway et al. [39]). Shortly, bacterial suspensions were centrifuged at 3000 g for 5 
minutes at room temperature (Heraeus Megafuge 16R) and pellet was resuspended 
in 800 µl PBS. 2 µl of FITC-Dextran (10 mg/ml, stored at -20°C, Sigma Aldrich) were 
mixed with 10 µl of bacterial suspension, 10 µl of mixture placed on a glass slide. 
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The coverslip then was pressed down firmly. Pictures were taken using a Zeiss Axio 
Imager.M1 fluorescence microscope with a 100x objective and photographed by a 
Zeiss AxioCam HRc camera. 
Statistical analysis 
To compare different groups, One-way ANOVA was used with Tukey’s 
correction for multiple testing. GraphPad Prism 6.3 was used for statistical analysis. 
For two-group comparisons, Student’s t-test was used.  
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Figures 
Figure 1 – Planktonic growth of pneumococcal serotypes 6B and 7F in CDM 
galactose and CDM glucose 
22 h of planktonic growth of strains 106.66 (serotype 6B), 208.41 (serotype 7F) in 
CDM supplemented with A) 5 mM glucose and B) 5 mM galactose.  
Error bars: SEM. 
Figure 2 – Biofilm growth of pneumococcal strains 106.66 (serotype 6B) and 
208. 41 (serotype 7F) and their isogenic capsule-switch mutants 
Planktonic and biofilm growth of 106.66 (6B), 208.41cps106.66 (6B),208.41 (7F) and 
106.66cps208.41 (7F) in A) CDM glucose and B) CDM galactose after 16h of 
incubation. Identical experiments are connected with a line. C) and D) show the 
relative amount of biofilm from total CFU counts in CDM glucose and CDM 
galactose, respectively. 
Statistical tests: Student’s t-test. *p<0.05, **p<0.01, ***p<0.001, ****p<0.0001 
Figure 3 – SCV formation of serotypes 6B and 7F  
Relative amount of SCVs from total biofilm CFUs in CDM galactose and CDM 
glucose. 
Figure 4 – SCV and normal-sized bacteria of serotypes 6B and 7F after one 
passage 
A) SCV of strain 208.41 (serotype 7F) after passaging once in BHI + 5% FCS and B) 
normal-sized bacteria of strain 208.41 (serotype 7F) after one passage. C) SCV 
variant of strain 106.66 (serotype 6B) which reverted to normal size after one 
passage and D) normal-sized bacteria of strain 106.66 (serotype 6B). Magnification 
1000x. 
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Figure 5 - Development of biofilms and small colony variants of serotypes 6B 
and 7F over time 
A) Planktonic and biofilm growth of 106.66 (6B) and 208.41 (7F) after 64 h of 
incubation. Identical experiments are connected with a line. B) Relative amount of 
biofilm CFU counts as percentage of total CFUs for serotypes 6B and 7F after 16 h 
and 64 h of incubation. C) Relative amount of SCVs from total biofilm CFU counts in 
CDM galactose after 16 h and 64 h of growth. 
Error bars: SEM. Statistical test: Student’s t-test. ** p<0.01 
 
Tables 
Table 1 – Details of pneumococcal strains used in this study. 
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Table 1 
 
Species Strain Sample location Year of isolation Country of isolation Serotype MLST Pneumolysin References 
S. pneumoniae 106.66 
nasopharynx  
(otitis media) 
1998 CH 6B 2244 yes [39] 
S. pneumoniae 208.41 
nasopharynx 
 (otits media) 
2001 CH 7F 191 yes [39] 
S. pneumoniae 208.41cps106.66 mutant  CH 6B 191 yes [39] 
S. pneumoniae 106.66cps208.41 mutant  CH 7F 2244 yes [39] 
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Figure 2 
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Figure 5 
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5.2 Interactions in biofilm formation between commensal streptococcal strains and 
S. pneumoniae serotypes 
Co-cultivation experiments of commensal streptococcal strains and S. pneumoniae 
 
Additional work required: mixed species planktonic growth curves to investigate behaviour 
over time to compare this data to CFU results 
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Interactions in biofilm formation between commensal streptococcal strains and S. 
pneumoniae serotypes 
 
Abstract 
On the mucosal surfaces of the human nasopharynx biofilms were identified which 
are generally composed of a high amount of different bacterial species. Between the different 
species, niche competition occurs where factors like space, nutrient limitation or bacteriocin 
secretion may play a dominant role.  
The commensal streptococci S. oralis, S. mitis and S. pseudopneumoniae with 
different biofilm forming potential were compared in mono- and mixed species biofilm 
formation with S. pneumoniae serotypes. A decrease of biofilm biomass as well as of biofilm 
CFU counts resulted from co-cultivation for all species tested. A chemically defined medium 
(CDM) supplemented with either 5 mM glucose or 5 mM galactose was used resulting in no 
carbon source-dependent differences in competition. Nutrient limitation only played a 
significant role for competition of S. pneumoniae with S. oralis. For the other co-cultivations 
tested, nutrient limitation is not a major factor. We identified that apart from nutrient limitation 
and competition for space some other factors as bacteriocins, H2O2 production or differences 
in the structural development of biofilms among the species tested might have a stronger 
effect on the process of mixed species initial biofilm formation.  
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Introduction 
The human pharynx harbors over 700 different bacterial species [1], including the 
resident commensal streptococci S. oralis, S. mitis and S. pseudopneumoniae as well as the 
transient commensal S. pneumoniae [2]. Niche competition occurs between commensal 
bacteria as well as between potential pathogens. Factors as nutrient limitation 
(carbohydrates, amino acids, micronutrients) [3], secretion of bacteriocins [4, 5], the induction 
of bacteriophages [6], and modification of the host immune response [7] contribute directly or 
indirectly to the competition between microorganisms for an anatomical niche. For example, 
S. pneumoniae secrets H2O2 which is bactericidal to S. aureus and H. influenzae [8, 9], and a 
negative association between carriage of S. pneumoniae and Streptococcus aureus has 
been shown [10]. S. pneumoniae typically carries the genetic information for bacteriocin 
production, which inhibits bacteria from the same species as well as S. mitis and S. oralis; 
but only a small proportion of clinical strains seems to express bacteriocin activity [11]. The 
immune-mediated pressure started by H. influenzae is able to reduce S. pneumoniae density 
in the nasopharynx [12].  
In nature, bacteria are generally organized in biofilms, and also for medical 
microbiology this growth stage is of main importance [13]. The human nasopharynx is 
assumed as being nutrient-poor and biofilm formation as the growth type predominating in 
nutrient-limited environments [3, 14]. Biofilm formation was observed on mucosal surfaces in 
the nasopharynx as well as in tonsillitis and chronic otitis media [15-18]. Biofilms are 
generally composed of a high amount of different bacterial species, in the oral cavity up to 50 
different species were identified adhering on one location [19]. In oral microbiology it was 
observed that bacteria producing plaque biofilms do not adhere to teeth randomly but in a 
highly organized coaggregation profile where differences between early and late colonizing 
bacteria can be observed suggesting both competitive and symbiontic interactions [20-22]. 
Three commensal streptococci (S. pseudopneumoniae, S. mitis and S. oralis) 
generally colonizing the human nasopharynx and with assumed different biofilm building in 
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vitro were used for co-cultivation experiments with S. pneumoniae [2, 23]. The primary 
objective of this study was to develop a static biofilm model to study mixed species growth of 
S. pneumoniae with S. pseudopneumoniae, S. mitis or S. oralis. We further aimed at 
investigating whether competition occurs between the different bacterial species and whether 
nutrient limitation is a driving force for this process using chemically defined medium (CDM) 
supplemented with either glucose or galactose. 
 
Material and methods 
Bacterial strains and growth conditions 
The pneumococcal strains and commensal streptococci used for mixed-species 
biofilm growth are listed in Table 1. Bacteria were plated on Columbia Sheep blood agar 
(CSBA) plates and incubated overnight at 37°C and 5% CO2, then grown overnight in a water 
bath in 5 ml of Chemically Defined medium (CDM) [24] with the following modifications: 
Copper sulphate solution, manganese sulphate solution and cysteine solution were stored 
separately from the rest of the medium to prevent precipitations. Copper sulphate and 
manganese sulphate were stored at -20°C, the cysteine solution at 4°C. For overnight 
growth, CDM was supplemented with 50 mM of filter-sterilized sucrose. The next day, 
bacteria were subcultured into 5 ml of CDM supplemented with 5 mM of filter-sterilized 
glucose and grown to an OD600 of 0.1 to 0.15 in a water bath. 800 µl aliquots supplemented 
with 10% glycerol prepared and stored at -80°C. 
Biofilm growth 
96-well microtiter polystyrene plates (Thermo Fisher Scientific, Denmark) were used 
for biofilm growth. 200 µl of CDM supplemented with either 5 mM glucose (CDM glucose) or 
5 mM galactose (CDM galactose) were added per well. To directly compare mono- and 
mixed cultural biofilm growth, bacteria were grown on the same day as monocultures as well 
as in a 1:1 mixture of pneumococcus and a commensal streptococcus. A total amount of 5 µl 
of frozen stock was used as starting culture per biofilm resulting in only 2.5 µl per species for 
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mixed culture. But as liquid cultures were only grown to an OD600nm of 0.15 before freezing, 
differences in starting CFU counts were estimated as non-significant and starting conditions 
for mono- and mixed species growth approximated as similar. As extracellular DNA was 
shown to increase biofilm formation [25, 26], also 2 µl of salmon sperm DNA (Sigma, Zürich, 
Switzerland) with a final concentration of 0.5 ng/ml were added per well. The plates then 
were incubated statically for 16h at 37°C and 5% CO2.  
Planktonic growth 
96-well microtiter polystyrene plates (Thermo Fisher Scientific, Denmark) were used 
for planktonic growth. The inside of the plate lid was covered with 3 ml of 0.05% Triton X-100 
(Merck, Darmstadt, Germany) in 20% ethanol and air-dried. 200 µl CDM supplemented with 
either 5 mM glucose or 5 mM galactose were added per well. 5 µl of frozen bacterial culture 
were used for monocultural growth, whereas for mixed species growth 2.5 µl of frozen stock 
from each species were used (for detailed description, see above). OD450nm was measured 
on an ELISA plate reader (THERMOmax Microplate Reader, Molecular Devices Corporation, 
California) every 30 minutes for 22 hours using SOFTmax Pro 3.1.2. 
Crystal violet staining of biofilms 
After 16h of incubation, the liquid medium with the planktonically growing bacteria 
was removed from the wells using a multichannel pipette. Biofilms then were washed twice 
with 200 µl of phosphate buffered saline (PBS), stained with 100 µl of 0.5% crystal violet 
(CV) (0.5% CV in PBS) for 30 minutes at room temperature. After an additional washing step 
using 200 µl PBS, plates were air-dried for at least 30 minutes. CV of stained biofilms then 
was solubilized by adding 200 µl of 95% ethanol and absorbance was measured on an 
ELISA plate reader (THERMOmax Microplate Reader, Molecular Devices Corporation, 
California) at 450 nm 
Colony forming units (CFU) counting of biofilms 
After 16h of incubation, the liquid medium and the planktonic cells were removed from 
the wells using a multichannel pipette. Biofilms then were washed twice with 200 µl PBS and 
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sonicated using a sonifier (Branson sonifier 250; duty cycle of 30, output control 2.5, sonicate 
for 3 seconds). Serial dilutions of biofilms were plated out on pure CSBA plates and on blood 
plates supplemented with an appropriate antibiotic (see Table 1 for an overview and Table 2 
for detailed information to antibiotic resistances of strains used) to distinguish between 
pneumococci and commensal streptococci. Plates then were incubated at 37°C and CO2. 
The next day, the bacteria were counted and the CFU/200 µl were calculated. 
CFU counting of planktonically grown bacteria 
After 14-16 h of incubation, serial dilutions of the supernatant were plated out on pure 
CSBA plates and on blood plates supplemented with an appropriate antibiotic (see Table 1 
for an overview and Table 2 for detailed information to antibiotic resistances of strains used) 
to distinguish between pneumococci and commensal streptococci. Plates then were 
incubated at 37°C and 5% CO2. The next day, the bacteria were counted and the CFU/200 µl 
were calculated. 
Statistical analysis 
GraphPad Prism 6.3 was used for statistical analysis. Student’s t-test was used to 
compare two groups. For mean values, the ratio of data points is added. 
 
Results and Discussion 
Biofilm forming potential of S. pneumoniae and commensal streptococci in monoculture 
First, CV staining was performed to determine the total adhering biomass (Figures 1A 
and 1B). S. oralis resulted in a non-significantly increased biomass in CDM galactose 
(p=0.09) and CDM glucose (p=0.14) compared to all other strains tested, whereas S. mitis, 
S. pseudopneumoniae and S. pneumoniae showed a similar amount of biofilm (p=0.7 in 
CDM glucose, p=0.3 in CDM galactose).  
To get the amount of living bacteria in the biofilm, CFUs were then counted (Figures 1C and 
1D). Mean CFU/200 µl of S. oralis (1x106; range: 5.3x104-3.2x106) were increased compared 
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to S. mitis, S. pseudopneumoniae and S. pneumoniae in both growth media tested. In CDM 
glucose, this effect was significant for S. mitis (p<0.05) and S. pneumoniae (p<0.01). 
Recently, the biofilm forming capacity of S. oralis, S. mitis and S. pseudopneumoniae 
was studied in C-medium [23]. S. oralis and S. pseudopneumoniae resulted in better biofilm 
formation than pneumococci with S. oralis resulting in the highest biomass, what is in 
accordance to our findings. Interestingly, S. mitis was shown to be unable to form biofilms in 
C-medium, whereas our results in CDM (with galactose or glucose) indicate a biofilm forming 
capacity comparable to S. pneumoniae. Individual lineages of S. mitis are quite distinct from 
one another and it was shown for oral streptococci that strains of the same species often 
differ in their ability to form biofilms [2, 27]. This might explain the different observations in S. 
mitis biofilm forming capacity. Different biofilm capabilities within the same species lineage 
were also found in our study (data not shown). However, differences in the total adhering 
biomass were not as apparent as between different species. We therefore pooled biofilm 
results of the same species for the subsequent experiments. 
In conclusion, commensal streptococci and pneumococci included in this study 
showed different biofilm forming capacity, making them ideal candidate strains to further 
investigate their different behavior in co-cultivation experiments. 
Therefore, we next investigated whether differences in biofilm growth behavior is also 
observed for mixed species growth (Commensal streptococci with pneumococcus). 
 
Biofilm formation of mixed bacterial species growth (CV staining) 
Mixed species biofilms were evaluated by CV staining after 16h in Glucose and 
Galactose and subsequently compared to the corresponding monocultural growth (Figure 2). 
Surprisingly, no additive effect in mixed species biofilm growth was measured for any of the 
combinations tested. When a commensal streptococcus was grown together with S. 
pneumoniae, biofilm formation was always reduced compared to commensal monocultural 
growth. This finding was significant in the case of S. oralis within both, galacotse (p<0.05) 
and glucose (p<0.05) but the same trend was also seen for S. mitis and S. 
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pseudopneumoniae (Figure 2A and 2B).The same amount of bacteria were added for mono- 
and mixed cultural growth, but mixed species biofilms resulted in less CFU counts. Space 
limitation did not occur, as S. oralis biofilm biomass reached significantly higher levels than 
the other species tested. Co-cultures therefore did not result in using all the space provided 
by our model. Other factors like nutrient limitation or bacteriocin production might influence 
biofilm growth. 
 
Biofilm formation of mixed bacterial species growth (CFU counting) 
To evaluate the amount of living cells of each species in mixed species biofilms, 
CFUs were then counted. S. pneumoniae CFU counts were significantly (p<0.05) reduced in 
mixed cultures compared to monocultural growth. This was true for growth in CDM glucose 
as well as in CDM galactose and with all commensal streptococci tested (Figure 3A and 3B). 
In this study, different pneumococcal serotypes (Hungary 19A, strain 106.66 (6B) and strain 
110.16 (19F)) showing different planktonic growth behaviour in CDM galactose and glucose 
were used. Interestingly, CFU counts in mixed species biofilm growth were reduced for all 
three pneumococci used indicating that the growth phase does not have a major impact on 
the outcome of competition during initial biofilm formation (data not shown). Using CDM 
galactose, commensal streptococci resulted in a non-significant decrease of CFU counts in 
mixed cultures for S. mitis (p=0.18), whereas the reduction in CFU counts was significant for 
S. oralis (p<0.05) and S. pseudopneumoniae (p<0.05). The same trend was observed with 
CDM glucose, where the reduction of CFU counts in mixed cultures was significant for S. 
pseudopneumoniae (p<0.05) and S. oralis (p<0.0001), whereas the reduction was not 
significant for S. mitis (p=0.7) (Figures 3C and 3D).  
Planktonic growth of mixed bacterial species (CFU counting) 
We were interested in investigating if nutrient limitation might play a dominant role in 
CFU reduction during mixed species growth. For this reason, planktonic growth of mixed 
cultures was performed. If nutrient limitation would occur, planktonic growth also might show 
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reduced amounts of CFU counts in mixed compared to monocultural growth, whereas other 
biofilm-specific factors like the more compact packing of bacteria and thus the closer 
interactions would have no influence. 
For planktonic growth in CDM galactose CFU counts of pneumococci remained on a 
slightly decreased level when monocultural growth was compared to planktonic growth in a 
mixture with S. pseudopneumoniae (p=0.3) and with S. mitis (p=0.4) whereas a non-
significant decrease was measured with S. oralis (p=0.06) (Figure 4A). In CDM glucose 
mixed cultural growth resulted in a non-significant (p=0.5) increase of pneumococcal CFU 
counts compared to S. pneumoniae monocultures (Figure 4B). Commensal streptococcal 
CFU counts in mixed cultures were non-significantly increased for S. pseudopneumoniae 
(p=0.25), remained stable S. mitis (p=0.51) and were non-significantly reduced for S. oralis 
(p=0.25) when growth was performed in CDM galactose (Figure 4C). In CDM glucose CFU 
counts of monocultures and mixed cultures showed no significant difference for S. 
pseudopneumoniae (p=0.7), S. mitis (p=0.7) and S. oralis (p=0.42) (Figure 4D).  
During planktonic growth, nutrient limitation is supposed to be the major factor 
influencing competition in mixed cultural growth. This was true for mixed cultural growth of 
pneumococcus with S. oralis: planktonic growth resulted in a decrease of CFU counts for 
both species and thus, nutrient limitation is a major factor of competition between these two 
species. The opposite effect occurred for mixed cultural growth of S. pneumoniae with S. 
pseudopneumoniae as increased levels of the commensal streptococcus were measured. 
For co-cultural growth of S. pneumoniae with S. mitis, CFU counts remained stable 
compared to monocultures. This indicates that nutrient limitation is not a driving force in 
competition among these species.   
There are clear limitations of our study: Competition occurs during initial biofilm 
formation in mixed species growth, but no information is available on which components play 
a dominant role. No conclusion about the importance of H2O2 or bacteriocins can be drawn. 
Additionally, no microscopic analysis are yet available to compare structures of mono- or 
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mixed species biofilms and to gain additional informations about how differences in the 
structural composition might influence initial biofilm formation. 
In summary, our results show that nutrient limitation is a major factor influencing 
growth of S. pneumoniae in mix with S. oralis, which was identified to be a good biofilm 
builder. But interestingly, competition also occurs in initial biofilm growth in mixed cultures of 
pneumococcus with S. pseudopneumoniae or S. mitis where nutrient limitation is not a major 
factor. Competition for space also does not occur as S. oralis monocultures resulted in more 
biofilm biomass than all other species tested indicating that co-cultures did not succeed in 
filling in all the space provided by our model with biofilm biomass. Thus, despite the 
competition for space and nutrients, other factors as bacteriocins [4, 5], H2O2 [8] or 
differences in the structural composition might play a more important role in the development 
of co-cultured initial biofilms.  
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Figure legends 
 
Figure 1 - Biofilm growth of commensal streptococci and pneumococcus in 
monoculture 
CV staining of monocultural biofilms grown in A) CDM galactose or B) CDM glucose and 
incubated for 16h of S. oralis, S. pseudopneumoniae, S. mitis and S. pneumoniae. Three 
different pneumococcal serotypes were used: 19A, 6B and 19F.  
CFU counts of 16h initial biofilms grown in CDM galactose C) or CDM glucose D) of S. oralis, 
S. pseudopneumoniae and S. mitis. For S. pneumoniae, serotypes 19A, 6B and 19F were 
used. 
Statistical test: One-way ANOVA with Tukey’s test to correct for multiple comparisons 
*p<0.05; **p<0.01. Error bars: SEM 
 
Figure 2 – Comparison of mono- and mixed cultural biofilm biomass of commensal 
streptococci and S. pneumoniae by CV staining 
CV staining of mono- and mixed cultural biofilm growth incubated for 16 h in A) CDM 
galactose and B) CDM glucose. Three different pneumococcal serotypes were used: 19A, 6B 
and 19F. 
Statistical test: Student’s t-test to compare monocultural with mixed cultural growth. *p<0.05. 
Error bars: SEM. 
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Figure 3 – CFU counts of mono- and mixed cultural biofilms of commensal 
streptococci and S. pneumoniae 
S. pneumoniae (serotypes 6B, 19A and 19F) CFU counts in biofilm monocultural growth and 
in mixed cultures with S. pseudopneumoniae, S. mitis and S. oralis in A) CDM galactose and 
B) CDM glucose. C) CFU counts of commensal streptococci in mono- and mixed cultural 
growth with S. pneumoniae in biofilm growth using CDM galactose and D) CDM glucose.  
Statistical test: Student’s t-test to compare monocultural with mixed cultural growth. *p<0.05, 
**p<0.01, ***p<0.001, ****p<0.0001. Error bars: SEM 
 
Figure 4 – CFU counts of mono- and mixed cultural planktonic growth of commensal 
streptococci and S. pneumoniae 
S. pneumoniae (serotypes 19A and 19F) CFU counts in planktonic monocultural growth and 
in mixed cultures with S. pseudopneumoniae, S. mitis and S. oralis in A) CDM galactose and 
B) CDM glucose. C) CFU counts of commensal streptococci in mono- and mixed cultural 
growth with S. pneumoniae in biofilm growth using CDM galactose and D) CDM glucose.  
Statistical test: Student’s t-test to compare monocultural with mixed cultural growth. *p<0.05. 
Error bars: SEM 
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Species Strain Sample location 
Year of 
isolation 
Country of 
isolation 
Serotype MLST Pneumolysin References Remarks 
S. pseudopneumoniae 411 nasopharynx early 1990s UK   yes This study 
Used for discrimination experiments 
(CFU counts in co-culturing) 
S. pseudopneumoniae 412 nasopharynx early 1990s UK 
  
yes This study  
S. pseudopneumoniae 413 nasopharynx early 1990s UK 
  
yes This study  
S. mitis 414 blood early 1990s UK   yes This study 
Used for discrimination experiments 
(CFU counts in co-culturing) 
S. mitis 415 blood early 1990s UK   no This study 
Used for discrimination experiments 
(CFU counts in co-culturing) 
S. mitis 416 blood early 1990s UK   no This study  
S. oralis 417 blood early 1990s UK   no This study 
Used for discrimination experiments 
(CFU counts in co-culturing) 
S. oralis 418 blood early 1990s UK   no This study 
Used for discrimination experiments 
(CFU counts in co-culturing) 
S. oralis 419 blood early 1990s UK   no This study 
Used for discrimination experiments 
(CFU counts in co-culturing) 
S. pneumoniae 110.16 nasopharynx  (otitis media) 1999 CH 19F  yes  tetracycline for discrimination 
S. pneumoniae Hungary 19A-6 lab strain  Internat. Reference 19A 268 yes  tetracycline for discrimination 
S. pneumoniae 106.66 nasopharynx (otitis media) 1998 CH 6B 2244 Yes [3] tetracycline for discrimination 
 
Table 1: Detailed information to strains used in this study. 
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number Comment erythromycin clindamycin oxacillin levofloxacin chloramphenicol tetracycline sulpha-trimethoprim vancomycin clindamycin Etest penicillin MIC Etest 
411 S. pseudopneumoiae UK 39 30 30 32 31 40.5 25.5 27 0.094 0.023 
412 S. pseudopneumoiae UK 16 31 30 30 30 16.5 26 29 0.125 0.023 
413 S. pseudopneumoiae UK 40 32 20 30 35 16 25 26 0.064 0.047 
414 S. mitis UK 46 38 30 23 36.5 23 25.5 28 0.023 0.012 
415 S. mitis UK 20 27 26.5 18 26 30 20 22.5 0.19 0.023 
416 S. mitis UK 20 30 27 21 29 13 0 21 0.125 0.023 
417 S. oralis UK 37 30 11.5 26 30 38.5 29 25 0.19 0.19 
418 S. oralis UK 39 34 14 22 32 39 30 27.5 0.094 0.125 
419 S. oralis UK 19 30 0 22 27.5 35 27 23 0.19 6 
 1.69 S. pneumoiae Hungary 19A-6 0 0 0 32 20.5 14 0 31 256+ 1 
110.16 S. pneumoiae (19F) 0 10 18 26 25 10 22.5 26.5 2 0.064 
 
Table 2: Overview antibiotic resistances of commensal and pneumococcal strains used in this study. No color: susceptible. Yellow: intermediate. Red: resistant. N.B. No antibiogram was performed for 
strain 106.66 (serotype 6B), but only resistance to tetracycline was tested. 
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Figure 2 
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Figure 3 
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Figure 4 
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6. Discussion  
 
The human nasopharynx, the major ecological reservoir of S. pneumoniae, is 
considered to be a nutrient-poor environment and in this environment pneumococcal biofilms 
have been isolated from mucosal epithelial cells [154, 180]. The niche is colonized by up to 
700 different bacterial species competing for nutrients (e.g. carbohydrates) and space and 
influencing one another’s growth by the secretion of bacteriocins or the induction of 
bacteriophages [173, 174, 180, 181]. Additionally, the upper airway epithelial cells are also 
the main target of RSV infection, which increases the adherence potential of S. pneumoniae 
resulting in more severe infections and modifies the host’s immune response [182-185]. 
Pneumococcal colonization of the nasopharynx generally occurs asymptomatically and 
transiently, with recruitment of FoxP3+ regulatory T-cells and induction of IL-10 secretion 
resulting in a reduction of immunological reactivity [5, 108, 186-188]. However, S. 
pneumoniae also has a serotype-associated potential to cause invasive diseases such as 
pneumonia, sepsis or meningitis [189-191]. As soon as the lungs are invaded, a massive 
infiltration of neutrophils and monocytes/macrophages is measured. T-cells also play an 
important role in early pneumococcal immunity [105, 108, 192]. 
The polysaccharide capsule of S. pneumoniae plays an important role in colonization 
and growth behaviour, but also has major impacts on invasiveness of pneumococcal strains 
and on the host’s immune responses [74, 180, 189, 190]. Capsule was the main focus of our 
studies. We first investigated the role of capsule and pneumolysin, the other main 
pneumococcal virulence factor [88], in CXCL8 and IL-6 induction in vitro and in vivo and 
studied the difference in lung infiltration between encapsulated and non-encapsulated 
isogenic pneumococcal strains as well as the resulting immune responses by measuring 
various cell types of innate immune response. Additionally, we were also interested in the 
impact of serotype on initial biofilm formation and structure in a static biofilm model in vitro, 
where a serotype 6B and a 7F strain were compared for the amount of biofilm formation as 
well as in its composition with a main focus on SCV formation. As competition between 
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pneumococci and commensal streptococci plays an important role in nasopharyngeal 
colonization, initial biofilm formation of monoculture and mixed cultures of S. pneumoniae 
with S. oralis, S. mitis and S. pseudopneumoniae was analyzed and the impact of nutrient 
limitation investigated by mixed culture planktonic growth. Lastly, the impact of RSV as 
mono-treatment or together with encapsulated and non-encapsulated S. pneumoniae or 
pneumolysin on CXCL8 and IL-6 secretion from bronchial epithelial cells was studied. 
 
Effect of pneumococcal capsule and pneumolysin on CXCL8 and IL-6 secretion 
The release of CXCL8 and IL-6 from the human pharyngeal cell line Detroit 562 was 
shown to be suppressed by the presence of capsule. This finding was true for S. 
pneumoniae strain D39 and its isogenic non-encapsulated mutant D39cps- as well as for the 
naturally non-encapsulated clinical strain 110.58 and its encapsulated isogenic mutant 
110.58::D39cps. The human bronchial epithelial cell line iHBEC resulted in much less 
CXCL8 and IL-6 release, but the levels also were affected by the presence of a capsule. In 
nasopharyngeal carriage in a mouse model the increase in CXCL8 after capsule deletion 
was only observed when pneumolysin also was deleted indicating that the effect of capsule 
on suppression of CXCL8 release was hidden by pneumolysin which is known to have a 
major effect on CXCL8 induction [177]. 
 Thus far, the effect of pneumococcal capsule on CXCL8 response has mainly been 
tested using laboratory strains (D39, TIGR4) [193, 194]. However, it would be interesting to 
investigate whether different serotypes result in different levels of CXCL8 secretion using 
isogenic capsule switch mutants which we already have available in our laboratory. 
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Nasopharyngeal carriage, lung infiltration and innate immune response 
In a nasopharyngeal carriage mouse model, only non-encapsulated strains were able 
to infiltrate the lungs. Encapsulated bacteria are responsible for the initiation of innate 
immunity leading to the infiltration of neutrophils and macrophages to enter the nasopharynx 
resulting in efficient opsonophagocytosis of the bacteria due to the polysaccharide capsule. 
CXCL8 chemotactic activity is important for immune cell infiltration in the nasopharynx, and 
restriction of the initial step of CXCL8 release might increase bacterial survival and result in 
longer term survival in the nasopharynx without host mediated clearance. Nasopharyngeal 
carriage was also observed to be associated with the stimulation of FoxP3+ regulatory T-
cells and an increase in IL-10 secretion involved in immune homeostatic processes [186, 
188], resulting in a moderate immune response and a prolonged carriage state of 
pneumococci in the upper respiratory tract. But as soon as lung infiltration occurs, a strong 
inflammatory response is initiated clearing not only the bacteria from the lungs but also from 
the nasopharynx.  
 As in vivo studies of immune responses to pneumococcal strains are complex and 
influenced by a huge amount of different factors, responses to encapsulated and non-
encapsulated strains could be studied on cell lines of macrophages or neutrophils in vitro to 
get a more detailed picture of the response generated by one cell type. Additionally, to get a 
deeper understanding of the differences in the infiltrating potential between different 
serotypes and to study differences in immune responses against encapsulated and 
nonencapsulated pneumococcal strains, clinical isolates which naturally cause infections 
and their encapsulated or nonencapsulated isogenic mutants should be tested in vivo. There 
are several clinical isolates and their isogenic mutants available in our lab. 
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RSV and pneumococcus: impact on CXCL8 and IL-6 secretion of bronchial epithelial 
cells 
 IL-6 secretion of human bronchial epithelial cells in vitro is increased for mixed 
treatment with RSV and pneumococcus compared to mono-stimulation with either pathogen 
when encapsulated bacteria are used. This trend was not observed for non-encapsulated 
pneumococci or free pneumolysin which did not have an effect on IL-6 secretion. The 
CXCL8 response also was increased for encapsulated bacteria in combination with RSV 
compared to non-encapsulated pneumococci, but additionally, also an effect of increasing 
pneumolysin concentrations was measured, which is in accordance with previous findings 
[177]. In summary, priming of epithelial cells with RSV opens the door for more severe 
pneumococcal infections, and damaging the cells with pneumolysin also favors secondary 
viral infections.  
 Recently it was shown that epithelial cell lines and primary epithelial cells from 
bronchial brushings from children differ strongly in their response to RSV infections [178, 
179]. Thus, our cytokine responses should be confirmed using primary epithelial cells from 
healthy children. Additionally, primary epithelial cells from cystic fibrosis (CF) patients also 
will be tested. Evidence from epidemiological studies and from animal models suggests that 
prior or ongoing viral infections of the respiratory tract may predispose individuals to the 
development of invasive pneumococcal disease and this is particularly true in CF patients in 
whom bacterial and viral co-infections are particularly common. Thus, a comparison of 
bacterial-viral interactions between primary cells from healthy children and from CF patients 
would be of interest. On other human cell lines such as macrophages and neutrophils 
interactions between virus and bacteria also can be examined. Additionally, cytokine results 
also might be studied in vivo using an infection mouse model. 
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Influence of serotype on biofilm formation 
Serotypes 6B as well as 7F both were able to form SCVs during biofilm growth in 
CDM supplemented with 5 mM glucose as well as in CDM supplemented with 5 mM 
galactose after 16h of incubation in a static in vitro biofilm model. The growth medium did not 
have an effect on SCV formation. We then also were interested in the development of 
biofilms and SCVs over time and analyzed growth after 64h of incubation. The biofilm 
composition was shown to be different between the serotypes: Serotype 6B resulted in a 
gradual increase in SCV formation and also in an increase of relative biofilm CFU counts 
between 16 and 64 h, whereas levels remained stable for serotype 7F. Our findings indicate 
an expression-regulated mechanism of SCV formation for serotype 6B allowing the 
adaptation to changing nutritional environments. Serotype 7F strains show a different 
mechanism which might be associated with the development of point mutations. As 
adaptation to a nutrient-poor environment and stable biofilm formation is important to get 
long-term access to the nasopharynx, this process also is interesting in terms of different 
colonizing and invading potential of different pneumococcal serotypes [158, 180, 195]. 
 The changes in biofilm composition in terms of SCV and normal colonies over time 
might be of interest, and timepoints in between 4 and 65h could be analyzed. Biofilm 
formation on a biotic surface, e.g. on fixed pharyngeal epithelial cells, or the use of a 
continuous flow bioreactor would give additional information about biofilm development in an 
environment more closely related to nasopharyngeal conditions. 
 
Planktonic and biofilm growth of mixed species cultures 
 The commensal streptococci S. oralis, S. mitis and S. pseudopneumoniae all were 
able to form initial biofilms in a static in vitro model using CDM supplemented with 5 mM 
glucose or 5 mM galactose as growth medium, with S. oralis resulting in an increased 
amount of biofilm CFU counts compared to S. mitis, S. pseudopneumoniae and S. 
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pneumoniae. In mixed species biofilms of S. pneumoniae with S. oralis, S. mitis or S. 
pseudopneumoniae, S. pneumoniae as well as the commensal streptococci all showed a 
reduction of CFU counts compared to mono-species biofilm growth.  Nutrient limitation 
tested by mixed species planktonic growth was shown to only play a significant role for 
growth of S. pneumoniae with S. oralis, but not for growth with either of the other two 
commensal streptococci. Initial biofilm formation in mixed species cultures of S. pneumoniae 
with S. mitis or S. pseudopneumoniae also resulted in a decrease of CFU counts for both 
species indicating that bacteriocins [173, 174], the production of hydrogen peroxide [175] or 
other bactericidal factors might play a more significant role in biofilm formation where 
bacteria are closer and interactions might be stronger than in planktonic growth. Additionally, 
differences in the biofilm structure between commensal streptococci and pneumococcus 
might also result in competition for adherence space. 
 Thus far, only CFU counts of planktonically grown bacteria in mixed cultural growth 
after 15h of incubation were counted, but no information about the growth behaviour over 
time is available. The next step would be to perform growth curves measuring OD450 over 
22h to investigate the impact of carbon source on mixed cultural planktonic growth over time 
and thus, to gain information about when the maximal OD450 is reached and to study the 
impact of pneumococcal autolysis. 
For further experiments, the advantage of growth in CDM could be used: as all 
components of the medium are known and thus, differences in the composition after growing 
either pneumococci or commensal streptococcal species biofilms could be analyzed to 
determine differences in the amount of the different components metabolized. This might 
give a closer insight into metabolic differences between pneumococcus and commensal 
streptococci. Additionally, also the supernatant of mixed species biofilm cultures could be 
analyzed to study the secretion of bactericidal substances as bacteriocins or hydrogen 
peroxide. In a follow-up experiment to study competition in a model more closely related to 
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nasopharyngeal conditions where a constant flow of nutrients and other components is 
influencing the micro-ecosystem, a flow model as published previously [176] could be used. 
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10. Appendix 
 
Chemically defined medium (CDM, modified from [198]) 
 
Substance Provider Product No. 
lron (II) sulfate, heptahydrate  Merck 3965 
lron (III) nitrate, nonahydrate Merck 3883 
Potassium phosphate dibasic, anhydrous  Fluka 17835 
Potassium phosphate monobasic, anhydrous  Merck 4873 
Magnesiumsulfate, anhydrous Sigma M7506 
Manganous sulfate, monohydrate(min.98%) Merck 5941 
L-Alanine (200x)  Sigma A7627 
L-Arginine (200x) Sigma A5006 
L-Aspartic acid (200x)  Sigma A9256 
L-Phenylalanine (200x) warm up to dissolve Merck 7256 
L-Proline 200x) Sigma P0380 
L-Serine (200x) Sigma S4500 
L-Glutamic acid, monosodium salt, monohydrate  Sigma G2834 
L-Glutamine (200x) Merck 289 
Glycine (200x) Merck 4201 
L-Threonine (200x) Merck 8411 
L-Trypotophan (200x) Sigma 8941 
L-Tyrosine (200x) Merck 8371 
L-Valine (200x) Merck 8495 
L-Histidine monohydrochloride, monohydrate  Sigma H8125 
L-Isoleucine (200x) Merck 5362 
L-Leucine (200x) Sigma L8912 
L-Lysine monochloride (200x)  Sigma L5626 
L-Methionine (200x) Merck 5707 
Folic acid (min. 98%) Sigma F8758 
Biotin (min. 99%) Sigma B4501 
Niacinamide Sigma N3376 
D-Calcium pantothenate  Sigma P2250 
Para-aminobenzoic acid  Sigma A9878 
Pyridoxal hydrochloride Sigma P9130 
Pyridoxine Sigma P9755 
Pyridoxamine, dihydrochloride  Sigma P9380 
Thiamine hydrochloride Sigma T4625 
Cyanocobalamin  Sigma V2876 
(-)-Riboflavine Sigma R4500 
Guanine hydrochloride Sigma 51030 
Diadenine sulfate salt, dihydrate Sigma A9126 
Uracil  Sigma U0750 
Calcium chloride, anhydrous Merck 2083 
Sodium acetate, anhydrous Merck 6268 
Sodium phosphate dibasic, anhydrous  Merck 6586 
Sodium phosphate monobasic, monohydrate  Merck 6346 
Choline chloride Sigma C7527 
Sodium bicarbonate (min. 99%) Merck 6329 
Cystein Sigma C7477 
β-NAD Sigma N1511 
Copper (II)sulfate Sigma C7631 
Manganese sulfate Merck 5941 
 
Table A1: List of chemicals required for CDM production  
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Substance Concentration for 1 l   Remarks Aliquots / storage 
lron (II) sulfate, heptahydrate  10mg/ml RWT1 0.5 ml always prepare freshly   
lron (III) nitrate, nonahydrate 10mg/ml RWT1 0.1 ml always prepare freshly   
Potassium phosphate dibasic, anhydrous    0.2 g always weigh in freshly (in SB)   
Potassium phosphate monobasic, anhydrous    1 g always weigh in freshly (in SB)   
Magnesiumsulfate, anhydrous 11.966 g/70 ml RWT1 2 ml dissolve in ice bath sterile filtered, 12 ml aliq./-15°C - -25°C 
Manganous sulfate, monohydrate(min.98%) 200 mg/40 ml RWT1 1 ml   sterile filtered, 6 ml aliq./-15°C - -25°C 
L-Alanine (200x)  2 g/100 ml RWT1 5 ml   autoclaved, 2°C - 8 °C 
L-Arginine (200x) 2 g/100 ml RWT1 5 ml   autoclaved, 2°C - 8 °C 
L-Aspartic acid (200x)  2 g/100 ml 0.2M HCl 5 ml   sterile filtered, 2°C - 8 °C 
L-Phenylalanine (200x)  2g/100 ml 0.01M HCL 5 ml warm up to dissolve autoclaved, 15°C - 30°C 
L-Proline 200x) 2 g/100 ml RWT1 5 ml   autoclaved, 2°C - 8 °C 
L-Serine (200x) 2g/100 ml RWT1 5 ml   autoclaved, 2°C - 8 °C 
L-Glutamic acid, monosodium salt, monohydrate  2,544g/100 ml RWT1 5 ml   sterile filtered, 2°C - 8 °C 
L-Glutamine (200x) 4g/100 ml 1 M HCl 5 ml   sterile filtered, 2°C - 8 °C 
Glycine (200x) 2g/100 ml RWT1 5 ml   autoclaved, 2°C - 8 °C 
L-Threonine (200x) 4g/100 ml RWT1 5 ml   autoclaved, 2°C - 8 °C 
L-Trypotophan (200x) 2g/100 ml 0.1 M NaOH 5 ml protect from light (aluminium foil) sterile filtered, 2°C - 8 °C 
L-Tyrosine (200x) 2,884g/100 ml 1 M NaOH 5 ml protect from light (aluminium foil) sterile filtered, 2°C - 8 °C 
L-Valine (200x) 2g/100 ml RWT1 5 ml   autoclaved, 2°C - 8 °C 
L-Histidine monohydrochloride, monohydrate  2,7g/100 ml RWT1 5 ml   autoclaved, 2°C - 8 °C 
L-Isoleucine (200x) 2g/100 ml RWT1 5 ml warm up to dissolve autoclaved, 2°C - 8 °C 
L-Leucine (200x) 2g/100 ml RWT1 5 ml warm up to dissolve autoclaved, 15°C - 30°C 
L-Lysine monochloride (200x)  2.498 g/100 ml RWT1 5 ml   autoclaved, 2°C - 8 °C 
L-Methionine (200x) 2g/100 ml RWT1 5 ml   autoclaved, 2°C - 8 °C 
Folic acid (min. 98%) 30 mg/6 ml 1 M NaOH 0.16 ml protect from light (aluminium foil) sterile filtered, 1ml aliq./-15°C - -25°C 
Biotin (min. 99%) 10 mg/100 ml RWT1 2 ml warm up to dissolve sterile filtered, 12 ml aliq./-15°C --25°C 
Niacinamide 40 mg/ 8 ml RWT1 0.2 ml   sterile filtered, 1.2 ml aliq./-15°C --25°C 
D-Calcium pantothenate  80 mg/8ml RWT1 0.2 ml   sterile filtered, 1.2 ml aliq./-15°C --25°C 
Para-aminobenzoic acid  8 mg/8 ml RWT1 0.2 ml   sterile filtered, 1.2 ml aliq./-15°C --25°C 
Pyridoxal hydrochloride 40mg/8 ml RWT1 0.2 ml protect from light (aluminium foil) sterile filtered, 1.2 ml aliq./-15°C --25°C 
Pyridoxine 40mg/8 ml RWT1 0.2 ml protect from light (aluminium foil) sterile filtered, 1.2 ml aliq./-15°C --25°C 
Pyridoxamine, dihydrochloride  40mg/8 ml RWT1 0.2 ml protect from light (aluminium foil) sterile filtered, 1.2 ml aliq./-15°C --25°C 
Thiamine hydrochloride 40mg/8 ml RWT1 0.2 ml protect from light (aluminium foil) sterile filtered, 1.2 ml aliq./-15°C --25°C 
Cyanocobalamin  5 mg/10 ml RWT1 0.2 ml protect from light (aluminium foil) sterile filtered 1.2 ml aliq./-15°C --25°C 
(-)-Riboflavin 50 mg /+ 06ML  20 ml     
 
Table A2: Preparation of CDM. RWT1: ultra-pure distilled water. SB: Sorenson phosphate buffer (see Table A3) 
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Substance Concentration for 1 l   Remarks Aliquots / storage 
  glacial acetic acid +400 ml RWT1     protect from light (aluminium foil) sterile filtered, 120 ml flask/-15- -25°C 
  dissolve, ad 500 ml mit RWT1     warm up to dissolve   
Guanine hydrochloride 0.4 g/100 ml 1 M HCl  5 ml   sterile filtered, 15°C - 30°C 
Diadenine sulfate salt, dihydrate 0.4 g/100 ml 1 M HCl  5 ml   sterile filtered, 15°C - 30°C 
Uracil  0.4 g/200 ml RWT1 10 ml warm up to dissolve autoclaved, 15° - 30°C 
Calcium chloride, anhydrous 202.4mg/40ml RWT1 1 ml   sterile filtered, Rö.à 6 ml/-15°C --25°C 
Sodium acetate, anhydrous   2.7126 g dissolve in 100 ml SB   
Sodium phosphate dibasic, anhydrous    7.35 g dissolve in 200 ml SB   
Sodium phosphate monobasic, monohydrate    3.195 g dissolve in 100 ml SB   
            
            
Choline chloride   1 g dissolve in 100 ml SB   
Sodium bicarbonate (min. 99%)   2.5 g dissolve in 200 ml SB   
            
measure pH and adjust to 6.85           
Volume up to    1000 ml in SB    
filter sterilization and storage at 4°C            
Use within three weeks           
            
The following substances           
have to be added by the user separately:           
Cystein 0.75g/10ml RWT1 10 ml added by user sterile filtered, 2°C - 8 °C 
β-NAD 10mg/ml RWT1 0.25 ml added by user sterile filtered 
Copper (II)sulfate 10mg/10ml RWT1 0.6 ml added by user sterile filtered, 0.5 ml aliq./-15°C --25°C 
Manganese sulfate 125 mg/5 ml 1 ml added by user sterile filtered, 0.8 ml aliq./-15°C --25°C 
 
Table A2 (continued): Preparation of CDM. RWT1: ultra-pure distilled water. SB: Sorenson phosphate buffer (see Table A3) 
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Sorenson phosphate buffer (pH 7) for 1 liter CDM: 
Solution A: 
Potassium hydrogen phosphate (Merck 4873) 3.632 g in 400 ml distilled H2O 
  
Solution B: 
Sodium phosphate dehydrate (Merck 6580) 8.316g in 700 ml distilled H2O 
  
Sørensen buffer (pH 7): 
Solution A: 392 ml  
Solution B: 608 ml  
 
Table A3: Preparation of Sorenson phosphate buffer 
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Lacks culture medium [196, 197] 
Component Amount/litre 
casein hydrolysat (difco vitaminfree 
casamino-acids) 5g 
tryptophan 6 mg 
cystine 35 mg 
sodium acetate 2 g 
K2HPO4 8.5 g 
MgCl2 x6 H2O 0.5 g 
CaCl2 2.5 mg 
MnSO4x4H2O 25 µg 
FeSO4x7H2O 0.5 µg 
CuSO4x5H2O 0.5 µg 
ZnSO4x7H2O 0.5 µg 
biotin 0.2 µg 
nicotine acid 0.2 mg 
pyridoxin HCl 0.2 mg 
thiamin HCl 0.2 mg 
riboflavin 0.1 mg 
calcium-Pantothenat 0.6 mg 
glucose 2 g 
BSA 4 % 12 ml 
catalase 3000 units 
fresh yeast extract 30 ml 
 
Table A4: Composition of Lacks culture medium 
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